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ABSTRACT
Characterization of the Substrate Specificity and Mechanism of Protein Arginine
Methyltransferase 1
by
Whitney Wooderchak, Doctor of Philosphy
Utah State University, 2008
Major Professor: Joan M. Hevel, Ph.D.
Department: Chemistry and Biochemistry
Protein arginine methyltransferases (PRMTs) posttranslationally modify protein
arginine residues. Type I PRMTs catalyze the formation of monomethylarginine (MMA)
and asymmetric dimethylarginine (ADMA) via methyl group transfer from S-adenosyl
methionine onto protein arginine residues.
symmetric dimethylarginine.

Type II PRMTs generate MMA and

PRMT-methylation affects many biological processes.

Although PRMTs are vital to normal development and function, PRMT-methylation is
also linked to cardiovascular disease, stroke, multiple sclerosis, and cancer.
Thus far, nine human PRMT isoforms have been identified with orthologues
present in yeast, plants, and fish. PRMT1 predominates, performing an estimated 85% of
all protein arginine methylation in vivo. Yet, the substrate specificity and catalytic
mechanism of PRMT1 remain poorly understood.
Most PRMT1 substrates are methylated within repeating ‘RGG’ and glycinearginine rich motifs. However, PRMT1 also methylates a single arginine on histone-H4
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that is not embedded in a glycine-arginine motif, indicating that PRMT1 protein
substrates are not limited to proteins with ‘RGG’ sequences. In order to determine if
PRMT1 displays broader substrate selectivity, I first developed a continuous
spectrophotometric assay to measure AdoMet-dependent methyltransferase activity.
Using this assay and a focused peptide library based on a sequence derived from the in
vivo PRMT1 substrate fibrillarin, we observed that PRMT1 demonstrates amino acid
sequence selectivity in peptide and protein substrates.

PRMT1 methylated eleven

substrate motifs that went beyond the ‘RGG’ and glycine-arginine rich paradigm,
suggesting that the methyl arginine proteome may be larger and more diverse than
previously thought.
PRMT1 methylates multiple arginine residues within the same protein to form
protein-associated MMA and ADMA. Interestingly, ADMA is the dominant biological
product formed and is a predictor of mortality and cardiovascular disease. To understand
why PRMT1 preferentially forms ADMA in vivo, we began to 1) probe the mechanism of
ADMA formation and 2) examine the catalytic role of certain active site residues and
their involvement in ADMA formation. We found that PRMT1 dissociatively methylated
several peptide substrates and preferred to methylate mono-methylated substrates over
their non-methylated counterparts.

Methylation of a multiple arginine-containing

substrate was systematic (not random), a phenomenon that may be important
biologically. All in all, our data help explain how PRMT1 generates ADMA in vivo.
(204 pages)
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CHAPTER 1
INTRODUCTION

Protein arginine methyltransferase (PRMT) enzymes are involved in a wide
variety of cellular communication in eukaryotes.

In addition to phosphorylation,

acetylation, and glycosylation, protein arginine methylation is one more post translational
modification that enables organisms to expand upon their limited genome. PRMTmethylation affects many biological processes including RNA processing, signal
transduction, DNA repair, transcriptional regulation (reviewed in [1]), viral infection [2],
chromatin remodeling [3], and neuronal cell differentiation [4].

The molecular basis for

these events lies in the fact that methylation of protein arginine residues has the ability to
enhance or disrupt certain protein-protein interactions, protein-DNA interactions, and
protein-RNA interactions (described further in Chapter 2).
Thus far, eleven PRMT isoforms have been identified in humans (PRMT1-11)
with orthologs present in yeast, protozoa, Caenorhabditis elegans, Drosophila
melanogaster, plants, and fish.

The breadth of these enzymes indicates the vital

biological importance of arginine methylation across the plant and animal kingdoms.
The significance of protein arginine methylation has also been demonstrated in PRMT1
null mice that died early during embryonic development [5] and PRMT4 null mice that
showed incorrect cell differentiation [6]. Although PRMTs are vital to survival, protein
arginine methylation has been linked to carcinogenesis [7], viral pathogenesis [2],
multiple sclerosis [8], spinal muscular atrophy [9], lupus [10], cardiovascular disease
[11], and stroke [12]. Therefore, the elucidation of the regulation and mechanism of
these enzymes will prove invaluable.
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PRMTs transfer a methyl group from S-adenosyl methionine (AdoMet/SAM)
onto a positively charged arginine residue in the protein substrate, and S-adenosyl
homocysteine (AdoHcy/SAH) is produced. Type I PRMTs (PRMT1, 3, 4, 6, and 8)
catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine
(ADMA) via the transfer of a methyl group from S-adenosyl methionine (AdoMet/SAM)
onto protein arginine residues. PRMT5 and 7, both type II enzymes, generate MMA and
symmetric dimethylarginine (SDMA). Opposing biological consequences result from
whether a protein has been asymmetrically or symmetrically dimethylated [reviewed in
1].
Although much research has been performed on PRMTs since their cloning a little
over ten years ago, the substrate specificity of PRMT1 (the most predominant PRMT
isoform that performs over 85% of all protein arginine methylation) [13], remains
unclear. Few in vivo PRMT1 protein substrates have been identified, and the mechanism
of PRMT1 remained uncharacterized until recently [14].

Importantly, in order to

understand how PRMTs impact biology, we must first understand how these enzymes
select certain substrates over others and perform catalysis.

The purpose of this

dissertation is to add to the overall understanding of PRMT catalysis and substrate
specificity by characterizing the mechanism and substrate selection of the most
predominant PRMT isoform, PRMT1.
In Chapter 3, I helped develop the first continuous spectrophotometric assay for
AdoMet-dependent methyltransferases and demonstrated the utility of this assay with
PRMT1.

Prior to this assay, PRMTs were assayed with peptide substrates and

radioactively-labeled AdoMet. Radioactively-methylated peptide was then hydrolyzed
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and analyzed by HPLC [15]. Because this method is laborious and expensive, it is not
practical for screening many peptides. In order to perform the types of kinetic analyses
needed to address PRMT1 substrate specificity, we needed a more robust, higher
throughput assay. In collaboration with Dr. Sunny Zhou, we developed a continuous
spectrophotometric coupled assay (see Chapter 3) to measure AdoMet-dependent
methyltransferase activity.

Our assay employs two recombinant coupling enzymes,

AdoHcy nucleosidase and adenine deaminase.

AdoHcy nucleosidase hydrolyzes

AdoHcy, a product and inhibitor of methyltransfer, into adenine and S-ribosyl
homocysteine. Adenine is then converted into hypoxanthine via adenine deaminase
which results in a decrease at 265 nm that can be monitored continuously with time. This
assay was used repeatedly in several chapters of this dissertation.
In Chapter 4, we investigated the substrate specificity of PRMT1. Before 2007,
little was known regarding the substrate specificity of PRMT1 other than the fact that
PRMTs methylate arginine residues in glycine/arginine rich areas of proteins within
‘RGG’ and ‘RXR’ motifs.

From recent studies, it is now known that 1) certain

negatively charged surface residues of PRMT1 are important for substrate binding [16],
2) substrate positive charge positioned near the active site is important for PRMT1
catalysis [17], and 3) the N-terminus of PRMT1 influences substrate specificity [18].
Our study advanced the current understanding of PRMT1 substrate selection by
examining the primary amino acid sequence determinants of PRMT1 substrates. Using
the continuous assay (discussed in Chapter 3) and a focused peptide library based on a
sequence derived from the in vivo PRMT1 substrate fibrillarin, we showed that PRMT1
displays substrate sequence selectivity at the amino acid level (see Chapter 4). We report
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that PRMT1 has the ability to methylate eleven motifs that go beyond the ‘RGG’ and
‘RXR’ glycine/arginine rich paradigm suggesting that the methyl arginine proteome may
be larger and more diverse than previously thought.
In Chapter 5, we tried to understand why PRMT1 predominantly forms ADMA in
vivo by investigating how PRMT1 dimethylates substrate arginine residues
mechanistically. Although PRMT1 is capable of forming both MMA and ADMA, most
PRMT1 substrates are found in vivo in the dimethylated state with multiple dimethylated
arginines on the same protein. Numerous studies have shown a relationship between
elevated ADMA concentration and cardiovascular disease [19], and PRMT1 has been
shown to be overexpressed in myocardial tissue taken from coronary heart disease
patients [20]. Two possible ways to explain the predominance of ADMA formation are
1) preference for the mono-methylated substrate over the nonmethylated substrate or 2)
processive methylation. Our data indicate that PRMT1 dissociatively methylates single
arginine-containing peptides despite any increase in peptide length.

PRMT1

preferentially methylated monomethylated substrates over unmodified substrates, a
preference that would inevitably increase the amount of ADMA.

Interestingly,

methylation of a multiple arginine-containing substrate was shown to be systematic
wherein one arginine was preferentially methylated over another. This is important
because the biological response may change depending on which protein arginine residue
is methylated first. Finally, PRMT1 was shown to dissociatively methylate a multiple
arginine-containing substrate. Based on these results, the predominance of dimethylated
protein substrates in vivo is likely due to the ability of PRMT1 to preferentially methylate
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monomethylated versus unmodified arginine-containing proteins (see Chapter 5), a
phenomenon that may depend on substrate sequence.
In Chapter 6, we investigated certain PRMT1 active site residues and their
catalytic roles. Cheng and coworkers proposed that a conserved methionine residue
among type I PRMTs (M155 in the PRMT1 active site) may ensure the formation of
ADMA due to steric hindrance afforded by a bulky methionine residue [21]. Type II
PRMTs such as PRMT5 have a smaller alanine residue at this site and form SDMA.
When analyzing the methylation products formed from M155A-PRMT1, a mutant
PRMT1 that alleviated any steric hindrance afforded by this active site methionine
residue, no SDMA was present. This suggests that Met155 does not affect asymmetric
versus symmetric dimethylation formation (see Chapter 6). Another conserved active site
methionine residue (M48 in PRMT1) adjacent to AdoMet and the substrate arginine in
the PRMT1 crystal structure was shown to be very important in catalysis. M48APRMT1 was nearly catalytically inactive while M48L-PRMT1 demonstrated a catalytic
efficiency approximately half that of WT-PRMT1. These results indicated that the length
of this amino acid residue is important in PRMT catalysis based on its proximity to the
substrate arginine (see Chapter 6). Further product analysis from an extended reaction
with M48L-PRMT1 revealed that this mutant was also not capable of generating SDMA.
Thus, removing steric bulk afforded by Met155 or Met48 in the PRMT1 active site is not
by itself sufficient to transform PRMT1 into a Type II PRMT.
Chapter 7 includes experimental results from several projects that have yet to be
completed. In one project, we found that the amino acid sequence of certain peptide
substrates directly affects the extent that a particular substrate is mono- and dimethylated.
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Furthermore, we noticed that substrate inhibition of PRMT1 occurred at high substrate
concentrations when using an ‘RGA’-containing fibrillarin-based peptide versus one
housing an ‘RGG’ sequence. Together, these data indicate how the composition of the
substrate sequence can alter the extent that a particular substrate is methylated. Next, I
examined the importance of an interaction between the substrate and the conserved THW
loop among PRMTs by mutating two residues (H293 and W294 to an alanine on
PRMT1) and assessing the activity of each with several substrates. In another project, I
showed how the AdoMet/AdoHcy ratio present in healthy and diseased individuals
affected PRMT1 activity. Finally, I determined the Ki for a fibrillarin-based peptide
containing ADMA.
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CHAPTER 2
LITERATURE REVIEW

METHYLATION
After DNA is transcribed into mRNA in the nucleus, processed mRNA can be
translated into amino acids by the ribosomal complex in the cytosol. After the emerging
string of amino acids from the ribosome is folded into a three-dimensional protein, this
protein can then be post translationally modified. While an organism’s genome has the
ability to code for a variety of proteins, post translational modifications such as
phosphorylation, acetylation, glycosylation, and methylation enable organisms to expand
upon their limited genomes.
Methylation requires the presence of 1) a methyl donor such as S-adenosyl
methionine (AdoMet/SAM) or tetrahydrofolate (THF) and 2) a methyl acceptor. AdoMet
is the second most widely used enzyme substrate in the cell [1]. The preference for
AdoMet over other methyl donors such as THF results from the favorable energetics of
the AdoMet-dependent methyltransferase reaction (-17 kcal/mol). This amount of energy
is more than twice the amount released during ATP hydrolysis. This energy does not
come without a cost.

The de novo biosynthesis of AdoMet costs the cell twelve

equivalents of ATP making AdoMet the most expensive metabolic compound on a per
carbon basis [2]. (Note, recycling AdoMet from AdoHcy costs the cell only 1 ATP.)
Thus far, five families of AdoMet-dependent methyltransferases have been
identified (Classes I through V) suggesting five independent evolutionary paths to
methyltransferases [3]. Classes I and V contain most of the protein methyltransferases
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while the other classes are comprised of small molecule, DNA, and RNA
methyltransferases. Although enzymes from the different families have diverse structural
requirements for the way in which they bind AdoMet, they all share the same basic
mechanism (Fig. 2-1). First, the positively charged sulfur moiety of AdoMet causes the
S-CH3 bond to be polarized. This polarization facilitates the nucleophilic attack of the
“+CH3” group by an electron rich nitrogen, oxygen, or carbon target atom. Ultimately,
the electrons push towards the sulfur moiety in AdoMet resulting in the formation of the
methylated target atom and S-adenosyl homocysteine (AdoHcy/SAH) [4].

target atom
:B

:

XHn

H3C

O

Adenine

H

HO
OH
H3N+

-

COO

S-adenosylmethionine
(AdoMet)

H

δ+

C

δ−

S:

O

Adenine

S

:

:

δ−

X

CH3

:

S+

XHn-1

+
HO

H

OH
H3N+

-

COO

S-adenosylhomocysteine
(AdoHcy)

Fig. 2-1. General reaction mechanism for AdoMet-dependent methyltransferases. A
general base (B:) abstracts a proton from the target atom (X=N, O, or C) prior to or
during the course of the SN2 reaction mechanism. A transition state is forms from the
nucleophilic attack of the polarizable target atom onto the methyl group carbon of
AdoMet. Ultimately, electrons push towards the sulfur moiety in AdoMet resulting in the
formation of AdoHcy and X-CH3.
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Among protein methyltransferases, nitrogen is the most dominant nucleophile.
N-methylation of exposed lysine and arginine residues does not alter the positive charge
of the amino acid, but it does increase the hydrophobicity and steric bulk of the residue
which can disturb the way in which the modified protein interacts with certain biological
molecules. Lysines can be mono, di, or tri-methylated, whereas the guanidino nitrogens
of arginine can be mono- or dimethylated.

In addition to lysine and arginine, the

imidazole ring of histidine and the side chain amide nitrogens of glutamine and
asparagine can be methylated. The methylation of protein histidine, glutamine, and
asparagine residues is not readily reversible under physiological conditions. On the other
hand, methyl groups transferred onto the nitrogens of DNA bases are readily removed
through enzymatic oxygenation resulting in the formation of formaldehyde and the
starting base [5].
In addition to nitrogen, proteins can also be methylated on oxygen atoms to form
methyl esters. O-methylation of surface protein aspartates and glutamates neutralizes the
negative charge on the carboxylate side chain and adds hydrophobicity to the protein
surface. This modification is readily reversible, and the hydrolysis of protein methyl
esters is often used as a signal during bacterial chemotaxis [6].
Although nitrogen and oxygen containing amino acid side chains are most
commonly methylated, certain Archaeal methanogenic bacteria methylate proteins on
electron-rich carbon and sulfur atoms. To date, methanogenic bacteria are the only
organisms on earth that have the ability to C-methylate protein arginyl and glutamyl side
chains. The methanogenic enzyme methyl-coenzyme M reductase, which helps catalyze
the last step in the formation of methane, was shown crystallographically to contain C-
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methylated arginine and glutamine side chains, an N-methylated histidine, and an Smethylated cysteine residue [7].

The function of these peculiar modifications in

methanogens is unknown.

PROTEIN ARGININE METHYLATION
Arginine residues were first shown to contain methyl groups in 1967 [8]. Since
then, arginine methylation has been shown to be a vital, relatively abundant
posttranslational modification.

Two percent of all protein arginine residues are

asymmetrically dimethylated in rat liver nuclei [9], and approximately 12% of all
arginine residues isolated from heterogeneous nuclear ribonucleoproteins (hnRNPs) are
asymmetrically dimethylated [10].
The enzymes responsible for methylating protein arginine residues in both the
nucleus and cytoplasm are the protein arginine methyltransferases (PRMTs). Thus far,
eleven PRMT isoforms have been identified in humans with homologues present in yeast,
protozoa, Caenorhabditis elegans, Drosophila melanogaster, plants, and fish [11]. The
breadth of these enzymes indicates the vital biological importance of arginine
methylation across the plant and animal kingdoms. The significance of protein arginine
methylation has also been demonstrated in PRMT1 null mice that died early during
embryonic development [12] and PRMT4 null mice that showed incorrect cell
differentiation [13].
PRMTs perform the general SN2 reaction mechanism characteristic of most
AdoMet-dependent methyltransferases where an active site glutamate residue is proposed
to abstract a proton from the substrate arginine residue (see Fig. 2-1). Methylation of
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positively charged protein-arginine residues occurs via the attack of the terminal
nucleophilic guanidino nitrogen onto the methyl group of AdoMet forming monomethyl
arginine (MMA) and AdoHcy (Fig. 2-2). PRMTs can transfer another methyl group onto
MMA resulting in the dimethylation of certain protein-arginine residues. Type I PRMTs
(PRMT1, 3, 4, 6, and 8) transfer a second methyl group onto the previously modified
guanidino nitrogen to form asymmetric dimethylarginine (ADMA). Type II PRMTs
(PRMT5 and 7) transfer another methyl group to the unmodified guanidino nitrogen
creating symmetric dimethylarginine (SDMA).

CH 3
HN +

CH 3
NH

NH
CH 3

+

H 2N

+

NH 2

Type I & II PRMTs
NH

H2N

Type II

SDMA

NH

AdoHcy
NH

AdoMet

MMA

AdoMet
AdoHcy

AdoMet
AdoHcy
CH 3

Type I
+

H2N

N
CH 3
NH

ADMA

Fig. 2-2. Reactions catalyzed by PRMTs. PRMTs catalyze the S-adenosylmethionine
(AdoMet) dependent methylation of a protein substrate arginine residue to form
monomethyl arginine (MMA). Type I methyltransferases, PRMT1, 3, 4, 6, 8, and 10
dimethylate arginine asymmetrically to form asymmetric dimethyl arginine (ADMA).
Type II methyltransferases, PRMT5, 7, and 9 catalyze the formation of symmetric
dimethyl arginine (SDMA) where each guanidino nitrogen is modified.
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PROTEIN ARGININE METHYLTRANSFERASE FAMILY
Despite the discovery of protein arginine methylation thirty years ago, the PRMTs
were not cloned until recently.

Thus far, eleven PRMT isoforms have been identified

(see Fig. 2-3). The most predominant mammalian type I methyltransferase, PRMT1, was
discovered based on its homology to the yeast arginine methyltransferase Hmt1/Rmt1
[14]. PRMT2 was recognized due to its homology to PRMT1 [15] while PRMT3 was
isolated as a PRMT1 binding partner in a yeast two-hybrid screen [16]. PRMT4/CARM1
was identified in a yeast two-hybrid screen bound to the p160 steroid receptor coactivator
GRIP1 [17]. PRMT5 was cloned as a Jak2-binding protein [18]. PRMT6 and PRMT8
were identified based on their homology to other type I PRMTs [19 and 20], and PRMT7
was discovered in a genetic screen looking for suppressor elements conferring resistance
to a topoisomerase II inhibitor [21]. PRMT9 was identified through a protein database
search using a consensus query sequence corresponding to the conserved PRMT AdoMet
binding domain. However, PRMT9 is structurally distinct from all other known PRMTs
[22]. PRMT10, a type I PRMT, was identified in plants and was shown to preferentially
asymmetrically dimethylate histone H4 in vitro [23]. PRMT11 was identified most
recently through a yeast two-hybrid screen bound to the methyl-DNA-binding 7 (MBD7)
protein in plants [24].
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Fig. 2-3. Protein arginine methyltransferases. PRMT1-PRMT11 are aligned based
upon their characteristic THW loop (in black) and AdoMet methyltransferase motifs I,
post I, post II, and post III (also in black). PRMT2 has an SH3 domain while PRMT3 has
a Zn2+ finger domain. PRMT7 and PRMT10 contain a repeat of the methyltransferase
motifs. PRMT11 has an F box domain near the N-terminus.

PRMT SUBSTRATES
With PRMTs present throughout the plant and animal kingdoms, the significance
of protein arginine methylation is evident. Yet, the methyl arginine proteome has only
recently begun to be characterized using mass spectrometry techniques [25], and the
substrate specificities of the different PRMT isoforms remain ill-defined. In general,
PRMTs methylate arginines located in glycine arginine rich (GAR) areas of proteins in
‘RGG’ or ‘RXR’ motifs.

Type I methyltransferases (PRMT1, 3, 6, and 8) mainly

methylate arginines located within GAR sequences. PRMT4, on the other hand, displays
a different degree of specificity and does not typically methylate GAR sequences. Type
II methyltransferases, PRMT5 and 7, methylate isolated arginines as well as arginines
within GAR motifs. PRMT9 has been shown to symmetrically dimethylate maltose
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binding protein (MBP) [22] which is also a substrate of PRMT5 (Fig. 2-4). PRMT10
is a type I PRMT that asymmetrically dimethylates histone H4 in vitro [23]. Finally, a
cell line lacking PRMT11 mRNA exhibited reduced levels of proteins with
asymmetrically dimethylated arginines, suggesting that PRMT11 is a type I PRMT [24].

PRMT1
CIRP
EWS
FGF-2
Fibrillarin
Histone H4
hnRNP A1
hnRNP A2
hnRNP K
hnRNP R
ILF3
Mre11
NIP45
Nucleolin
p1 37GP1
PABPII
RBP58
RNA helicase A
SAF-A
SAMT1
Sam68
SPT5
TAFII68
TLS/FUS
ZF5

PRMT3
Fibrillarin
PABPN1
rpS2

PRMT6
Fibrillarin
HIV tat
PRMT6

PRMT4
Histone H3
HuR
PABP1
p300/CBP
Sm B/B'
TARPP

PRMT7
Fibrillarinpeptide
Sm proteins
PRMT8
GAR peptide

PRMT5
PRMT9
Collin
Histone H2A MBP
Histone H3
PRMT10
Histone H4
LSm4
Histone H4
MBP
Sm B/B'
Sm D1
PRMT11
Sm D3
MBD7
SPT5

Fig. 2-4. PRMT substrates. Protein substrates are listed underneath the PRMT
isoform that performs the modification. Many arginine methylated proteins have been
identified since using mass spectrometry [25]; however, the enzyme responsible for the
methylation remains unknown. Abbreviations are as follows: CIRP, cold inducible RNA
binding protein; EWS, Ewing Sarcoma; ILF3, interleukin enhancer binding factor 3;
TLS/FUS, translocated in liposarcoma; ZF5, Zn2+ finger 5; SAMT1, substrate of arginine
methyltransferase 1; TARPP, thymocyte cyclic AMP-regulated phosphoprotein; LSm4,
Sm-like protein 4; MBP, maltose binding protein, MBD7, methyl-DNA binding protein
7. PRMT2 has no reported activity.
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Of the eleven mammalian PRMT isoforms, PRMT1 predominates performing
an estimated 85% of all protein arginine methylations in vivo [26].

Most PRMT1

substrates are methylated at multiple sites within the same glycine arginine rich region of
proteins such as fibrillarin [27], heterogeneous nuclear ribonuclear proteins (hnRNPs)
[28], and Sam68 [29]. In addition to ‘RGG’, ‘RXR’ motifs located on the surface of the
Poly(A)-binding protein II (PABPII) are also modified by PRMT1 [30]. Although the
predominant feature of known PRMT1 protein substrates is a glycine and arginine rich
region, PRMT1 has also been shown to specifically methylate a single arginine residue
on the histone H4 tail that is not embedded in an ‘RGG’ or ‘RXR’ motif [31], indicating
that PRMT1 substrates are not limited to proteins bearing ‘RGG’ and ‘RXR’ sequences.
Several recent studies have helped identify how PRMT1 recognizes its substrates.
First, acidic surface residues along the substrate binding groove of PRMT1 have been
shown experimentally to be important for PRMT1 substrate binding through a pull down
assay [32]. Complementing this finding, positively charged residues on the substrate
distal from the active site were shown to be important for PRMT1 catalysis [33]. The Nterminus of PRMT1 was also shown to affect substrate specificity and activity [34].
Finally, eleven new PRMT1 substrate motifs that go beyond the typically methylated
‘RGG’ and ‘RXR’ motifs were identified using a fibrillarin-based peptide library screen
[35]. This suggests that the PRMT substrate proteome is larger than previously thought.

STRUCTURE OF PRMT1
What is it about the PRMT1 active site that allows for the select modification of
certain arginines but not others? In 2003, rat His-PRMT1 was co-crystallized with

19
AdoHcy and R3, a 19 amino acid peptide substrate derived from fibrillarin
(GGRGGFGGRGGFGGRGGFG) [36] (Fig. 2-5, A).

Due to a lack in observable

electron density for R3, few inferences could be made concerning the substrate
specificity of PRMT1. The crystal structure depicted three acidic substrate binding
grooves (P1, P2, and P3) on the surface of PRMT1 that have the ability to interact with
substrate arginine residues (Fig. 2-5, B). Except for the substrate arginine in the active
site substrate binding groove (P1), the electron density of the side chains from all other
18 amino acids of the R3 peptide was not observed and any important PRMT1-peptide
side chain interactions went undetected (Fig. 2-5, A). Fortunately, the majority of the
carbon-nitrogen peptide backbone of R3 was resolved. Because of this, the authors stated
that the substrate could be fitted equally well in either linear orientation into the active
site. Electron densities from the four glycines that flank the central arginine were not
observed and created a sequence gap in the model. This lack in observable substrate
electron density suggests that the sequence surrounding the substrate arginyl group does
little to govern PRMT1 substrate selection. Our recent studies suggest otherwise [35].
Importantly, the crystal structure provided much insight into the reaction
mechanism. First, the structure revealed that two active site glutamates (E144 and E153)
stabilize the substrate arginine guanidino nitrogen through hydrogen bonding. Upon
mutating these residues to non-acidic glutamines, PRMT1 activity reduced 3,000 fold.
Second, this study revealed that PRMT1 dimerization was essential for AdoMet binding
and that enzymatically active PRMT1 exists as a homodimer consisting of two 42 kDa
subunits.
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A.

B.

P3

P1

P2
Fig. 2-5. The Crystal Structure of Rat PRMT1. (A) PRMT1, shown in gray, was
crystallized as a ternary complex with R3 (hot pink) and AdoHcy (red). The guanidino
nitrogens of the substrate arginine residue (shown in ball and sticks) are oriented toward
the sulfur moiety in AdoHcy (yellow). While most of the R3 peptide backbone was
observed in the crystal structure, the electron densities from the other R3 peptide side
chains were not observed. (B) This surface representation of PRMT1 highlights the
negatively charged surface amino acid residues (green) located along the substrate
binding grooves P1, P2, and P3. The P2 and P3 grooves are found on one protein face
while the P1 groove is on the opposite face of PRMT1. The R3 peptide backbone
(colored pink) is situated in the P1 substrate binding groove. PDB ID=10R8
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LOCALIZATION OF PRMT1
PRMT1 is found in the nucleus, the cytoplasm, and has most recently been
proposed to localize to the plasma membrane. Interestingly, PRMT1 has the ability to
heterodimerize with PRMT8, an isoform that is highly homologous in sequence to
PRMT1. PRMT8 has a myristolation site and has been shown to localize to the cell
membrane when modified by a fatty acid chain. Therefore, PRMT1 which has already
been shown to shuttle between the nucleus and the cytoplasm [37] has now been
proposed to localize to the plasma membrane upon the myristolation of its heterodimeric
counterpart, PRMT8 [20]. Clearly, the cellular distribution of PRMT1 and the diversity
of PRMT1-methylated protein substrates emphasize its physiological role as the
dominant PRMT in the cell.

MECHANISM OF PRMT1
In September 2008, the kinetic mechanism of PRMT1 was elucidated by
Thompson and coworkers [38]. They reported that human PRMT1 utilizes a rapid
equilibrium random sequential mechanism to methylate the histone H4 peptide. In this
type of reaction mechanism, the order of substrate (AdoMet and the unmodified peptide)
binding to the enzyme and product (AdoHcy and the methylated peptide) release from the
enzyme does not matter.
Next, the mechanism was examined further.

Does PRMT1 1) perform

dissociative methylation wherein the monomethylated species is released before
rebinding and being dimethylated, or 2) perform processive methylation wherein the
substrate binds and is mono- and dimethylated sequentially without releasing the
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intermediate? Interestingly, PRMT1 was found to catalyze the dimethylation of the
histone H4 peptide in a partially processive manner [38].

PRMT1 catalyzed the

production of MMA and ADMA containing H4 peptides in approximately equimolar
amounts, even in the presence of excess unmethylated peptide substrate. This ruled out a
fully processive mechanism in which the concentration of the monomethylated
intermediate does not rise above the concentration of the enzyme. Additionally, the
monomethylated histone H4 peptide was not preferred over the unmodified peptide [33].

BIOLOGICAL IMPORTANCE OF PRMTs
PRMTs play important roles in biology, yet the biological consequence of protein
arginine methylation is not fully understood.

Studies have shown that PRMTs are

important not only for the proteins they methylate, but also for the response that the
modified protein elicits in the cell.

PRMT activity has been implicated in RNA

processing, signal transduction, DNA repair, transcriptional regulation (reviewed in [11]),
viral infection [39], chromatin remodeling [40], and neuronal cell differentiation [41].
Arginine methylation also regulates transcription initiation and elongation.
Specifically, PRMT4 methylates the transcription factor CBP/p300 [42] which inhibits its
interaction with the p160 coactivator glucocorticoid receptor interacting protein (GRIP1)
in vitro and in vivo [43]. Also, methylation of the transcription elongation factor SPT5
by PRMT1 and PRMT5 regulates its interaction with RNA polymerase II and may be
involved in regulating the transcriptional elongation properties of SPT5 in response to
viral and cellular factors [44].

Although PRMT1-PRMT11 have unique biological

functions (summarized in Table 2-1), arginine methylation ultimately regulates these and
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other biological processes at the molecular level by altering biomolecular interactions
such as 1) protein-protein interactions, 2) protein-RNA interactions, and 3) protein-DNA
interactions [45].

PRMT
PRMT1
PRMT2
PRMT3
PRMT4
PRMT5
PRMT6
PRMT7
PRMT8
PRMT9-11

Table 2-1 Biological functions of the PRMT family
Biological Function
Transcriptional activation (H4R3), transcriptional elongation, DNA
repair, signaling, chromatin remodeling, neuronal cell differentiation
Viral infection, apoptosis, transcriptional coactivator, nuclear retention
Ribosome assembly
Transcriptional activation (H3R2, H3R17, H3R26), chromatin
remodeling, muscle differentiation, T cell development, tumorigenesis
Transcriptional repression (H3R8 and H4R3), transcriptional elongation,
RNA processing, signaling, mitosis, muscle and germ cell differentiation,
tumorigenesis, chromatin remodeling
HIV replication, DNA repair
Imprinting in male germ cells (H4R3)
Involved in the somatosensory and limbic systems
Unknown

Arginine (R) residues modified by each PRMT on either histone H3 or histone H4 are
indicated in parenthesis.

1. Protein-Protein Interactions
First, protein arginine methylation alters protein-protein interactions by either
blocking or facilitating contact between proteins [46]. In particular, arginine methylation
can disrupt the formation of Asp-Arg salt bridges between proteins. For example, an
arginine residue in Fyn (a protein involved in signal transduction and host cell activation)
hydrogen bonds to an aspartate on the human immunodeficiency virus-1 (HIV-1) Nef
protein stabilizing the interaction between the two proteins. Arginine methylation of Fyn
disrupts the Asp-Arg salt bridge and blocks further interactions between the two proteins
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[47]. Another Asp-Arg salt bridge is disrupted when the adaptor protein Sam68 is
methylated by PRMT1. Arginine methylated Sam68 can no longer associate with sarc
homology 3 (SH3) domain containing proteins; however, it can still interact with proteins
with WW (two tryptophan) domains [48]. Finally, arginine methylation also has the
ability to disrupt key pi-cation interactions. Methylation of an arginine residue on the
KIX domain of the CREB-binding protein (CBP)/p300 blocks a key pi-cation interaction
and ultimately CREB activation by distrupting the interaction between the KIX domain
of CBP and the kinase inducible domain (KID) of CREB [49].
Other protein interactions are facilitated by arginine methylation.

PRMT1

methylates NIP45, a nuclear factor of activated T-cells (NF-AT) coactivator, and
facilitates its interaction with NF-AT.

This interaction promotes cytokine gene

expression [50] and helps mediate the immune response. Arginine methylation also
strengthens interactions between the spinal muscular atrophy gene product, SMN, and
certain small nuclear ribonucleoproteins (SmB/B’, SmD1, and SmD3) [51]. When the Cterminus of SmB and SmD are methylated, their association with SMN is enhanced [52].
In fact, the symmetric dimethylation of arginine residues in Sm proteins by PRMT5 and
PRMT7 facilitates the assembly of small nuclear ribonucleoprotein particles [53].

2. Protein-RNA Interactions
Second, protein arginine methylation affects interactions between proteins and
ribonucleic acids. The glycine arginine rich hnRNP proteins A1, A2, K, R, and U that
assist in the processing and folding of RNA during mRNA translation are highly
modified by the PRMTs [28]. Arginine methylation of hnRNP A1 decreases its ability to
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bind RNA [54]. In addition to the hnRNPs, Sam68 and Hu antigen protein R (HuR)
have arginines that hydrogen bond to the secondary and tertiary structures of RNA.
Arginine methylation has the ability to disrupt certain protein-RNA interactions by
preventing hydrogen bonding and/or sterically hindering van der Waals interactions [55].
Other studies have shown that arginine methylation does not significantly affect proteinRNA interactions [56].

So far, the effect of arginine methylation on protein-RNA

interactions remains unclear.

3. Protein-DNA Interactions
In 1967, it was recognized that histones were substrates of methyltransferases [8],
and now it is understood that both types of PRMTs methylate histones. In the nucleus,
DNA is packaged around histone protein octamers forming higher ordered structures
known as chromatin. Histone tails that point away from the protein octamer can be
highly post-translationally modified by methylation of arginines; acetylation,
methylation, and ubiquitination of lysine residues; and phosphorylation of serine and
threonine residues.

These modifications regulate the tightness of the histone-DNA

interaction which ultimately mediates dynamic changes in gene function and expression
[57]. Therefore, histone-DNA interactions and the proteins that modify histones are vital
to the genetic stability of the organism. Rett syndrome and Rubinstein-Taybi syndrome,
inherited developmental disorders characterized by physiological deformities and a loss
of developmental skills, result from the deregulation of gene transcription caused by
altered histone-DNA interactions [58].
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Both type I and type II PRMTs have been shown to methylate histones in vitro.
PRMT4 methylates three arginine residues on the histone H3 tail while PRMT5
methylates a single arginine (Arg 3) on both the histone H2A and H4 tails [59]. PRMT1
has also been shown to dimethylate arginine 3 in H4 both in vitro and in vivo [40]. In
fact, arginine methylated H4 has been shown to be a better substrate than unmodified H4
for the histone acetyltransferase p300. Thus, arginine methylation of H4 facilitates lysine
acetylation of H4 by p300 which ultimately stimulates gene transcription [60].
In addition to histones, other protein-DNA interactions are modulated by arginine
methylation. High mobility group proteins (HMGs) modulate chromatin structure and
transcription. HMGA1a is a PRMT1 substrate that has three positively charged motifs or
AT hooks that bind DNA.

These AT hooks are rich in RG sequences that once

methylated may disrupt the interactions between the HMG protein and DNA [61]. An
increase of HMGA1a arginine methylation could be related to heterochromatin and
chromatin remodeling of apoptotic cells [62].

REGULATION OF PRMTS AND ARGININE
METHYLATION
1. Regulation of PRMTs
PRMT activity is regulated by a variety of factors. Several isoforms of the PRMT
family have different mRNA splice variants that when translated can lead to a set of
proteins with unique activities and/or substrate specificities. PRMT1, for example, has
seven N-terminal splice variants in humans [15] that have different activity and substrate
specificity [34]. In addition to splice variants, the cellular localization of the PRMTs and
the availability of their protein substrates dictate the level of protein arginine methylation
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that can occur. Finally, PRMT methylation is regulated by protein interaction partners.
For example, PRMT1 methylation is stimulated towards select substrates in vivo by the
binding of its two protein interaction partners, BTG1 and TIS21/BTG2 [14]. Another
protein that interacts with BTG1, hCAF1 (CCR4-associated factor 1), has been shown to
regulate PRMT1 activity in a substrate-dependent manner [63].
PRMTs are also regulated by their oligomeric status.

Monomeric PRMTs

combine to form biologically active homodimers that can bind AdoMet and methylate
protein substrates [36]. In addition, PRMT1 and PRMT8 have the unique ability to
heterodimerize. Depending on the abundance of the PRMT1-PRMT8 heterodimer in
vivo, the concentration of available PRMT1 monomers and the amount of active PRMT1
homodimers in the cell would be reduced. Although this could be a very important
regulatory mechanism of PRMT1, it remains unclear how the PRMT1-PRMT8
heterodimer affects the substrate selection or activity of PRMT1.

2. Regulation of arginine methylation
Once a protein is arginine methylated, can it then be demethylated? Protein
arginine demethyliminase 4 (PAD4) has been shown to demethyliminate methylarginine
residues in histones and reverse the biological consequence of methylation [64]. PAD4 is
not a true demethylase, however, because it converts MMA into citrulline instead of
arginine (Fig. 2-6). Recently, a true arginine demethylase was discovered. The Jumonji
domain-containing 6 (JMJD6) protein is a JmjC-containing iron- and 2-oxoglutaratedependent dioxygenase that was shown to reverse the effects of protein arginine
methylation on histones H3 and H4 in both biochemical and cell-based assays [65].
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Since JMJD6 acts on mono- and dimethylated histone proteins only, is the effect of
protein arginine methylation reversible on other methyl-arginine containing proteins in
the cell? The characterization of JMJD6 will help define how arginine methylation is
regulated on histone proteins and may lead to the identification of other true protein
demethylases.
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Fig. 2-6. Reversing the effects of arginine methylation. PRMTs methylate protein
arginine residues to form MMA (shown here), ADMA, and SDMA. PAD4, a protein
arginine demethyliminase, converts MMA into citrulline but not back into arginine.
JMJD6 is a true protein demethylase that targets methylated arginine residues on histone
proteins. R=(CH2)3CH(NH3+)COO-

PROTEIN ARGININE METHYLATION & DISEASE
Although PRMTs are vital to normal development and function [12], arginine
methylation also leads to disease. Arginine methylation has mainly been implicated in
the progression of 1) cardiovascular disease [66] and stroke [67], 2) multiple sclerosis,
and 3) spinal muscular atrophy [11], and 4) cancer [68].

Fortunately, the cellular

concentration of the PRMT inhibitor AdoHcy regulates methyltransferase activity.
PAD4 and JMJD6 reverse the effects of protein arginine methylation by demethylating
methylated protein arginine residues.

Finally, the activity of dimethylarginine

dimethylaminohydrolase (DDAH) helps keep free MMA and ADMA levels in check.
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1. Cardiovascular Disease
Several studies have shown that free ADMA, a downstream product of the
PRMTs, has a clear role in cardiovascular disease (reviewed in [66]) and stroke [67] by
serving as an endogenous inhibitor of nitric oxide synthase [69]. When proteins that have
been modified by the PRMTs are sent to the proteasome and degraded, free MMA,
SDMA, and ADMA are released. MMA and ADMA specifically inhibit inducible nitric
oxide synthase (iNOS). Since the nitric oxide produced by NOS acts as a vasodilator
maintaining cardiovascular health, the inhibition of NOS contributes to atherosclerosis
[70].

Free MMA and ADMA levels are controlled by dimethylarginine

dimethylaminohydrolases (DDAHs). Although DDAHs keep the methylarginine levels
in check, misregulation of DDAH or the hyperactivity of PRMTs may contribute to
cardiovascular disease [71]. In fact, PRMT1 has been shown to be overexpressed in
myocardial tissue taken from coronary heart disease patients [72].
Numerous studies have shown a relationship between elevated ADMA
concentration and cardiovascular disease (CVD).

Elevated ADMA concentration is

highly prevalent in hypercholesterolemia, hyperhomocysteinemia, diabetes mellitus,
peripheral arterial occlusive disease, hypertension, chronic heart failure, and coronary
artery disease (reviewed in [66]). Although these studies were case studies and did not
provide insight into exactly how ADMA was involved in promoting CVD, the
observation that ADMA levels increase early in the development of atherosclerosis
suggests that ADMA has the potential to be not only a marker but a mediator of vascular
lesions [73]. In addition to CVD, elevated levels of ADMA increase the risk for ischemic
stroke in the elderly [67].
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2. Multiple Sclerosis
PRMT5 methylation of myelin basic protein (MBP) is involved in the progression
of multiple sclerosis (MS), a demyelination disease of the central nervous system that
targets myelin sheaths that surround and protect nerve axons. The demyelination of this
protective coat contributes to the pathogenesis of MS. A recent study showed that myelin
basic protein, which accounts for 35% of all protein in the myelin sheath, is a PRMT5
substrate.

Arginine 107 on all three MBP isoforms was found to be mono- and

symmetrically dimethylated in MS patients, and increased arginine methylation of MBP
was shown to precede symptoms of MS in mice [74]. In addition, methylated MBP may
also serve as an autoantigen, as is the case with methylated Sm and collin in lupus
erythematosus [75].

3. Spinal Muscular Atrophy
Arginine methylation also plays a role in spinal muscular atrophy (SMA), an
autosomal recessive disease that results from deletions or loss-of-function mutations
within the SMN1 gene. A lack in the survival motor neuron (SMN) protein leads to
motor neuron axonal guidance failure contributing to the progression of SMA [76]. SMN
has been shown to be required for proper ribonucleoprotein assembly, a process that also
requires arginine methylation [77]. Recently, point mutations were identified in the SMN
Tudor domain in patients with SMA. This domain normally associates with SDMA on
spliceosomal Sm proteins D1, D3, and B/B’ [50] aiding in the proper localization of the
Sm proteins. Mutations in the Tudor domain in SMA patients cause the mislocalization
of the Sm proteins and the improper assembly of ribonucleoproteins [78].
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4. Cancer
PRMTs have also been directly linked to oncogenesis and may act as novel
therapeutic targets in human cancer.

PRMT1 has been shown to be an essential

component of the mixed lineage leukaemia (MLL) oncogenic transcriptional complex
that has both histone acetylation and H4-R3 methylation activities. An oncogenic MLL
fusion complex that mediates step-wise histone modifications may facilitate an open
chromatin structure for active gene expression and promote oncogenic transformation. In
fact, the direct fusion with MLL to PRMT1 or SAM68, a bridging molecule in the
complex for PRMT1 interaction, enhanced self-renewal of primary haematopoietic cells.
Furthermore, the specific knockdown of SAM68 or PRMT1 expression suppressed MLLmediated transformation. Taken together, PRMT1 plays an essential role in a novel
protein arginine methyltransferase-dependent oncogenic pathway [68].
PRMTs are also known coactivators for nuclear receptors and are likely to be
overexpressed in hormone-dependent cancers such as prostate and breast cancer. In fact,
an increase in PRMT4 expression correlates with androgen independence in human
prostate carcinoma [79]. Importantly, however, small molecules that inhibit both PRMT1
and PRMT4 suppress estrogen and androgen receptor-mediated transcriptional activation
[80].

CONCLUSION
Protein arginine methyltransferases play an important role in a diverse set of
biological processes.

PRMTs methylate a variety of protein substrates including

histones, RNA-binding proteins, and various enzymes. Protein arginine methylation
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alters protein-protein, protein-RNA, and protein-DNA interactions. PRMT1 performs
over 85% of all protein arginine methylation and is critical for survival. Yet, PRMTs
have been linked to heart disease, spinal muscular atrophy, multiple sclerosis, and cancer.
While PRMT biology has remained in the forefront, much of the biochemistry for this
class of enzymes has received little attention until recently. Once the substrate specificity
and mechanism of PRMT1 become clear, more specific, novel therapeutic targets can
then be developed. Inhibiting PRMT activity could potentially slow the progression of
cardiovascular disease and cancer in certain patients. It will be interesting to see how an
increased biochemical understanding these enzymes will impact biology and medicine.
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CHAPTER 3

AN ENZYME-COUPLED CONTINUOUS SPECTROPHOTOMETRIC ASSAY FOR
S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES1
ABSTRACT
Modification of small molecules and proteins by methyltransferases impacts a
wide range of biological processes. Here we report an enzyme-coupled continuous
spectrophotometric assay to quantitatively characterize S-adenosyl-L-methionine
(AdoMet/SAM)-dependent methyltransferase activity. In this assay, S-adenosyl-Lhomocysteine (AdoHcy/SAH), the transmethylation product of AdoMet-dependent
methyltransferases, is hydrolyzed to S-ribosylhomocysteine and adenine by recombinant
S-adenosylhomocysteine/5’-methylthioadenosine
3.2.2.9).

nucleosidase

(SAHN/MTAN,

EC

Subsequently, adenine generated from AdoHcy is further hydrolyzed to

hypoxanthine and ammonia by recombinant adenine deaminase (EC 3.5.4.2).

This

deamination is associated with a decrease in absorbance at 265 nm that can be monitored
continuously. Coupling enzymes are recombinant and are easily purified. The utility of
this assay was shown using recombinant rat protein arginine N-methyltransferase 1
(PRMT1, EC 2.1.1.125) which catalyzes the mono- and dimethylation of guanidino
nitrogens of arginine residues in select proteins. Using this assay, the kinetic parameters
of PRMT1 with three synthetic peptides were determined. An advantage of this assay is
the destruction of AdoHcy by AdoHcy nucleosidase, which alleviates AdoHcy product
1
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Cui, Z.S. Zhou, J.M. Hevel, An enzyme-coupled continuous spectrophotometric assay for Sadenosylmethionine-dependent methyltransferases. Anal. Biochem. 350 (2006) 249-255.
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feedback inhibition of S-adenosylmethionine-dependent methyltransferases. Finally,
this method may be used to assay other enzymes that produce AdoHcy, 5’methylthioadenosine, or compounds that can be cleaved by AdoHcy nucleosidase.
INTRODUCTION
S-Adenosyl-L-methionine (AdoMet/SAM)-dependent methyltransferases play an
important role in biological systems, including signal transduction, protein repair,
biosynthesis, chromatin regulation, and gene silencing [1,2]. Small molecule, RNA,
DNA, lipid, and protein methyltransferases exist [2-5]. More recently, data supporting
the idea that protein arginine methylation plays a more dynamic role in the histone code
has been put forth [6-9]. Defining how the protein methyltransferases work and what
determines which proteins/residues will become methylated is pivotal for understanding
the role these enzymes play in biology.
The majority of methyltransferase activity assays currently used are based on
radioactive labeling using the AdoMet substrate labeled with 14C or 3H [10-12]. This is
because there is very little detectable spectral change between the AdoMet substrate and
its

common

transmethylation

product, S-adenosylhomocysteine

(AdoHcy/SAH).

However, radioactive assays require subsequent separation of the product and substrate,
which is often time-consuming. Another problem associated with this technique is that in
many cases, the AdoHcy product acts as a potent feedback inhibitor to the
methyltransferase, adding to the overall margin of error experienced in determining its
kinetic parameters [13-16]. Two recently developed discontinuous assays make use of
recombinant coupling enzymes that hydrolyze AdoHcy to homocysteine, which is
detected by either chromogenic [15] or fluorescent [17] thiol-reactive reagents.

We report here a continuous enzyme-coupled photometric assay for AdoMet-
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dependent methyltransferases. As shown in Figure 3-1, AdoHcy can be converted to Sribosylhomocysteine and adenine by AdoHcy nucleosidase. Earlier studies demonstrated
that AdoHcy nucleosidase effectively cleaves the AdoHcy transmethylation product
[15,16], eliminating the error associated with product inhibition. The adenine product of
the reaction is then converted to hypoxanthine by adenine deaminase, resulting in an
absorbance decrease at 265 nm that can be easily detected by UV spectrometry. The
rapid and continuous detection of the conversion of substrate to product also helps to
improve the accuracy over discontinuous assaying. We demonstrate the utility of this
assay by characterizing the activity of recombinant rat PRMT1, a protein
methyltransferase known to methylate a variety of proteins including histone 4, fibrillarin
and RNA binding proteins (for a review, see [18]).
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Fig. 3-1.
Continuous assay scheme used to detect AdoMet-dependent
methyltransferase activity. AdoHcy is converted into adenine and S-ribosylhomocysteine
via AdoHcy nucleosidase. The deamination of adenine into hypoxanthine by adenine
deaminase is associated with a decrease in absorbance at 265 nm, which can be
monitored continuously using a spectrophotometer. Nu, nucleophile.

MATERIALS AND METHODS
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Materials
AdoMet p-toluenesulfonate salt and AdoHcy were purchased from Sigma.
Hypoxanthine was purchased from the California Foundation for Biochemical Research.
Amylose resin was purchased from New England BioLabs. Adenine was purchased from
Acros Organics.

Recombinant AdoHcy nucleosidase containing a histidine tag was

expressed and purified as previously described [19]. All other chemicals were of ACS
grade or better.
Expression and purification of
MBP-adenine deaminase
The DNA encoding Bacillus subtilis adenine deaminase was PCR-amplified from
the pHH1010 plasmid [20] and ligated into a pMAL-c2x plasmid vector (New England
BioLabs) between EcoR1 and SalI sites. Escherichia coli TB-1 cells were transformed
with the resulting plasmid and grown aerobically in 1 L LB broth at 37oC for 11 hours.
Expression of maltose binding protein (MBP)/adenine deaminase fusion protein was
induced with 0.8 mM IPTG for 10 hours. Cells were harvested by centrifugation and resuspended in ~30 mLs column buffer (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM
EDTA, and 0.2 mM DTT).

Cells were lysed via sonication using four 2 min

discontinuous cycles on ice using, and the cell debris and unbroken cells removed by
centrifugation at 55,000 x g, 4oC for 25 minutes. The supernatant was filtered through a
0.45 μm filter and incubated with 10 mL amylose resin slurry (New England BioLabs) at
4oC for 90 min with gentle agitation. After washing the resin with 30mL column buffer,
MBP-adenine deaminase was eluted in 5 mL fractions with column buffer containing 10

mM maltose. Fractions demonstrating >95% purity by SDS-PAGE were concentrated
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by Centricon-Plus Concentrators (30,000MWCO, Amicon) and the buffer exchanged to
column buffer as per the manufacturer’s instructions. The purified protein was stored at 80oC in 25% glycerol. Protein concentration was determined spectrophotometrically
using ε280nm=85,770 M-1cm-1. Approximately 18mg of purified protein was obtained
from 1L of broth.
Purification of His-PRMT1
The DNA encoding rat PRMT1 was PCR amplified from the GST-PRMT1 vector
with Pfu polymerase and ligated into a pET28b vector (Novagen) to yield an N-terminal
His-tagged PRMT1 construct. E. coli BL21(DE3) cells carrying the pET28b/PRMT1
plasmid were grown in LB broth at 37ºC. Protein expression was induced with 1.2 mM
IPTG for 5 h. Cells were harvested by centrifugation and resuspended in wash buffer (50
mM sodium phosphate pH 7.5 and 20 mM imidazole). Cells were lysed by sonication
using three 15s cycles and centrifuged at 100,000 x g at 4ºC for 1 h. The resulting crude
supernatant was incubated with Ni Sepharose™ High Performance resin (Amersham
Biosciences) for 4 h at 4ºC. The slurry was loaded into a 1.7 x 13 cm column, and the
flow through was collected. The column was washed with 65 mL wash buffer, and the
protein was eluted with 10 mL of wash buffer containing 250 mM imidazole. The eluate
was concentrated in Centricon-Plus Concentrators (30,000 MWCO, Amicon), the buffer
exchanged to 50 mM sodium phosphate buffer pH 7.5, and 10% glycerol was added to
the pure protein before storing it at -80ºC. Approximately 5.4 mg pure protein was
obtained from 1 L of broth and was >95% pure by SDS-PAGE.
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Procedure for the enzyme-coupled
photometric assay

Assays were performed in thermostatted 1cm quartz cuvettes at 37oC. Manganese
sulfate (MnSO4) was added to a final concentration between 10 to 1050 µM. Between 10
to 1050 µM of manganese, the same activity was observed. Manganese or other divalent
ions (e.g., zinc) are required for the deaminase activity ([21] and Dorgan & Zhou,
unpublished results). The assay involving the conversion of adenine to hypoxanthine was
run using adenine at various concentrations, 1050 µM MnSO4, and 0.02 µM adenine
deaminase buffered in 200 mM Tris pH 8.0. The assay monitoring the conversion of
AdoHcy to hypoxanthine contained 54.3 μM AdoHcy, 1050 µM MnSO4, 0.02 µM
adenine deaminase, and 17.3 nM AdoHcy nucleosidase buffered in 200 mM Tris pH 8.0.
Between 3.0 to 20.0 nM adenine deaminase, the same rate was observed. Measurement
of PRMT1 activity was performed in 50 mM sodium phosphate pH 7.0 with 168 µM
AdoHcy nucleosidase, 0.02 µM adenine deaminase, 10-1050 µM MnSO4, and various
concentrations of PRMT1. Use of AdoHcy nucleosidase at concentrations ranging from
10 nM - 168 μM yielded the same methyltransferase rate. Reactions were initiated with
differing amounts of peptide substrates as indicated in the figures.
Radioactive assay used to determine
PRMT1 activity
Methyltransferase assays were equilibrated at 37 ºC for 15 minutes before
initiating with 211 µM R3 peptide.

Each 65 µL reaction contained S-adenosyl-L-

[methyl-3H] methionine (specific activity 79 µCi/µmol, Amersham Biosciences), 4 µM
PRMT1, 250 µM AdoMet, 100 µM MnSO4, 0.02 µM adenine deaminase, 168 µM

AdoHcy nucleosidase, and 100 mM sodium phosphate pH 7.0. Aliquots of 10 µL were

50

spotted directly onto P81 paper (Whatman) under vaccum in a S&S Minifold® I Slot Blot
System (Schleisher & Shuell) at specific time points and washed three times with 500 µL
50 mM sodium phosphate buffer pH 7.5. After the filter paper dried, each piece was
placed in 5 mL Scintisafe™ cocktail (Fisher) and counted (Beckman LS 6500).
Internal tritium standards were used initially to examine counting efficiency;
however, we determined that the presence of protein had a profound effect on counting
efficiency. Instead, various volumes of the control reaction, which did not contain
peptide substrate, were spotted onto P81 membranes and counted. Linearity between
observed cpms and volume spotted was demonstrated. Counting efficiency was 4-6%
and all calculations were adjusted accordingly. Data were plotted against time and fitted
using linear regression.
High-performance liquid chromatograph (HPLC)
analysis of reaction products
HPLC analysis of the hypoxanthine product formed during peptide methylation
by PRMT1 was performed on an Apollo C-18 reverse-phase column (4.6 mm x 25 cm,
Alltech, Deerfield, Il).

The column was eluted with an isocratic mixture from 0-3

minutes of 100 mM ammonium bicarbonate (A) at pH 7.8 (90%) and methanol (B)
(10%). A gradient mixture was used from 3-8 minutes where the composition changed
from 90% A and 10% B to 10% A and 90% B. From 8-10 minutes a gradient mixture
was used and changed the composition from 10% A and 90% B to 90% A and 10% B.
Finally, an isocratic mixture was used from 10-15 minutes. A 1.0 mL/min flow rate was

used and the analytes (AdoMet, AdoHcy, adenine, and hypoxanthine) were monitored
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at 245 nm.
RESULTS AND DISCUSSION
Conversion of AdoMet to hypoxanthine
using the coupling enzymes
In order to yield valid kinetic parameters in the coupled assay, the coupled
enzymes used should not be rate limiting, so that the measured rate is determined solely
by the methyltransferase activity.

The kinetics for the conversion of adenine to

hypoxanthine via adenine deaminase were investigated first. Adenine absorbs maximally
at 260 nm with an extinction coefficient of 13,400 M-1 cm-1 [22]. Upon adding adenine
deaminase, an absorbance decrease at 265 nm was observed as adenine was converted to
hypoxanthine rapidly in a stoichiometric fashion (Fig. 3-2).

The kcat for adenine

deaminase in 100mM Tris pH 8.0 was 35.2 ± 0.92 sec-1. The difference spectrum shown
in Fig. 3-2B shows the maximal change in absorbance at 265 nm. In the presence of 13.3
μM adenine, concentrations of hypoxanthine ranging from 3.5 μM to 142 μM did not
inhibit adenine deaminase (data not shown).

Complete conversion of AdoHcy to

hypoxanthine using both the coupling enzymes, AdoHcy nucleosidase and adenine
deaminase, was accompanied by a similar absorbance change (data not shown). The
reaction, like that of adenine deaminase was found to be very rapid. The kcat for AdoHcy
nucleosidase in 100mM Tris, pH 8.0 was 4.12 ± 0.10 sec-1.

In comparison, most

AdoMet-dependent methyltransferases display kcat in the 0.016 sec-1 (1 min-1) range. The
two coupling enzymes are over 100-fold more active than most of the methyltransferases,
and thus are well suited for kinetic analysis described in this paper. The relationship
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between AdoHcy concentration and absorbance change at 265 nm was linear and
yielded a Δε265 of 6,700 ± 150 M-1cm-1 based on the ε260 of 15,400 M-1 cm-1 for AdoHcy
[22] (Fig. 3-3).

Fig. 3-2. (A) Absorbance change associated with the conversion of adenine to
hypoxanthine catalyzed by adenine deaminase over 5 minutes. The reaction mixture
contained 54.3 µM adenine, 1050 µM MnSO4, and 0.02 µM adenine deaminase buffered
in 200 mM Tris pH 8.0 and 37 ºC. The reaction was completed in 5 minutes. The arrow
indicates the decrease in absorbance at 265 nm with time. In (B) the spectrum of the
original solution of adenine (dotted line), the reaction at completion (bold solid line) and
difference spectrum (thin solid line) are shown.
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Fig. 3-3. Linear correlation between the absorbance change at 265nm and AdoHcy
concentration. The assay monitoring the conversion of AdoHcy to hypoxanthine was
performed using varying amounts of AdoHcy, 110 μM MnSO4, 28 nM adenine
deaminase, and 17.3 nM AdoHcy nucleosidase in 50 mM potassium phosphate pH 7.4.

Investigation of PRMT1 Activity Using
the Coupled Assay
We next investigated the proposed coupled methyltransferase assay using protein
arginine N-methyltransferase 1 (PRMT1) as our test enzyme and a peptide corresponding
to a 19-amino acid stretch of the in vivo PRMT1 protein substrate fibrillarin [23].
Initiation of the reaction with R3 peptide resulted in a decrease in absorbance at 265 nm
as in the coupling enzyme control reactions (data not shown). Figure 3-4 demonstrates
that the reaction rate was dependent upon methyltransferase concentrations. The rate
obtained with 2 μM PRMT1 using this continuous spectrophotometric assay with 211 μM
R3 (5.1 ± 0.2 μM AdoHyc formed/min) was verified by following [3H] incorporation
from S-adenosyl-L-[methyl-3H] methionine into the R3 peptide. The rate observed using
the radioactive assay was 4.9 ± 0.6 μM AdoMet consumed/min. Furthermore, the overall

reaction rates were independent on the coupling enzyme concentrations under our
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assays conditions. For instance, using a different preparation of PRMT1, the rates of
PRMT1 catalyzed methylation of 200 μM R3 peptide using 10 nM, 100 nM, and 1μM,
168 μM AdoHcy nucleosidase were 8.71 + 0.58, 9.05 + 0.10, 9.15 + 0.16, and 8.90 +
0.09, respectively.

Fig. 3-4. PRMT1 activity with R3 peptide is dependent upon PRMT1 concentration.
Reaction mixtures contained 59 µM AdoMet, 1050 µM MnSO4, 0.02 µM adenine
deaminase, 168 µM AdoHcy nucleosidase, and 211 µM R3 peptide in 50 mM potassium
phosphate pH 7.0. Reactions also contained 0 (closed circles) 3.9 (open circles), 7.7
(closed squares), 11.4 (open squares), and 14.9 (open triangles) µM PRMT1,
respectively. The inset shows that activity (ΔAbs 265 nm/min) is a function of protein
concentration.

Formation of hypoxanthine and the lack of intermediate build-up during
methylation of R3 by PRMT1 were confirmed using HPLC.

Standards of 80 μM

hypoxanthine, AdoMet, AdoHcy, and adenine were used for comparison, and were found
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to elute at 6.0, 8.5, 9.7, and 10.1 minutes, respectively. The formation of hypoxanthine
with a corresponding disappearance of AdoMet was observed in the assay, with no
detectable accumulation of the adenine or AdoHcy intermediates (Fig. 3-5).

Fig. 3-5. HPLC chromatogram to confirm reaction products. The top trace shows an
HPLC chromatogram of a mixture of authentic 80 µM samples of AdoMet, AdoHcy,
adenine (Ade), and hypoxanthine (Hxan). The middle trace is an HPLC chromatogram
of an aliquot of the reaction mixture prior to the addition of R3 peptide. The bottom trace
is the chromatogram of an aliquot of the reaction mixture when there was a change at 265
nm. An impurity from AdoMet (I) is seen in the bottom two traces. All traces were
monitored at 245 nm.

Using this assay we investigated the kinetic parameters of PRMT1 with R3
peptide from fibrillarin, an R3 analog peptide containing only one substrate arginine
residue (JMH1), and H4 peptide from histone 4 (Table 3-1). The R3 peptide contains
three possible arginine methylation sites, each capable of being mono and/or
dimethylated (6 potential methylation events). The JMH1 peptide lacks the additional 2

substrate arginine residues of R3 but maintains the positive charge at these positions.
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Although Vmax for R3 and JMH1 were similar, the Km for R3 could only be estimated to
be under 10 µM with this assay. A few peptide substrates have previously been used to
study

native

PRMT1

activity

and

have

yielded

values

for

Km of 0.2 - 60 μM [24, 25]. We believe that the dramatic increase in V/K for R3 is a
result of processive methylation at multiple arginine residues on the same peptide
substrate and are currently investigating this further. Compared to the JMH1 peptide, the
H4 peptide also contains only one arginine residue and demonstrated a Km,app of 745 + 70
μM and Vmax of 5.7 + 0.2 μM min-1. These results are consistent with reports that
substrates containing the RGG repeats, such as hnRNPA1 and fibrillarin, are better
(catalytic efficiency) PRMT1 substrates than histone 4 [26].

Peptide
R3
JMH1
H4

Table 3-1 Kinetic parameters for peptide substrates of PRMT1
Sequence
Km (μM)
Vmax (μM min-1)
<10
10.7 ± 0.8
AcGGRGGFGGRGGFGGRGGFG
450 ± 90
14.8 ± 1.7
AcKGGFGGRGGFGGK
745 ± 70
5.7 ± 0.2
AcSGRGKGGKGLGKGGAK

#Arg
3
1
1

Reactions were performed at 37º C in 50 mM potassium phosphate, pH 7.0, using 250
μM AdoMet, 4 μM PRMT1, 1050 μM MnSO4, 168 μM AdoHcy nucleosidase, 0.02
adenine deaminase, and various amounts of peptide. Initial rates (< 10% product
formation) were plotted and the data fit with the Michaelis-Menton equation using nonlinear regression. Vmax is expressed as μM AdoHcy min-1.

This study shows that this continuous assay can be used to characterize PRMT1
enzyme activity and is currently being amended to other AdoMet-dependentmethyltransferases (personal communication, Zhou). This assay system is similar to that
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described by Coward and co-workers in 1973 for catechol-O-methyltransferase [27]
which uses adenosine deaminase from Aspergillus oryzae to convert AdoHcy to Sinosylhomocysteine. However, the fungal adenosine deaminase has not been cloned, so
purification of the enzyme from Taka-Diastase is achieved with a multi-step/multicolumn procedure [28]. In comparison the present assay utilizes recombinant fusiontagged coupling enzymes that are easily purified in large amounts in a single day. More
importantly, the structures of S-inosylhomocysteine and S-adenosylhomocysteine only
differ by one atom (an oxygen versus a nitrogen), thus are very similar to each other.
Hence, the use of MTA nucleosidase and adenine deaminase avoids potential product
inhibition by S-inosylhomocysteine [29], the product of the fungal adenosine deaminase
reaction.
Despite the versatility of the assay, there are some potential limitations. For
instance, if the methyltransferase substrates strongly absorb around 265 nm, a narrow
range of absorbance changes will be available for activity measurement, and analysis will
be subject to the detection limits of the spectrophotometer. However, even with 1 mM
each of dATP, dCTP, dGTP, dTTP we were still able to detect the change of 35 μM of
AdoHcy to hypoxanthine (data not shown). Use of protein substrates exhibiting a strong
UV absorbance may not be feasible.

However, we were able to monitor

methyltransferase activity using the small in vivo PRMT1 protein substrate histone 4 (H4)
(Fig. 3-6). Several methyltransferases such as catechol O-methyltransferase (COMT)
display for the methyl acceptor of ~100 μM [27,31], but some enzymes display much
lower Km values. Determination of Km values lower than 10 μM may be limited by the
small absorption changes at low substrate concentrations, but may be performed using

progress curve analyses [32].
maximum rate.

In any case, the assay can be used to determine
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Finally, since AdoMet contributes to the background absorbance,

concentrations of AdoMet should be kept at or below 250 μM or smaller pathlength
cuvettes should be used to keep the total absorption around 265 nm within the linear
range of the spectrophotometer for accurate measurement.

Fig. 3-6. The continuous assay monitors methylation of histone 4 (H4) protein.
Reactions containing 250 μM AdoMet, 10 μM MnSO4, 10 nM AdoHcy nucleosidase,
0.02 μM adenine deaminase, and 0 (open circles) or 5.0 μM of purified [30] H4 protein
(closed circles) were equilibrated to 37 ºC for 10 minutes and initiated with 4 μM
PRMT1. The decrease in absorbance associated with the methylation of H4 was
monitored at 265 nm.

The

potential

for

this

assay

goes

further

than

AdoMet-dependent-

methlytransferases. The AdoHcy/MTA nucleosidase displays broad substrate specificity
cleaving not only AdoHcy and MTA, but also structural analogs with hydrophobic

residues at the C5 position [19,33] (Cornell, Dorgan, Zhou unpublished results). In
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addition, the adenine deaminase also shows broad substrate specificity for purine analogs
[34,35] (Dorgan, Zhou unpublished results). Therefore we predict that the assay will be
applicable to a number of other enzymes whose products can be cleaved by
AdoHcy/MTA nucleosidase to generate adenine or adenine analogs that can be used by
adenine deaminase. Two examples include polyamine synthesis and acylhomoserine
lactone synthesis, both of which produce MTA [36,37]. Other enzymes can be found in a
recent review on AdoMet utilizing this enzyme [38].
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CHAPTER 4
SUBSTRATE PROFILING OF PRMT1 REVEALS AMINO ACID SEQUENCES
THAT EXTEND BEYOND THE ‘RGG’ PARADIGM1

ABSTRACT
Protein arginine methyltransferase 1 (PRMT1) catalyzes the mono- and
dimethylation of certain protein arginine residues.

Although this posttranslational

modification has been implicated in many physiological processes, the molecular basis
for PRMT1 substrate recognition is poorly understood. Most modified arginine residues
in known PRMT1 substrates reside in repeating ‘RGG’ sequences. However, PRMT1
also specifically methylates Arg3 of histone H4 in a region that is not glycine-arginine
rich, suggesting that PRMT1 substrates are not limited to proteins bearing ‘RGG’
sequences. Because a systematic evaluation of PRMT1 substrate specificity has not been
performed, it is unclear if the ‘RGG’ sequence accurately represents the consensus target
for PRMT1. Using a focused peptide library based on a sequence derived from the in
vivo substrate fibrillarin we observed that PRMT1 methylated substrates that had amino
acid residues other than glycine in the ‘RX1’ and ‘RX1X2’ positions. Importantly, eleven
additional PRMT1 substrate sequences were identified.

Our results also illustrate that

the two residues on the N-terminal side of the modification site are important and need
not both be glycine. PRMT1 methylated the eukaryotic initiation factor 4A1 (eIF4A1)
protein, which has a single ‘RGG’ sequence. Methylation of eIF4A1 and the similar
1

Coauthored by W.L. Wooderchak, T. Zang, Z.S. Zhou, M. Acuña, S.M. Tahara, J.M.
Hevel, Substrate profiling of PRMT1 reveals amino acid sequences that extend beyond the
‘RGG’ paradigm, Biochemistry 47 (2008) 9456-9466.
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eIF4A3 could be affected using single site mutations adjacent to the modification site,
demonstrating the importance of amino acid sequence in PRMT1 protein substrates.
Dimethylation of the parent library peptide was shown to occur through a dissociative
mechanism. In summary, PRMT1 selectively recognizes a set of amino acid sequences
in substrates that extend beyond the ‘RGG’ paradigm.

INTRODUCTION
Protein arginine methyltransferase (PRMT) enzymes perform an important
biochemical reaction resulting in the methylation of many cellular proteins. PRMTs
transfer a methyl group from S-adenosyl methionine (AdoMet or SAM) onto the terminal
guanidino nitrogen of a protein arginine residue resulting in the formation of monomethyl
arginine (MMA) and S-adenosyl homocysteine (AdoHcy or SAH).

Type I

methyltransferases catalyze a second methylation event onto the previously methylated
guanidino nitrogen of MMA to form asymmetric dimethylarginine (ADMA) (Scheme 41). Type I PRMTs include PRMT1 [1], PRMT3 [2], coactivator-associated arginine
methyltransferase 1 (CARM1/PRMT4) [3, 4], PRMT6 [5], and PRMT8 [6]. Type II
methyltransferases catalyze the formation of symmetric dimethylarginine (SDMA)
whereby the second methyl group is transferred onto the unmodified guanidino nitrogen
of MMA. Jak-binding protein 1 (JBP1/PRMT5) exhibits Type II activity [7, 8], but
conflicting reports have been made for PRMT7. PRMT7 has been shown to generate
MMA with a peptide substrate [9] and both asymmetric and symmetric dimethylarginine
residues on protein substrates [10].

The F-box only protein 11 (FBXO11/PRMT9)
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catalyzes the formation of MMA, ADMA, and SDMA on protein arginine residues
[11]. No methyltransferase activity has been found for PRMT2.

MMA
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NH2

NH
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NH

AdoMet
AdoHcy
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+
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Scheme 4-1. Reactions catalyzed by PRMT1. All PRMT isoforms catalyze the Sadenosylmethionine (AdoMet)-dependent methylation of protein arginine residues to
form monomethyl arginine (MMA). PRMT1, a type I PRMT, transfers a second methyl
group from AdoMet onto the previously modified guanidino nitrogen to form asymmetric
dimethylarginine (ADMA). S-Adenosyl homocysteine (AdoHcy) is a product and
inhibitor of this AdoMet-dependent methyltransferase reaction.

PRMT enzymes participate in a variety of cellular processes in eukaryotes.
PRMT activity has been implicated in development [12, 13], RNA processing,
transcriptional regulation, signal transduction, DNA repair, and chromatin remodeling
[14, 15, 16]. In fact, the recent discovery of a histone protein arginine demethylase,
Jumonji domain-containing 6 protein (JMJD6), validates that protein arginine
methylation is a reversible post translational modification on certain histone tails [17].
Thus far, eleven putative PRMT isoforms (PRMT1-11) have been identified in humans
with orthologs present in yeast [18], protozoa, Caenorhabditis elegans, Drosophila
melanogaster [19], plants [20], and fish [21]. The breadth of these enzymes indicates the
biological importance of arginine methylation across the plant and animal kingdoms.
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Although PRMTs are vital to normal development and function, protein arginine
methylation has also been linked to the progression of carcinogenesis, viral pathogenesis,
multiple sclerosis, spinal muscular atrophy, lupus, and cardiovascular disease (reviewed
in 14).

Overall, PRMTs play important roles in biology, yet much of the basic

biochemistry for this class of enzymes remains unexplored. Unlike the protease and
kinase fields where substrate specificity has been studied in detail [22, 23], the molecular
basis for substrate recognition by the PRMTs is poorly understood.
Of the eleven mammalian PRMT isoforms, PRMT1 predominates, performing an
estimated 85% of all protein arginine methylations in vivo [18].

The prevailing

observation is that PRMT1 methylates a variety of proteins that are glycine and arginine
rich within repeating ‘RG’ or ‘RGG’ motifs such as fibrillarin (GGRGRGG)2 [24] and
the heterogeneous nuclear ribonuclear proteins or hnRNPs (GGRGGS) [25]. The ‘RGG’
motif is a recognized RNA-binding domain and is characterized by a variable number of
closely spaced arginine-glycine-glycine repeats interspersed with other amino acids [26].
It is also common to observe a ‘GG’ sequence flanking the N-terminal side of the
modification site. Many of these methylated proteins have been initially identified using
commercially available anti-methyl arginine antibodies that recognize MMA or ADMA
within the tandem ‘RGG’ context. Although the predominant feature of known PRMT1
protein substrates is a glycine/arginine rich region, PRMT1 has also been shown to
specifically methylate several arginines within ‘RXR’ sequences on the surface of the
Poly(A)-binding protein II (PABPII) [27] and the ‘MSGRGKG’ sequence on the histone
H4 tail [28].

It should be noted, that methylated histones are not detected by the

commercially available anti-methyl arginine antibodies (e.g. Asym24 and Asym25 from
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Upstate are directed against peptides with ADMA-glycine or ADMA-glycine-glycine
repeats, respectively) [29], most likely due to the specificity of antibodies for arginine–
glycine repeats [30].

Consequently, only a sub-set of methylated proteins can be

recognized by anti-methyl arginine antibodies.

This suggests that there may be a

diversity in PRMT1 protein substrates that has previously gone unnoticed.
The crystal structure of PRMT1 complexed with AdoHcy and the R3 peptide
substrate

(GGRGGFGGRGGFGGRGGFG)

provided

insight

into

the

reaction

mechanism [31]; however, due to a lack in electron density afforded by the peptide
substrate, few inferences could be made concerning the substrate specificity of PRMT1.
Additionally, the electron densities from the four glycines that flank the substrate
arginine of the R3 peptide substrate were not observed and created a gap in the linear
sequence of R3. The lack in observable substrate electron density suggests that the
substrate specificity of PRMT1 may be much broader than the typical ‘RGG’-containing
substrate.
Together, these results prompted us to investigate the substrate specificity of
PRMT1. The goals of this work were 1) to determine if PRMT1 displays substrate
selectivity at the amino acid sequence level and 2) to identify novel PRMT1 substrate
sequences. A focused directional peptide library based on the in vivo substrate fibrillarin
was used to determine which peptide sequences are methylated by PRMT1. Our results
show that PRMT1 demonstrates substrate selectivity at the amino acid sequence level in
peptide substrates.

We found that the selection of PRMT1 protein substrates is more

complex, wherein the amino acid sequence surrounding the substrate arginyl group of the
protein substrate is one important factor. In summary, our data show that PRMT1 has the
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ability to discriminate between peptide and protein substrates at the amino acid
sequence level. Furthermore, substrate profiling indicated that PRMT1 can methylate
sequences that go beyond the ‘RGG’ paradigm.

MATERIALS AND METHODS
All chemicals used were of ACS reagent grade or better. AdoMet was purchased
from Sigma as a chloride salt (≥80%, from yeast). The custom PepScreen peptide library
was ordered from Sigma Genosys using AcKGGFGGRGGFGGKW as the parent peptide.
The two glycines C-terminal to the arginine (underlined) were substituted with all other
amino acids except arginine one at a time to give rise to 36 unique peptides. The
tryptophan on the C-terminus was added in order to accurately determine the
concentration of each peptide in solution by UV-vis spectrometry.

Peptides were

analyzed by MALDI mass spectrometry to confirm their molecular weight and sampled
by HPLC to assess purity.

Peptide Library Kinetics
A continuous spectrophotometric assay for AdoMet-dependent methyltransferases
(see Chapter 3) was used to assay PRMT1 with peptides from the peptide library.
Briefly, recombinant AdoHcy nucleosidase (MTAN) was used to hydrolyze the AdoHcy
generated from methyltransfer. The resulting adenine was deaminated by recombinant
adenine deaminase. Importantly, this strategy alleviates any product inhibition that could
occur from AdoHcy. Each 110 µL reaction contained 4 µM His-PRMT1 (purified as
described in Chapter 3), 0.02 µM adenine deaminase (purified as described in Chapter 3),
250 µM AdoMet, 10 nM MTAN (purified as in [32]), 100 µM MnSO4, and 50 mM
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sodium phosphate buffer pH 7.1. Reactions were equilibrated at 37 ºC for 10 minutes
before they were initiated with various amounts of peptide. The decrease in absorbance
at 265 nm was monitored continuously using a Cary 300 Bio UV-visible
spectrophotometer. Initial rate data representing no more than 10% of product formation
were fit to the Michaelis-Menten equation [33] to obtain kcat,

app

values.

Mass

spectrometry results with the parent peptide (Fig. 4-1) indicate that the time frame
utilized in fitting the raw spectrophotometric data is representative of a single
methylation event. Apparent kinetic parameters are listed due to technical limitations of
the spectrophotmetric assay; that is, concentrations of AdoMet >250 μM were not
feasible due to high background absorbance in the assay (see Chapter 3). However, the
AdoMet concentration in the assay did not support Vmax conditions (Km, AdoMet= 38 ± 12
μM when using the parent peptide as the methylacceptor). Each reaction was performed
at least in duplicate, and at least two enzyme preparations were used to confirm trends in
substrate utilization. The limit of detection for the spectrophotometric assays was 0.1 μM
CH3/min corresponding to a kcat of 0.025 min-1. A radioactive assay (see Chapter 3) was
also used to confirm the methylation rates of peptides at saturating conditions. The
formation of MMA or ADMA was also confirmed using amino acid analysis [34].
Briefly, peptides were hydrolyzed in 6 M HCl, derivatized with AccQ-Fluor™ (Waters
Corporation) and separated by reverse phase HPLC. This method provides base-line
separation of MMA, ADMA, and SDMA.
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Construction of FLAG-eIF4A1 and
His-eIF4A1 plasmids
N-terminal FLAG epitope eIF4A1 fusion proteins were constructed by amplifying
the DNA encoding mouse eIF4A1 from pc4A1 [35] using a sense primer
5’

GGCGCCATATGTCTGCGAGTCA3’

and

an

antisense

primer

5’

CCCCGAATTCAAATGAGGTCAGC3’. The FLAG-eIF4A1 (pST020 in Table 4-1)

was created when this PCR product was digested with NdeI and EcoRI and inserted into
the pAED4FLAG vector [36]. Mutation of the eIF4A1 Gly363 codon was accomplished
by PCR amplification [37] with complementary oligonucleotide primers (see
supplementary table 1) spanning the desired site of mutation using pST020 as template.
In particular, G363Sforward and G363Sreverse were the primers used along with the pST020
template to give FLAG-eIF4A1(G363S) (pST202 in Table 4-1).

Name
pST020
pST202
pST210
pST211
pST212
pMA300
pMA301

Table 4-1 eIF4A1 Plasmid Constructs
Description
FLAG-eIF4A1 in pAED4FLAG
FLAG-eIF4A1(G363S) in pAED4FLAG
6XHis-eIF4A1(G363A) in pET20b
6XHis-eIF4A1(G363H) in pET20b
6XHis-eIF4A1(G363Y) in pET20b
6XHis-eIF4A1 (wt) in pET20b
6XHis-eIF4A1(G363S) in pET20b

The eIF4A1 constructs used in this work are listed followed by their descriptions. The
pET20b vector was used to create the N-terminal histidine tagged eIF4A1 constructs, and
the pAED4FLAG vector was used to generate the N-terminal FLAG tagged eIF4A1
constructs.
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Construction of the N-terminal His-eIF4A1 and His-eIF4A1(G363S) plasmids
(pMA300 and pMA301, respectively in Table 1) was performed by PCR amplifying
pST202

with

the

following

primers:

CCCATATGCATCATCATCATCATCACATGTCTGCGAGTCAG
antisense=

sense=
GATTC

GGGATCCTCAAATGAGGTCAGCAACGTTGAGGGGCA.

and
PCR

products were digested with NdeI and BamHI and ligated into the pET20b vector
(Novagen) to yield N-terminal His-tagged eIF4A1 constructs. Next, N-terminal HiseIF4A1(G363A), His-eIF4A1(G363H), and His-eIF4A1(G363Y) constructs were
obtained using pMA301(G363S) as the template and the corresponding primers. In
particular, the G363H and G363Y mutations were made simultaneously using a sense
oligo with YAT mismatch replacing WT G363 to create either a His or Tyr codon. The
complementary antisense primer had a purine (A/G) at the position corresponding to the
C/T in the sense primer. All plasmid inserts were sequenced in their entirety to confirm
insert junctions and desired base substitutions.

Purification of FLAG-eIF4A1 proteins
FLAG-eIF4A1 proteins expressed in BL21(DE3) CodonPlus cells (Stratagene, La
Jolla, CA) were incubated overnight at 4 °C with 0.5 μg M2 antibody (Sigma-Aldrich,
St. Louis, MO) in radio-immunoprecipitation assay (RIPA) buffer [38]. Immune
complexes were collected by incubation with protein G-agarose (Pierce Chemicals,
Rockford, IL) for 1 hou at room temperature. Unbound proteins were removed by
resuspension in RIPA buffer followed by brief centrifugation to collect bound proteins.
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Samples were washed with RIPA buffer two more times followed by a single wash in
1X HMT (20 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 0.4 mM EDTA).

Fluorography
Methylation was performed by adding 1.1 μCi [3H]-AdoMet (76.4 Ci/mmol,
Perkin-Elmer, Boston, MA) to the adsorbed FLAG-eIF4A proteins (0.8 μg) and 0.5 μg
His-PRMT1 in a total liquid volume of 30 μL HMT buffer. Reactions were allowed to
incubate for 1 hour at 37 °C and were stopped by adding sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) Laemmli sample buffer. Proteins were
resolved in 12.5% polyacrylamide gels, treated with Enlightning (Perkin-Elmer), dried
and exposed to X-ray film (RPI, Mt. Prospect, IL) for 2-7 days as indicated.

His-eIF4A1 protein purification
E. coli BL21(DE3) cells carrying the wild type (WT) and mutant eIF4A1 plasmid
vectors were grown in Luria-Bertani (LB) broth at 37 ºC. Protein expression was induced
with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 5 hours, and cells were
harvested by centrifugation and re-suspended in wash buffer (50 mM sodium phosphate
[pH 7.5] with 20 mM imidazole).

Cells were lysed by sonication, and the crude

supernatant was obtained by centrifugation.

His-eIF4A1 was purified using Ni2+-

sepharose high performance resin (Amersham Biosciences) according to the
manufacturer’s instructions. Purified protein was eluted with wash buffer containing 250
mM imidazole, and the eluate was concentrated in a Centricon-Plus Concentrator (30,000
MWCO, Amicon). The buffer was exchanged to 50 mM sodium phosphate buffer (pH
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7.5) and the pure protein was stored at -80 ºC. Proteins were > 95% pure as judged by
SDS-PAGE.

Rates of in vitro methylation of eIF4A1 protein
Reactions were performed using the same conditions that were used to test the
peptides from the peptide library with the following modifications: 50 nM His-PRMT1,
500 μM AdoMet with 0.3 μM [H3]-AdoMet (Specific activity=83 μCi/μmol), and 50 mM
sodium phosphate buffer (pH 8.0). After equilibrating at 37 ºC for 10 minutes, reactions
were initiated with 25 μM WT or mutant histidine tagged eIF4A1 protein. Various time
point aliquots were taken out and quenched with an equal volume of cold 20%
trichloroacetic acid (TCA). These time points were then loaded onto glass fibers (1.2
μm) in a UniFilter-96 well plate using a filter mate harvester (Perkin Elmer) and washed
to rid the samples of remaining [H3]-AdoMet. Radiolabeled eIF4A1 protein was counted
using Ultima Gold F scintillation cocktail and a TopCount NXT (Perkin Elmer). Rates of
protein methylation were corrected by subtracting the background counts associated with
the control reaction that lacked eIF4A1.

Analysis of products by mass spectrometry
A reaction prepared as described in the peptide kinetics methods was initiated
with 300 μM WT-eIF4A1 peptide (YIHRIGRGGR), 300 μM eIF4A1-S peptide
(YIHRIGRSGR), or 400 μM eIF4A1-Y peptide (AcYIHRIGRYGR). After 120 minutes,
the reactions were terminated 1:1 with 20% TCA. Precipitated protein was removed by
centrifugation, and the peptide samples were analyzed for methyl incorporation using MS
and MS/MS analysis. For MALDI analysis, peptide samples were diluted in HPLC grade
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water to a final concentration of 0.5-5 µM. Diluted peptide samples (0.5 μL) were
spotted on a polished standard 192-well stainless steel MALDI sample plate followed by
an alpha-cyano-4-hydroxy cinnamic acid (CHCA) matrix solution (0.4 μL, 10 mg/mL in
a mixture of acetonitrile/water/TFA, v:v:v, 50:50:0.05). The resulting mixtures were air
dried and analyzed using an AB 4700 MALDI-TOF/TOF Proteomics Analyzer (Applied
Biosystems, Framingham, MA). MS and MS/MS spectra were acquired in reflector
positive mode. A peptide standard, human angiotensin I ([M+H]+=1296.67), was used
for the external calibration. Data were analyzed using Data Explorer software 4.6. In
addition, unmodified, mono, and dimethylated peptides were analyzed by LC/MS using a
Surveyor HPLC system coupled to a LCQ Deca XP mass spectrometer (Thermo Fisher,
Waltham, MA). The peptides were diluted to 1 µM in 0.1% formic acid and a 2 µL
aliquot was injected into a self-packed reversed phase column (75 µm i.d. × 15 cm,
Magic C18 resin, 3 µm particle size, 200 Å pore size, Michrom Bioresources, Auburn,
CA) and eluted at 200 nL/min with a linear gradient from 99:1 solvent A:B to 5:95
solvent A:B. Solvent A was water containing formic acid, 0.1%, v/v. Solvent B was
acetonitrile containing formic acid (0.15, v/v). Data were processed using Xcalibar Data
System 2.0 (Thermo Fisher, Waltham, MA).

RESULTS
Design of the peptide library
In order to determine if PRMT1 displays substrate selectivity at the amino acid
sequence level, and if PRMT1 can methylate peptidyl arginine residues that are not
present in either ‘RGG’ or ‘RXR’ sequences, we constructed a peptide library based on a
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peptide (R3 in the literature) derived from the in vivo substrate fibrillarin. Although the
R3 peptide has been widely used to study PRMTs and has been co-crystallized with
PRMT1 [31], it contains three arginine residues, each of which can be methylated. In
order to simplify the kinetics, the two flanking arginines of the R3 peptide were replaced
with positively charged lysines. This fibrillarin-based peptide (KGGFGGRGGFGGKG)
displayed saturation kinetics (data not shown) and was both mono- and dimethylated in a
dissociative fashion as deduced by the lag in dimethylated product formation (Fig. 4-1).
In order to allow for more accurate peptide quantification, a tryptophan was added to the
C-terminus. The resulting peptide,

AcKGGFGGRGGFGGKW,

was used as the parent

substrate in the peptide library. This peptide demonstrated saturation kinetics (data not

Fig. 4-1. Time-dependent formation of monomethylarginine and dimethylarginine by
PRMT1.
A reaction was performed with 100 μM fibrillarin-based peptide
(KGGFGGRGGFGGKG), 250 μM AdoMet, and 2.5 μM PRMT1. At 0.2, 2, 4, 12, and
16 minutes, 120 μL aliquots were terminated with TFA (0.8% final) and analyzed by
LC/MS. Substrate and product peak intensities were normalized for ionization
differences between time points using an internal standard peptide with a similar amino
acid composition as the fibrillarin-based peptide. The ratio of the intensity of peptide
product(s) peak(s)/substrate peak is plotted as a function of time. Solid lines connecting
(●) or (○) indicate ratios of mono- and dimethylated peptide product/substrate,
respectively. The data support a distributive, or dissociative, mechanism.
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shown). As an initial step to ascertain the importance of the amino acid sequence
adjacent to the methylation site, two residues C-terminal to the arginyl group (underlined
in the sequence above) were independently altered to all of the other amino acids except
arginine to generate 36 peptides. Of the 36 peptides in the library, 26 peptides were
soluble in sodium phosphate buffer and were tested for their methyl acceptor activity
with PRMT1. Such a screen is important for determining the ability of PRMT1 to
methylate sequences outside the ‘RGG’ paradigm.

PRMT1 demonstrates amino acid sequence
selectivity with peptide substrates
Soluble peptides were incubated with PRMT1 and AdoMet to determine if
methylation could occur at sequences other than ‘RGG’ and ‘RXR’. Peptides were
examined kinetically using PRMT1 and a continuous spectrophotometric assay for
AdoMet-dependent methyltransferases (see Chapter 3). Peptides that were methylated by
PRMT1 displayed a linear decrease in absorbance at 265 nm which was monitored
continuously with time. Initial rates (first 10% of product formation) were used to obtain
Michaelis-Menten kinetic parameters, which are shown graphically in relation to the
parent peptide which had a Km, app= 89 ± 35 μM and a kcat, app= 3.0 ± 0.5 min-1 (Fig. 4-2).
For comparison, the R3 peptide (GGRGGFGGRGGFGGRGGFG) had a Km= <10 μM
and a kcat= 2.7 ± 0.2 min-1 (see Chapter 3).
Table 4-2 and Fig. 4-2 summarize the kinetic data (kcat,

app

and kcat/Km values)

obtained when PRMT1 was assayed with peptides modified from the parent peptide in
the X1 (Fig. 2, A) or the X2 (Fig. 4-2, B) positions. Overall, PRMT1 was capable of
methylating less than half of the peptides tested that possessed an amino acid other than

glycine in the X1 position (Fig. 4-2A). Peptides containing ‘RLG’, ‘RYG’, ‘RFG’,

79

‘RTG’, and ‘RKG’ sequences were PRMT1 substrates (see Table 4-2). Importantly, the
maximum velocity for each peptide substrate and incorporation of a methyl group was
confirmed using a [3H]-AdoMet radioactive assay [21] (data not shown).
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Fig. 4-2. PRMT1 methylates sequences that extend beyond ‘RGG’. kcat, app values
were obtained for soluble peptides in the peptide library. The library was constructed
based on a peptide sequence (AcKGGFGGRGGFGGKW) derived from the in vivo
PRMT1 substrate, fibrillarin. Kinetic parameters were obtained using a continuous
spectrophotometric assay. Reactions containing 4 µM PRMT1 and 250 µM AdoMet
were initiated with 25-2000 µM peptide. PRMT1 substrates displayed a linear decrease
in absorbance at 265 nm that was monitored continuously with time. Initial rate data was
fit to the Michaelis-Menten equation to determine kinetic constants. (A) kkat, app values
for peptides that varied in the X1 position (X in ‘RXG’), (B) kkat, app values for peptides
that varied at X2 are represented in bar graphs. The letter under each bar indicates the
amino acid that ‘X’ is equivalent to in either the X1 or X2 position. Peptides containing
boxed amino acid residues in either position were very poor PRMT1 substrates. Peptides
with residues in the X1 or X2 positions labeled (*) were not methylated by PRMT1.

We also confirmed that MMA was formed by performing amino acid analysis on
acid-hydrolyzed peptide products [34]. Using reverse phase HPLC, all PRMT1 peptide
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substrates displayed a peak that co-eluted with authentic MMA (data not shown).
Peptides bearing an aspartate, alanine, glutamate, or asparagine directly C-terminal to the
substrate arginine were classified as very poor PRMT1 substrates.

The maximum

velocity exhibited by PRMT1 for each of these peptides using radiolabel incorporation
was only slightly above the control reaction rate.

The limit of detection for the

radioactive assay was 0.05 μM CH3/min corresponding to a kcat of 0.013 min-1.
Methylation of peptides bearing serine or histidine in the X1 position was not detected
using either kinetic assay.

Table 4-2 Peptide Library Kinetics
Name Sequence
kcat/Km (M-1sec-1)
560
G-X1 KGGFGGRGGFGGKW
1
KGGFGGRLGFGGKW
34
L-X
62
Y-X1 KGGFGGRYGFGGKW
1
KGGFGGRFGFGGKW
130
F-X
710
T-X1 KGGFGGRTGFGGKW
1
KGGFGGRKGFGGKW
160
K-X
2
KGGFGGRGGFGGKW
560
G-X
430
A-X2 KGGFGGRGAFGGKW
2
KGGFGGRGLFGGKW
160
L-X
50
F-X2 KGGFGGRGFFGGKW
2
KGGFGGRGTFGGKW
95
T-X
1.0 x 103
K-X2 KGGFGGRGKFGGKW
220
S-X2 KGGFGGRGSFGGKW
Peptide names are listed followed by their sequences and catalytic efficiencies (kcat/Km
(M-1s-1)).

PRMT1 was also able to methylate peptides with amino acids other than glycine
in the X2 position. The kcat,

app

values for PRMT1 with peptides modified in the X2

position (X in ‘RGX’) are shown in Fig. 4-2, B.

Although PRMT1 preferentially

methylated the ‘RGG’ containing parent peptide over all other X2 position modified

81

peptides, new PRMT1 substrate sequences were identified. Peptides harboring leucine,
phenylalanine, threonine, lysine, alanine, or serine in the X2 position were shown to be
PRMT1 substrates (also see Table 4-2). Peptides with ‘RGP’, ‘RGI’, ‘RGW’, ‘RGQ’,
and ‘RGE’ sequences were very poor PRMT1 substrates; i.e., kcat values were only
slightly above the limit of detection. Finally, PRMT1 did not tolerate tyrosine, aspartate,
or methionine in the X2 position (kcat values were lower than the limit of detection).
Overall, the data from the peptide library shows that 1) PRMT1 methylates sequences
that go beyond the glycine arginine rich paradigm and 2) PRMT1 prefers certain amino
acids over others in either the X1 or X2 positions.

PRMT1 demonstrates amino acid sequence
selectivity with a protein substrate
In order to determine if PRMT1 demonstrates the same sequence selectivity at the
protein level as it does at the peptide level, a model protein substrate was chosen and the
sequence C-terminal to the substrate arginyl group was modified. Since many known
PRMT1 protein substrates contain multiple arginine residues that can be methylated, we
searched for a protein substrate that was methylated by PRMT1 at a single arginine
residue to use as a model protein substrate. We observed that eIF4A was specifically
methylated by PRMT1 (Bochinski et al., in preparation). The eukaryotic initiation factor
4A (eIF4A) family of DEAD-box proteins, of which several structures have been solved
[39], has seven motifs characteristic of nucleic acid helicases, including a 14 amino acid,
arginine-rich motif VI located towards the C-terminus. eIF4A1, an eIF4A isoform that
has an ‘RGG’ sequence located in motif VI (ENYIHRIGRGGR) of the DEAD-box
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domain, was chosen as our model protein substrate. Wild-type eIF4A1 incorporated
tritium from [3H]-AdoMet when incubated with PRMT1 (Fig. 4-3) in a time-dependent
manner (data not shown). An R362K-eIF4A1 mutant did not incorporate radiolabel from
[3H]-AdoMet in the presence of PRMT1 (data not shown). These results suggest that
eIF4A1 is methylated at a single arginine residue and will serve as a good model
substrate.
In order to examine if the amino acid sequence surrounding the substrate arginyl
group affects the ability of PRMT1 to methylate protein substrates, mutants of eIF4A1 at
the X1 position were examined as PRMT1 substrates. Mutations were selected based on
either the results of the fibrillarin-based library or forthcoming experiments as discussed
below.

Mutants bearing ‘RYG’ (G363Y), ‘RAG’ (G363A), and ‘RSG’ (G363S)

sequences were incubated with PRMT1 and [3H]-AdoMet. As Fig. 4-3 shows, none of
the mutant proteins incorporated radiolabel. These results show that amino acid sequence
in both peptides and proteins is an important factor dictating PRMT1 substrate selection.

Fig. 4-3. Effect of single site mutations in the PRMT1 protein substrate eIF4A1. 0.83
µM eIF4A1 protein was incubated with 0.69 µM [3H]-AdoMet and 5 µM PRMT1.
Reactions were quenched with SDS loading dye and run on an SDS-PAGE gel that was
stained with Coomassie (CB panel) and later exposed to film (3H panel). Lanes contain
the following proteins: WT, G363A, G363S, and G363Y-eIF4A1, respectively. Lanes
containing G363S-eIF4A1 and G363Y-eIF4A1 were purposely overloaded in this
particular gel but no radiolabel incorporation was observed in these mutants.
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Discrimination of eIF4A isoforms by PRMT1
A sequence alignment was performed for eIF4A1 against other DEAD-box
domain containing proteins. Two human eIF4A isoforms, eIF4A2 and eIF4A3, were
most similar in sequence to eIF4A1, with eIF4A2 and eIF4A1 sharing 90% sequence
identity. Although eIF4A3 shares 66% sequence identity with eIF4A1, eIF4A1 and 3
share over 80% structural similarity (blue residues in Figure 4-4). The single amino acid
difference between eIF4A1 and 3 in motif VI (boxed amino acids in Figure 4-5A) occurs
at G368 in eIF4A1 (S368 in eIF4A3), directly C-terminal to the methylation site. We
asked if PRMT1 could methylate the eIF4A3 protein, which has an ‘RSG’ instead of an
‘RGG’ sequence at the same position.

Fig. 4-4. Sequence conservation of eIF4A isoforms. The crystal structure of the yeast
eIF4A1 protein (PDB accession 1FUU_1) highlights the proposed site of PRMT1methylation, Arg362, shown in ball and stick representation on a flexible loop. Yeast
eIF4A1 was aligned with human eIF4A3 sequence (NCBI accession# P38919) using the
Dali Server. Strictly conserved residues are shown in blue while functionally conserved
residues are shown in dark gray. Functionally distinct, non-conserved residues are shown
in orange. The conserved arginine is blue while the non-conserved amino acid directly
C-terminal to it is orange.
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Based on previous results with the G363S mutant of eIF4A1, we predicted that
eIF4A3 would not be a good PRMT1 substrate. No tritium incorporation into eIF4A3
protein was observed upon incubation with [3H]-AdoMet and PRMT1 (Fig. 4-5, B)
indicating that the eIF4A3 protein is not a PRMT1 substrate. However, an S368GeIF4A3 mutant did incorporate tritium when incubated with [H3]-AdoMet and PRMT1
(data not shown). Thus, despite the high sequence and structural similarity between the
two isoforms, the eIF4A1 protein is a PRMT1 substrate while the eIF4A3 protein is not.
Furthermore, a single change in the amino acid residue adjacent to a substrate arginyl
group dictates whether or not the eIF4A1/3 proteins are methylated.

A
eIF4A1
eIF4A3

NRENYIHRIGRGGR 365
NRELYIHRIGRSGR 370

B

Fig. 4-5. Comparison of eIF4A1 and eIF4A3 isoforms as PRMT1 substrates. (A) The
sequences from the human eIF4A1 (accession# NP_001407) and eIF4A3 (accession#
P38919) isoforms were aligned using CLUSTALW and were shown to be 66% identical.
Residues 352-365 from motif VI (boxed residues) of the eIF4A1 DEAD box domain are
shown. The proposed site of PRMT1-methylation is bolded. Position 363, the glycine
residue immediately C-terminal to the eIF4A1 substrate arginine residue (R362), is
indicated by an arrow. Instead of glycine at this position in motif VI, eIF4A3 has a
serine. In (B), eIF4A3 protein was examined as a PRMT1 substrate using conditions
described in Fig. 4-2.
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Effect of substrate sequence context
on PRMT1 activity
The amino acid sequence surrounding the substrate arginine residue is different
between the G363Y eIF4A1 protein (…YIHRIGRYGR…) and the fibrillarin-based
‘RYG’ peptide (AcKGGFGGRYGFGGKW). It is possible that the inability of PRMT1 to
methylate the ‘RYG’ sequence in the eIF4A1 mutant could be due to sequence context.
That is, amino acids in one position affect whether or not amino acids in a second
position are favored. We therefore examined PRMT1 catalyzed methylation of peptides
which were based on the wild-type and mutant eIF4A1 sequences. PRMT1 was capable
of methylating all eIF4A1-peptides tested (Table 4-3).
methylated (kcat/Km,
(kcat/Km,

app=

app=

The eIF4A1-Y peptide was

80 ± 18 M-1s-1) albeit at a much slower rate than wild-type

610 ± 18 M-1s-1). This result suggests that the inability of PRMT1 to

methylate the G363Y eIF4A1 protein was not due to sequence context. Additionally,
these results show that while the sequence surrounding the reactive arginyl group is
important (e.g., eIF4A1 mutant proteins which are not PRMT1 substrates), other factors
also contribute to protein substrate selection. For example, we note that the loop in
which eIF4A1 is methylated consists of only six amino acid residues. This loop is
restrained by a beta sheet and alpha helix at its termini and may display limited flexibility
compared to a peptide substrate. The ability of peptides corresponding to the loop region
or single amino acid mutants of the loop region to be PRMT1 substrates while the
corresponding proteins were not PRMT1 substrates may be related to decreased
flexibility within the protein loop.
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Table 4-3 eIF4A peptide kinetics with PRMT1
Name

Peptide sequence Km, app (μM) kcat/Km, app (M-1s-1)

eIF4A1

YIHRIGRGGR

39 ± 2.4

610 ± 99

eIF4A1-Y

YIHRIGRYGR

250 ± 28

80 ± 18

eIF4A1-S (eIF4A3)

YIHRIGRSGR

47 ± 3.9

170 ± 22

Peptide sequences and kinetic parameters (Km, app and kcat/Km, app) are listed for peptides
derived from eIF4A1 and eIF4A3. The peptide arginine residue that gets methylated by
PRMT1 is bolded. Kinetics were performed as described in Fig. 4-2.

We also noted that the ‘RSG’ sequence presented within the fibrillarin context
(AcKGGFGGRSGFGGKW) was not a PRMT1 substrate while the same sequence
presented within the eIF4A1 context (YIHRIGRSGR) was a PRMT1 substrate. The
eIF4A1-S peptide was in fact, a better substrate than the eIF4A1-Y peptide (Table 4-3).
This suggests that PRMT1 substrate specificity is contextual with respect to the amino
acid sequence surrounding the substrate arginyl residue.
Because the eIF4A1 peptides have three arginine residues, it was possible that
changing the peptide sequence shifted the methylation site. In order to address this issue,
we determined the methylation site in each peptide by MS/MS. Analysis of the WTeIF4A1 peptide after incubation with PRMT1 and AdoMet showed that only the arginine
within the ‘RGG’ sequence (bolded R7 in

AcYIHRIGRGGR)

was both mono and

dimethylated (Fig. 4-6 and Fig. 4-7, A).
The eIF4A1-S peptide,

AcYIHRIGRSGR,

with an ‘RSG’ sequence was also

methylated at R7 (data not shown). Mass spectrometry analysis of the eIF4A1-Y mutant

peptide,
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YIHRIGRYGR,
housing
an
‘RYG’
sequence
showed
a
+14
peak
Ac

corresponding to monomethylation, which could not be ascribed to R4 or R10
methylation (Fig. 4-7, C). The presence of MMA in PRMT1 reaction mixtures using
each of the three eIF4A1-derived peptides was confirmed by amino acid analysis via
HPLC (data not shown). Importantly, these results suggest that the methylation site did
not shift when the eIF4A1 peptide sequence was altered. In summary, all eIF4A1derived peptides were methylated by PRMT1.
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Fig. 4-6. MALDI-TOF/TOF-MS/MS spectra of (A) 1184.68 (1184.68 calculated)
[M+H]+ precursor ion corresponding to the unmodified WT-eIF4A1 peptide, (B) 1198.62
(1198.69 calculated) [M+H]+ precursor ion corresponding to the monomethylated WTeIF4A1 peptide, confirms the modification site to be Arg7, and (C) 1212.64 (1212.71
calculated) [M+H]+ precursor ion corresponding to the dimethylated WT-eIF4A1 peptide,
confirms the modification site to be Arg7. The peptide sequence is labeled with observed
b and y ions.
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Fig. 4-7. MALDI-MS spectra of methylation reactions of (A) WT-eIF4A1, (B)
eIF4A1-S and (C) eIF4A1-Y peptides. Labeled peaks are for the unmodified (native),
mono-methylated (+14 Da) and dimethylated (+28 Da), sodium adduct (+22 Da),
disodium adduct (+44 Da), and dimethylated plus sodium adduct (+50 Da) peptides,
respectively.
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DISCUSSION
PRMT1 substrate selectivity goes beyond
the ‘RGG’ paradigm
When PRMT1 was crystallized with the R3 peptide and AdoHcy, the electron
density for the two amino acid residues C-terminal to the fully resolved substrate arginine
was not observed. Because no stabilizing interactions were observed in the enzymesubstrate complex between PRMT1 and substrate side chains, one might predict that the
active site residues of PRMT1 have little influence over which substrate sequences can
interact with the enzyme.

The results from the peptide library show that PRMT1

substrate selectivity exists (Fig. 4-2, the X1 and X2 positions); however, the variety of
sequences that are methylated extends beyond the ‘RGG’ paradigm.
Our results show that the ‘RGG’ sequence is not a necessity of a PRMT1
substrate. We confirmed the PRMT1-dependent methylation of several novel sequences
using a coupled spectrophotometric assay, radiolabel incorporation, and amino acid
analysis. The ability to methylate a variety of peptide sequences indicates that PRMT1
has evolved a certain degree of flexibility with regard to substrate binding and/or
catalysis.

The arginine of all PRMT1 substrates must be recognized, and PRMT1

residues that fulfill this function can be seen in the crystal structure [31].

This

recognition appears strict as even a peptide where the arginine has been replaced with a
citrulline, (where one of the guanidino nitrogens has been replaced with a carbonyl
group) does not compete with substrate peptides (data not shown), suggesting that
citrulline does not bind in the active site. Of the eleven peptide sequences that were
methylated by PRMT1, the amino acid residues allowed in either the X1 or X2 positions

90
possess a diverse range of chemical properties including residues with aromatic rings
and/or hydroxyl groups, hydrophobic amino acids, and positively charged residues.
Even though the experimental design of this study was geared toward substrate
profiling using a peptide screen, certain observations from the screen are worthy of
noting. In addition to the ‘RGG’ and ‘RXR’ PRMT1-methylation sequences identified
prior to this study, peptides containing leucine, phenylalanine, threonine, or lysine in
either the X1 or X2 positions were methylated by PRMT1 (Fig. 4-2). Surprisingly,
alanine was not favored by PRMT1 in the X1 position despite its resemblance to glycine
in size and charge but was favored in the X2 position.

Interestingly, tyrosine and

phenylalanine, both larger amino acids, were allowed in the X1 position.
Serine was favored in the X2 position (‘RGS’) within the context of the fibrillarin
sequence. We note that the R3 peptide substrate which was complexed with PRMT1 in
the crystalline state could be modeled into the substrate binding groove in either
orientation. Therefore, our data is consistent with the possibility that the fibrillarin-based
‘RGS’ peptide and a peptide derived from histone H4 that is methylated by PRMT1 in an
‘SGR’ sequence [40] bind PRMT1 in opposite orientations. This data suggests that a
hydrogen bond afforded by serine in this position (‘RGS’ or ‘SGR’) may contribute to
binding/catalysis. However, in order for us to be able to describe specific PRMT1substrate interactions between the newly discovered substrate sequences and PRMT1,
more structural information about positions of substrate side chain residues and
directionality of the peptide substrate are needed.
Our study reveals that directional peptide libraries are useful to begin
characterizing the substrate selectivity of PRMT1, but they are not the end-all approach
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because PRMT1 displayed contextual recognition of peptide substrates. Specifically,
the ‘RSG’ containing peptide modeled from eIF4A3 was a PRMT1 substrate while the
‘RSG’ containing fibrillarin-based peptide was not. Compensatory interactions have also
been observed in the deacetylase SIRT1 [41]. Alternatively, the ability of PRMT1 to
differentially methylate peptides containing the ‘RSG’ sequence (eIF4A3 peptide versus
fibrillarin-based peptide) may reside in the ability of PRMT1 to bind peptide substrates in
either an NT to CT or CT to NT orientation. This characteristic would be consistent with
the crystal structure. Since it is expected that the binding mode of protein substrates
would be fixed in one orientation, it would follow that not all peptide sequences (NT to
CT) which are PRMT1 substrates may be PRMT1 protein substrates.

Selection of PRMT1 protein substrates
Our results with the eIF4A proteins show that even at the protein level, the amino
acid sequence of the substrate protein surrounding the reactive arginine group is one
factor that dictates PRMT1 substrate selectivity.

Even proteins bearing remarkable

sequence and structural similarity can be distinguished by a single amino acid difference
near the substrate arginyl group. Comparison of the eIF4A1 proteins and corresponding
peptides as PRMT1 substrates illustrates that recognition of protein substrates is not
governed by amino acid sequence alone. Nonetheless, the peptide data suggest the
possibility of a more diverse methylarginine proteome than the previously recognized
‘RGG’-containing

proteins.

Using

the

MSDmotif

server

at

EMBL-EBI

(http://www.ebi.ac.uk/msd-srv/msdmotif/), the pdb was queried for structures harboring
potential PRMT1 methylation sites. A PSI-BLAST on loop sequences yielded several
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proteins with ‘GRYG’, ‘GRFG’, and ‘GRGF’ sequences (Table 4-4). Human protein
and human pathogens with diverse functions are represented. The structures of these
proteins confirm that the target arginine is present on an accessible region of the protein.
Presently, a more diverse PRMT1 recognition sequence is also supported by the
methylation of histone 4 and HNF4 [42] in ‘RGK’ and ‘RYG’ sequences, respectively.

Sequence

PDB ID

Table 4-4 Potential PRMT1 Targets
UniProt ID. Protein Class

GRFG

2CS5

P29074

Hydrolase, Tyrosine phosphatase, pdz domain

GRYG

2YQP

Q5T1V6

Hydrolase, RNA helicase ddx59

GRYG

2HTV

Q6XV46

Hydrolase, influenza A virus

GRYG

1DTD

P48052

Hydrolase, Carboxypeptidase a2.

GRGF

2PIE

O76064

Ligase, E3 ubiquitin-protein ligase rnf8.

GRGF

1W8K

O61130

Antigen, Plasmodium vivax

GRGF

1X4L

Q14192

Metal-binding portein, lim domain

GRGF

1N9D

P01236

Hormone, prolactin

GRGF

2C35

P62487

Polymerase, rpb7

The sequences indicated were queried against the pdb using the MSDmotif server as
discussed in the text. All protein listed are either human or are human pathogens.

Although the amino acid sequence of a protein substrate may play a role in
PRMT1 substrate recognition and catalysis, PRMT1 substrate selectivity may not be
limited to the PRMT1 active site and its ability to distinguish between different
sequences. It has already been shown that peptide length and the presence of positively
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charged peptidyl residues distant from the PRMT1 active site chemistry affect substrate
binding and catalysis [40]. This feature is also illustrated in the eIF4A1 methylation site
which is flanked by five positive residues. In addition to interactions within the PRMT1
active site, PRMT1 may also take advantage of specific protein-protein interactions distal
from the methylation site, a type of “proximity-induced catalysis” that has been observed
in ERK2 [43].

Mono- and dimethylation of substrates
Using mass spectrometry, we demonstrated that the dimethylation of a fibrillarinbased peptide substrate occurs through a dissociative mechanism (Scheme 4-2) based on
an observable lag in the formation of the dimethylated product (Fig. 4-1). Our results are
consistent with Frankel and co-workers [44], but are different from the findings of
Thompson and co-workers [40] who defined a partially processive dimethylation of a
histone 4 peptide by PRMT1. Because the mechanism of methyltransfer is dissociative,
formation of the dimethylated peptide product depends upon how easily PRMT1 can
recapture the monomethylated product. Frankel and co-workers [44] have reported that
the monomethylated peptide substrate is a better substrate for PRMT6 than the naked
peptide. We have observed similar results with PRMT1 and a fibrillarin-based peptide
(Wooderchak and Hevel, manuscript in preparation) and suggest that sequence
differences between a fibrillarin-based peptide and a histone 4-based peptide may be the
basis for the different observations.
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Scheme 4-2. Dissociative reaction mechanism catalyzed by PRMT1. PRMT1 binds a
single arginine containing peptide substrate and catalyzes methyl group transfer from
AdoMet. The monomethylated product is released before re-binding PRMT1 and being
dimethylated. R=arginine

Conclusion
Limited studies and selective tools have promoted the idea that PRMT1 substrates
conform to an ‘RGG’ sequence with a few rare exceptions [25, 27, 28, 45]. Importantly,
our data clearly show that PRMT1 is capable of methylating sequences that go beyond
the ‘RGG’ paradigm. Additionally, our results suggest that residues N-terminal to the
arginyl modification site are also important in substrate recognition. This suggests that
the methyl arginine proteome may be larger and more diverse than previously thought. It
will be interesting to see if any of the candidate proteins identified in our study are indeed
methylated by PRMT1.
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CHAPTER 5
EXAMINING THE FORMATION OF ADMA BY PRMT11
ABSTRACT
Protein arginine methyltransferase 1 (PRMT1) performs over 85% of all protein
arginine methylation in the cell having the ability to both mono- and asymmetrically
dimethylate protein arginine residues. Interestingly, many PRMT1 protein substrates are
dimethylated instead of monomethylated on multiple arginines of certain proteins such as
the hnRNPs, SAM68, and fibrillarin.

Consequently, we sought to understand how

PRMT1 preferentially asymmetrically dimethylates protein arginine residues in vivo
using kinetic and mass spectrometry analysis. PRMT1 may have evolved a way to
ensure the formation of a dimethylated product through 1) preference for the
monomethylated substrate over the nonmethylated substrate or 2) processive methylation.
We show here that PRMT1 did not processively methylate a single arginine-containing
peptide substrate. PRMT1 preferred to methylate a peptide substrate that had already
been monomethylated over an unmodified peptide substrate.

A multiple arginine-

containing peptide was found to be dissociatively dimethylated at a single arginine
residue using a modified pulse-chase experiment analyzed by mass spectrometry.
Interestingly, methylation of a multiple arginine-containing peptide was systematic (not
random). Based on these results, the predominance of dimethylated protein substrates in
vivo is likely due to PRMT1 preferentially methylating monomethylated substrates over
naked substrates.
1

Coauthored by W.L. Wooderchak, D. Chen, J.M. Hevel, Examining the formation of
ADMA by PRMT1, Biochemistry (2009), manuscript in preparation.
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INTRODUCTION
Protein arginine methyltransferases (PRMTs) post-translationally modify a
number of protein arginine residues. Targeted methylation of these proteins affects a
variety of cellular processes including RNA processing, transcriptional regulation, signal
transduction, and DNA repair (reviewed in [1]). Type I PRMTs (PRMT1, 3, 4, 6, and 8)
catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine
(ADMA) via the transfer of a methyl group from S-adenosyl methionine (AdoMet/SAM)
onto protein arginine residues (Scheme 5-1) [2-7]. Type II methyltransferases (PRMT5
and PRMT7) catalyze the formation of symmetric dimethylarginine (SDMA) where the
second methyl group is transferred onto the unmodified guanidino nitrogen of MMA [8,
9].

CH 3
HN +

CH 3
NH

NH
CH 3

+

H 2N

+

NH 2

Type I & II PRMTs
NH

H2N

Type II

SDMA

NH

AdoHcy
NH

AdoMet

MMA

AdoMet
AdoHcy

AdoMet
AdoHcy
Type I

CH 3

+

H2 N

N
CH 3
NH

ADMA

Scheme 5-1. Reactions catalyzed by PRMTs.
PRMTs catalyze the Sadenosylmethionine (AdoMet) dependent methylation of a protein substrate arginine
residue to form monomethyl arginine (MMA). Type I methyltransferases, PRMT1, 3, 4,
6, and 8 dimethylate arginine asymmetrically to form asymmetric dimethyl arginine
(ADMA). Type II methyltransferases, PRMT5 and PRMT7 catalyze the formation of
symmetric dimethyl arginine (SDMA).
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Thus far, nine PRMT isoforms (PRMT1-11) have been identified in humans
with orthologs present in yeast [10], protozoa, Caenorhabditis elegans, Drosophila
melanogaster [11], plants [12], and fish [13].

Of the eleven isoforms, PRMT1

predominates, performing an estimated 85% of all protein arginine methylation in vivo
[10]. PRMT1 has the ability to methylate protein substrates at multiple sites within a
single protein. Even though PRMT1 is capable of forming both MMA and ADMA, most
PRMT1 substrates are found dimethylated in vivo. Fibrillarin [14], hnRNPs [15], and
Sam68 [16] are asymmetrically dimethylated by PRMT1 at multiple sites within the same
protein.
Although PRMTs are vital to normal development and function [17, 18], protein
arginine methylation has also been linked to carcinogenesis [19], viral pathogenesis [20],
multiple sclerosis [21], and spinal muscular atrophy (reviewed in [1]). In addition,
several studies have shown that free ADMA, a downstream proteolytic product of PRMT
substrates, has a clear role in cardiovascular disease [22] and stroke [23] by serving as an
endogenous inhibitor of nitric oxide synthesis [24]. ADMA competitively inhibits nitric
oxide synthase which generates the vascular smooth muscle relaxant, nitric oxide. Only
20% of ADMA is excreted in urine while approximately 80% of ADMA is cleared by
dimethylarginine dimethylaminohydrolases (DDAHs).
citrulline and dimethylamine.

DDAHs convert ADMA to

However, the misregulation of DDAHs or the

hyperactivity of PRMTs may contribute to cardiovascular disease [22]. In fact, PRMT1
has been shown to be overexpressed in myocardial tissue taken from coronary heart
disease patients [25].

In addition to contributing to cardiovascular ailments,
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pathophysiological concentrations of ADMA have also been shown to elicit
significant changes in coronary artery endothelial cell gene expression [26].
It was discovered early on that ADMA was the most abundant of the three
possible PRMT modifications.

Two percent of all protein arginine residues are

asymmetrically dimethylated in rat liver nuclei [27], and approximately 12% of all
arginine residues isolated from heterogeneous nuclear ribonucleoproteins (hnRNPs) are
asymmetrically dimethylated [28].

Most methylated proteins derived from cellular

extracts have a far greater amount of dimethylated arginine residues than
monomethylated arginine residues. Yet, the mechanism that the Type I PRMTs use to
ensure ADMA formation is unclear. Because ADMA is an important molecule that
mediates a variety of cellular processes [26], it is important to understand how ADMA is
formed.
In order to understand how ADMA is the major biological product of PRMT1methylation, we investigated the enzymatic mechanism of PRMT1. We hypothesized
that this biological phenomenon is achieved by the nature of PRMT1 preferentially
methylating monomethylated substrates rather than naked substrates.

Alternatively,

PRMT1 could perform processive arginine methylation wherein the substrate binds to the
enzyme and is not released until the arginine residue is fully dimethylated (see Scheme 52). We show here that PRMT1 dissociatively dimethylates peptides containing a single
arginine residue using mass spectrometry (MS) and HPLC analysis. Further kinetic
analysis revealed that PRMT1 prefers to methylate monomethylated peptide substrates
over their non-methylated counterparts. Methylation of a multiple arginine-containing
peptide (R2) was systematic (not random), and the analysis of the R2 peptide using a
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modified pulse-chase experiment and MS revealed that PRMT1 dissociatively
methylates fibrillarin-based peptides.
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Scheme 5-2. Dissociative versus processive methylation. Dissociative and processive
mechanisms are depicted for PRMT1. In a dissociative mechanism, PRMT1 (or
E=enzyme) monomethylates the arginine-containing peptide and releases it. When the
monomethylated species re-binds, another methyl group is transferred from AdoMet onto
the monomethylated peptide to yield the fully dimethylated product. In a processive
mechanism, PRMT1 mono- and dimethylates the single arginine-containing peptide
without releasing the monomethylated species from the active site.

MATERIALS AND METHODS
All chemicals used were of ACS reagent grade or better. AdoMet was purchased
from

Sigma

as

a

chloride

salt

(≥80%,

from

yeast).

JMH1-long

(GGKGGFGGRGGFGGKGGFG) was synthesized by Sigma Genosys. N-terminally
acetylated peptides based on the in vivo PRMT1 substrate fibrillarin, JMH1
(AcKGGFGGRGGFGGK),

JMH1W

(AcKGGFGGRGGFGGKW),

JMH1W-CH3

107
(AcKGGFGGRmethylGGFGGKW), and R2 (AcGGRGGFGGKGGRGGFG), were
synthesized and purified by the Keck Institute (Yale University). Two peptides based on
the in vivo PRMT1 substrate eukaryotic initiation factor 4A1 (eIF4A1), the eIF4A1
peptide (YIHRIGRGGR) and the eIF4A1-CH3 peptide (YIHRIGRmethylGGR), were
synthesized and purified by the Keck Institute. All peptides used in this study are listed
in Table 5-1.

Table 5-1 Peptides used to study PRMT1 formation of ADMA
Name
Peptide Sequence
KGGFGGRGGFGGK
JMH1
GGKGGFGGRGGFGGKGGFG
JMH1-long
KGGFGGRGGFGGKW
JMH1W
KGGFGGR(CH3)GGFGGKW
JMH1W-CH3
YIHRIGRGGR
eIF4A1
YIHRIGR(CH3)GGR
eIF4A1-CH3
GGRGGFGGKGGFGGRGGFG
R2
Peptide names with their corresponding sequences are listed. Arginine residues that are
methylated by PRMT1 are shown in bold.

HPLC analysis of a single arginine-containing peptide
HPLC analysis was used to analyze the formation of MMA and ADMA with time
[29]. Briefly, a reaction containing 2.5 µM PRMT1, 250 µM AdoMet, 100 nM AdoHcy
nucleosidase (purified as in [30]) in 50 mM sodium phosphate buffer (pH 7.5) was
initiated with 100 µM eIF4A1 peptide (see Table 5-1) at 37 ºC. Time points were taken
out and quenched in 10% TFA (final).

Precipitated protein was removed through

centrifugation. Soluble eIF4A1 peptide in the supernatant was hydrolyzed in 6 M HCl,
derivatized with the AccQ-Fluor™ reagent (Waters Corporation), and separated by
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reverse phase HPLC. This method provides base-line separation of arginine, MMA,
ADMA, and SDMA [29]. The area under the MMA and ADMA peaks were integrated.
Standard curves of known MMA and ADMA concentrations were used to calculate the
amount of MMA and ADMA in each sample.
Mass spectrometry analysis of a single
arginine-containing peptide
A reaction with 2.5 µM PRMT1, 250 µM AdoMet, and 100 nM MTAN in 50 mM
sodium phosphate buffer (pH 7.5) was initiated with 100 µM JMH1-long peptide (see
Table 5-1).

At various times points, 10 µL aliquots were quenched with TFA (10%

final) and analyzed by LC/MS. The intensities of substrate and product peaks were
normalized for ionization differences between time points using an internal standard
peptide with a similar amino acid composition as the fibrillarin-based peptide.
Kinetic analysis
A continuous spectrophotometric assay for AdoMet-dependent methyltransferases
(see Chapter 3) was used to assay PRMT1 with several fibrillarin-based methyl-accepting
peptides and two eIF4A1-based peptides (eIF4A1 and eIF4A1-CH3).

Briefly,

recombinant AdoHcy nucleosidase (MTAN) was used to hydrolyze the AdoHcy
generated from methyltransfer. The resulting adenine was deaminated by recombinant
adenine deaminase. This strategy alleviates any product inhibition that could occur from
AdoHcy. Each 110 µL reaction contained 4 µM His-PRMT1 (purified as in Chapter 3),
0.02 µM adenine deaminase (purified as in Chapter 3), 250 µM AdoMet, 10 nM MTAN
(purified as in [30]), 100 µM MnSO4, and 50 mM sodium phosphate buffer pH 7.1.
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Reactions were equilibrated at 37 ºC for ten minutes before they were initiated with
various amounts of peptide. The decrease in absorbance at 265 nm was monitored
continuously using a Cary 300 Bio UV-visible spectrophotometer. All rates were well
above the limit of detection of 0.1 μM CH3/min corresponding to a kcat of 0.025 min-1,
and the time frame utilized in fitting the raw spectrophotometric data was representative
of a single methylation event (see Chapter 4).
For calculation of kinetic constants, the concentration of peptide was varied at
several fixed concentrations of AdoMet (40 µM - 250 µM). The average initial velocity
representing no more than 10% of product formation was obtained from two
measurements for each pair of substrate concentrations and was used to construct
Michaelis-Menten plots. The data were graphed as Lineweaver-Burk plots, and linear
regression was employed to construct slope and intercept replots [31]. These replots
were linear and were used to calculate the values of the kinetic parameters.
Intrinsic fluorescence
An RF-5301PC spectrofluorophotometer (Shimadzu) was used for fluorescence
measurements. For peptide affinity determinations, an excitation wavelength of 290 nm
was used and emission spectra from 300-420 nm were collected.

The change in

fluorescence intensity at the maximum emission (333 nm) was monitored. The excitation
and emission slit was 5 nm and the scan speed was 100 nm/min using 1325 µL of 0.7 µM
PRMT1 in 150 mM sodium phosphate buffer pH 7.1. Increasing concentrations from 1
to 50 µM peptide ligand were added at 2-3 min intervals. Data from at least two
titrations were averaged and analyzed using a Stern-Volmer plot [32]. The linearity of

110
the Stern-Volmer plot suggests that cofactor binding is the dominant fluorescencequenching phenomenon over the range of concentrations tested. Data were evaluated by
least squares linear regression analysis to obtain the slope which corresponds to the
dissociation constant (KD).
HPLC analysis of multiple argininecontaining peptides
HPLC analysis was used in order to determine the time frame of the mass
spectrometry pulse-chase experiment and to quantify the amount of MMA produced at
various time points over the course of the reaction [29]. Reactions containing various
concentrations of PRMT1, 1200 µM AdoMet, 100 nM AdoHcy nucleosidase in 150 mM
sodium phosphate buffer (pH 7.1) were initiated with 200 µM R2 peptide on ice. Time
points were taken out and quenched in 10% TFA (final), and precipitated protein was
removed through centrifugation.

The R2 peptide in the resulting supernatant was

hydrolyzed in 6 M HCl, derivatized with the AccQ-Fluor™ reagent (Waters
Corporation), and the individual amino acids were separated by reverse phase HPLC
[29]. The area under the MMA peak was integrated, and a standard curve of known
MMA concentrations was used to calculate the amount of MMA formed in each reaction
mixture.
Mass spectrometry peptide methylation analysis
and De Novo sequencing study
A reaction with 4 µM PRMT1, 800 µM AdoMet, and 100 nM MTAN in 50 mM
sodium phosphate buffer (pH 7.1) was initiated with 200 µM R2 peptide.

At various

times points, 10 µL aliquots were quenched with TFA (10% final) and analyzed by
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LC/MS followed by MS/MS of the desired peaks.

Peptides with and without

methylation were analyzed using nano-LC-MS-MS on a Q-Tof Primer tandem mass
spectrometer (Waters, Manchester, UK). Peptide samples were loaded (3 µl) using a
NanoACQUITY Sample Manager (Waters, Manchester, UK) onto a trapping column
(Symmetry® C18, 180µM x 20mm) (Waters, Manchester, UK). Samples were washed
with 99% H2O and 1% acetonitrile for one minute at 15 µl/min to a waste container and
then eluted with a 30 min gradient (1-4% B in 0.1 minutes, 4-60% B in 20 minutes, 6085% B in 3 minutes, 85-1% B in 1 minute, and 1% B for 6 minutes where A = 99.9%
H2O, 0.1% formic acid and B = 99.9% acetonitrile, 0.1% formic acid) at 800nL/min
using an NanoACQUITY UPLC (Waters, Manchester, UK) over a 100 µm x 100 mm
BEH 130 C18 column. MS survey and product ion MS/MS scan times were 1.0 second.
The collision offset was automatically determined based on precursor mass and ion
charge state. MS/MS data was used for the De Novo sequencing of methylated peptides
by Waters BioLynx software (Waters, Manchester, UK).
Modified pulse-chase experiment to test
processivity of mono- to dimethylated R2
A reaction with 4 µM PRMT1, 1200 µM AdoMet, and 100 nM MTAN in 50 mM
sodium phosphate buffer (pH 7.1) was initiated (or pulsed) with 200 µM R2 peptide on
ice. At t=5.5 minutes, a 10 µL time point was quenched with TFA (10% final) to verify
that only monomethylation of R2 had taken place. At t=6 minutes, the reaction was
chased with 1 mM JMH1W-CH3 peptide. Note, a methylated chase peptide was used
instead of an unmodified peptide in order to design a fair competition experiment. To
determine if this portion of the reaction was processive, subsequent time points (t=6.5, 9,
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12, 15, and 20 minutes) were taken out and quenched in TFA (10% final).
Precipitated protein was removed, and soluble R2 and JMH1W-CH3 peptides (and their
methylated products) were analyzed using the MS analysis techniques described
previously. The sum of all peak intensities associated with the R2 peptide was used to
normalize each product peak intensity; e.g. the data point plotted for trimethylated R2
=peak intensity of trimethylated R2/sum of all peaks associated with R2.
Modified pulse-chase experiment to test
processivity of di- to trimethylated R2
A reaction with 4 µM PRMT1, 1200 µM AdoMet, and 100 nM MTAN in 50 mM
sodium phosphate buffer (pH 7.1) was initiated (or pulsed) with 200 µM R2 peptide at 37
ºC. At t=59.5 minutes, a 10 µL time point was quenched with TFA (10% final) to verify
that only mono- and dimethylation of R2 had taken place. At t=60 minutes, the reaction
was chased with 1 mM JMH1W-CH3 peptide. To determine if this portion of the reaction
was processive, additional time points (t=60.5, 70, 80, 100, 120, 150, and 200 minutes)
were taken out and quenched in TFA (10% final). Precipitated protein was removed, and
the soluble R2 peptide and JMH1W-CH3 peptide (and their methylated products) were
analyzed using the MS and data analysis techniques described previously.
RESULTS
PRMT1 dissociatively methylates a single
arginine-containing peptide
Many PRMT1 protein substrates are observed to have multiple methylated
arginines. Yet, it is unclear why or how the enzymatic conversion of all designated
arginines within a protein substrate is accomplished without generating diversity. If all
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designated arginines are required to be dimethylated for the biological effect, how
does PRMT1 accomplish this? One way to ensure a dimethylated product is to perform
processive methylation.

Previously, we showed by mass spectrometry analysis that

PRMT1 methylates a single arginine-containing fibrillarin-based peptide substrate
(AcKGGFGGRGGFGGK) in a dissociative manner (see Chapter 4). Here we show data
that suggests that PRMT1 dissociatively methylates another arginine-containing peptide
(YIHRIGRGGR) based on the eukaryotic initiation factor 4A1 (eIF4A1) protein based on
an initial lag in the formation of the dimethylated product (Fig. 5-1, A). Kinetic analysis
revealed that 4.7 ± 1.0 μM AdoHcy was generated in 45 seconds, a time in which mass
spectrometry results suggest no presence of dimethylated peptide. This amount was
higher than the concentration of enzyme (2.5 μM). In a processive mechanism, the
concentration of MMA would never exceed the concentration of enzyme in the reaction.
These data suggest that PRMT1 methylates the eIF4A1 peptide in a dissociative manner.
Note, only the central arginine (R7) of the eIF4A1 peptide is methylated by PRMT1 (see
Chapter 4).
Previous studies [33, 34] have shown that PRMT1 activity increases with peptide
length. In order to determine if peptide length also influences the manner in which the
substrate is methylated, we next increased the length of the dissociatively methylated
fibrillarin-based peptide (see Chapter 4) by six amino acids (AcKGGFGGRGGFGGK→
AcGGKGGFGGRGGFGGKGGFG)

to see if the longer peptide could be processively

methylated. Despite an increase in length, mass spectrometry analysis of a reaction with
the longer peptide displayed an obvious lag in the formation of dimethylated product
(Fig. 5-1, B) suggesting that methylation was dissociative. Kinetic analysis revealed that
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3.6 ± 1.1 μM AdoHcy was generated in 1 minute, a time in which mass spectrometry
results suggest no presence of dimethylated peptide. Because this amount was higher
than the concentration of enzyme (2.5 μM), the results support a dissociative mechanism.
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Fig. 5-1. Time-dependent formation of mono- and dimethylarginine. Reactions
containing 250 μM AdoMet and 2.5 μM PRMT1 in 50 mM sodium phosphate buffer (pH
7.5) were initiated with 100 μM eIF4A1 peptide (YIHRIGRGGR) in (A) or 100 μM
fibrillarin-based peptide (GGKGGFGGRGGFGGKGGFG) in (B). Aliquots were
quenched in TFA (10% final) at various times, analyzed by LC/MS, and peak intensities
of peptide product peaks were plotted as a function of time. Substrate and product peak
intensities were normalized for ionization differences using an internal standard peptide
with a similar amino acid composition as the fibrillarin-based peptide. Solid (●) and
dashed (○) lines indicate ratios of mono- and dimethylated peptide product/substrate,
respectively. The data support a distributive, or dissociative, mechanism.
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PRMT1 preferentially methylates monomethylated
substrates
As an alternative to processive methylation, another way to ensure the formation
of a dimethylated product biologically is if PRMT1 were to preferentially methylate a
substrate that has already been methylated. To test this, we compared how well PRMT1
could

methylate

the

monomethylated

peptide

substrates

(JMH1W-

CH3=AcKGGFGGRmethylGGFGGKW; eIF4A1-CH3=YIHRIGRmethylGGR) versus the
naked peptide substrates (JMH1W=AcKGGFGGRGGFGGKW; eIF4A1=YIHRIGRGGR)
using a continuous spectrophotometric assay for AdoMet-dependent methyltransferases
(see Chapter 3). Kinetic data were collected and analyzed as described in the methods
section.

Michaelis-Menten plots for the JMH1W-CH3 and JMH1W peptides with

PRMT1 show that the peptides were able to saturate PRMT1 at a variety of fixed
AdoMet concentrations (data not shown). A Lineweaver Burk plot of the data indicated
that PRMT1 performs a sequential reaction mechanism with the JMH1W-CH3 and
JMH1W peptides (data not shown). This type of reaction mechanism is consistent with
the PRMT6 reaction mechanism [34, 35].

PRMT1 preferentially methylated the

monomethylated substrate, JMH1W-CH3 (see Table 5-2). The Km was smaller (Km,
peptide=

5.78 µM) and the catalytic efficiency was higher (kcat/Km= 4890 M-1s-1) for the

monomethylated substrate in comparison to the values obtained for the unmodified
JMH1W peptide (Km, peptide= 54.7 µM; kcat/Km= 1640 M-1s-1).
The same trend was observed with an additional peptide substrate pair (Table 5-2)
based on the PRMT1 protein substrate eIF4A1 (see Chapter 4). Michaelis-Menten plots
for the eIF4A1-CH3 and eIF4A1 peptides with PRMT1 showed that peptides were able to
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saturate PRMT1 at a variety of fixed AdoMet concentrations. A Lineweaver Burk
plot of the eIF4A1-CH3 and eIF4A1 peptide data indicated that PRMT1 performs a
sequential reaction mechanism with each peptide (data not shown). PRMT1 preferred to
methylate the monomethylated eIF4A1 substrate (kcat/Km= 2610 M-1s-1) versus the
unmodified substrate (kcat/Km= 1960 M-1s-1) (see Table 5-2). Such a preference for
arginine residues that have already been monomethylated by PRMT1 would lead to an
increasing amount of asymmetrically dimethylated protein arginine residues.

Table 5-2 Kinetic constants for PRMT1 with naked and monomethylated peptides
Peptide Sequence
Km, SAM
Km,
Vmax
kcat/Km
(μM)
(μM
(M-1s-1)
peptide
(μM)
CH3/min)
KGGFGGRGGFGGKW
117
54.7
21.5
1640
JMH1W
KGGFGGR(CH
)GGFGGKW
3
15.1
5.78
6.79
4890
JMH1W-CH3
YIHRIGRGGR
35.3
52.4
21.4
1960
eIF4A1
YIHRIGR(CH
)GGR
3
49.1
28.2
17.7
2610
eIF4A1-CH3
All kinetic constants were obtained using a continuous spectrophotometric assay for
AdoMet-dependent methyltransferases (see Chapter 3). Substrate arginine residues are
bolded.

Peptide binding
In order to discern if the preference for PRMT1 to modify monomethylated
arginine residues was also due to preferential binding, we measured the dissociation
constants between PRMT1 and the eIF4A1 peptide substrate pair. The PRMT1 crystal
structure depicts two tryptophans at positions 145 and 294 which lie in the catalytic
region near the substrate arginine residue opposite the AdoMet binding region [36]. The
intrinsic fluorescent-properites of PRMT1 were exploited in a fluorescence-quenching
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assay to determine the dissociation constants for the eIF4A1 and eIF4A1-CH3
peptides with PRMT1. The Stern-Volmer plot [32] was used to analyze the quenching
data (Fig. 5-2, A). A Stern-Volmer plot for the eIF4A1 and eIF4A1-CH3 peptides (Fig. 2,
B) revealed that both the methylated and nonmethylated eIF4A1 peptides had nearly the
same affinity for PRMT1 as judged by the similar Kd values (Table 5-3). These results
indicate that preference for the monomethylated substrate is not due to binding.
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Fig. 5-2. Naked and monomethylated substrates bind similarly to PRMT1. (A)
Steady-state fluorescence emission spectra of PRMT1 with the eIF4A1-CH3 peptide
where buffer (○), enzyme (●), 1 μM peptide (Δ), and 15 μM peptide (▲) are shown. (B)
Stern-Volmer plot of quenching of PRMT1 fluorescence by the eIF4A1-CH3 peptide.
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Table 5-3. Peptide dissociation constants.
Fluorescence quenching (%)
Peptide Ligand
KD (nM)
51 ± 7.2
30 ± 2.0
eIF4A1
41 ± 5.0
25 ± 4.7
eIF4A1-CH3
Dissociation constants were obtained using intrinsic fluorescence quenching assays
(performed at least in duplicate) as described in the methods section. The quenching
observed was consistent with the number of active site tryptophans relative to the total
number of tryptophans.

Methylation of a multiple arginine-containing
substrate is systematic
Most PRMT1 protein substrates harbor regions that contain multiple sites of
arginine methylation. It is unknown which of these sites undergoes methylation first. Is
one site preferentially methylated on a substrate containing multiple arginine residues
(systematic methylation), or is there no preference for which arginine on a multiple
arginine-containing substrate gets methylated first (random methylation)? To examine
how PRMT1 methylates substrates containing multiple arginine residues (random versus
systematic methylation), we designed another fibrillarin-based peptide substrate,
R2=AcGGRGGFGGKGGFGGRGGFG.

The R2 peptide was first assessed by mass

spectrometry to assess purity (bottom spectrum, Fig. 5-3, A). The R2 peptide was then
purified (top spectrum, Fig. 5-3, A) and used in all experiments thereafter.
First, we analyzed the product formation of the purified R2 peptide with time
using mass spectrometry. This technique allowed us to identify the methylated products
at various time points and distinguish which arginine residue that had been modified. A
reaction containing 4 µM PRMT1, 800 µM AdoMet, and 10 nM MTA-nucleosidase was
initiated with 200 µM purified R2 peptide. The bottom mass spectrum of Fig. 5-3, B
shows that R2 (561.9 m/z) was monomethylated (566.6 m/z) within seconds of initiating
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the reaction. MS/MS analysis was used to further analyze the dimethylated peptide
product peak (571.3 m/z) (top spectrum, Fig. 5-3, B). We observed that only the Nterminal arginine of the R2 peptide had been di-methylated. MS/MS sequencing data
shown

in

Fig.

5-3,

C

methyl)GGFGGKGGFGGRGGFG.

gave

the

following

sequence:

GGR(2-

No methylation of the C-terminal arginine of R2 was

detected (Fig. 5-3, C). This indicates that the N-terminal arginine of R2 was first monoand then dimethylated. After an extended reaction (8 hours), MS/MS analysis was used
to confirm the location of methylation of the tetramethylated R2 peptide.

MS/MS

analysis of the tetramethylated peptide peak (581 m/z) (MS data not shown) revealed that
R2 had also been dimethylated on the C-terminal arginine (Fig. 5-3, D).

MS/MS

sequencing data shown in Fig. 5-3, D gave the following sequence: GGR(2methyl)GGFGGKGGFGGR(2-methyl)GGFG.

Scheme 5-3 summarizes the series of

methylation events and indicates that methylation of R2 was systematic and not random.
Like R2, preliminary MS/MS data suggests that the R3 peptide that has an additional
arginine

residue

is

also

methylated

at

its

N-terminal

GGR(methyl)GGFGGRGGFGGRGGFG (data not shown).

arginine

first

Altogether, these results

demonstrate that 1) one arginine is preferentially methylated over another, 2) both arginyl
groups in R2 can be converted to ADMA, and 3) methylated product species can be
effectively separated and detected using MS.

R2

R2

co ntam in an ts

Fig. 5-3. MS data shows that methylation of a multiple arginine-containing substrate is systematic.
(A) Mass spectrums of the R2 peptide (561.9 m/z) before (bottome) and after purification (top). (B) A
reaction containing 4 μM PRMT1 and 800 μM AdoMet was initiated with 200 μM R2 (pure). The
modified peptide was analyzed by MS. The 0.5 minute time point (bottom) depicts the formation of
monomethylated R2 at 566.66 m/z (mono). The 24.5 minute sample (top) shows the formation of
dimethylated R2 at 571.3 m/z (di). (C) MS/MS was used to confirm the location of methylation of the
dimethylated R2 peptide. (D) After an extended reaction (8 hours), MS/MS analysis was used to
confirm the location of methylation of the tetramethylated R2 peptide peak (581 m/z).
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Scheme 5-3. Methylation of R2 is systematic, not random. The Nterminal arginine of
R2 (AcGGRGGFGGKGGFGGRGGFG) is monomethylated first. Dimethylation of this
modified arginine occurs next followed by the mono- and subsequent dimethylation of
the Cterminal arginine.

Methylation of a multiple arginine-containing
substrate is dissociative
One way to ensure dimethylated product formation would be to perform
processive methylation. Although we have shown that PRMT1 methylates substrates
containing a single arginine residue in a dissociative manner (Fig. 5-1 and Chapter 4), it
is possible that multiple arginine-containing substrates are processed differently.
Because most PRMT1 protein substrates are found to be dimethylated on multiple
arginine residues within the same protein, we examined how PRMT1 methylates a
multiple arginine-containing substrate (processive versus dissociative methylation) at two
different levels. First, examined how a single arginine residue in a multiple arginine-
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containing substrate was methylated. Second, we examined if methylation from one
arginine residue to the next arginine residue on the same substrate was processive.
Using the R2 peptide, which we have shown is first mono- and then dimethylated
at the N-terminal arginine (Fig. 5-3), we tested if PRMT1 could processively dimethylate
the

N-terminal

arginine

residue

(GGRGGFGGKGGFGGRGGFG

→

GGRdimethylGGFGGKGGFGGRGGFG). First, reverse phase HPLC analysis [29] of the
acid-hydrolyzed product R2 peptide was used to verify the reaction time in which only
monomethyl arginine was present (Fig. 5-4). This method along with a standard curve of
MMA was then used to quantify the amount of MMA generated up until the time that the
reaction was quenched with TFA. At 20 minutes, approximately 4.2 μM MMA had been
formed. This amount was greater than the 10 nM enzyme in the reaction. Since R2 is
monomethylated at the N-terminal arginine first followed by the dimethylation of that
same arginine residue (and not the monomethylation of the C-terminal arginine residue),
a higher concentration of MMA than enzyme in the reaction indicates that methylation is
dissociative.

If the mechanism had been processive, the concentration of MMA

(monomethylated-R2) would have never exceeded the concentration of enzyme.
A modified pulse-chase experiment (Fig. 5-5, A) coupled to mass spectrometry
analysis was used to verify that the dimethylation of the N-terminal arginine
(GGRGGFGGKGGFGGRGGFG

→

GGRdimethylGGFGGKGGFGGRGGFG)

was

dissociative. A reaction containing 4 µM PRMT1 and 1200 µM AdoMet was pulsed
with 200 µM R2 peptide substrate at 37 ºC. At 6 minutes, a time point where only the
monomethylated product peak was detected by mass spectrometry (bottom spectrum in
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Fig. 5-4. HPLC chromatogram verifies the presence of arginine and MMA only. A
reaction containing 10 nM PRMT1, 1200 µM AdoMet, and 10 nM MTA-nucleosidase in
150 mM sodium phosphate buffer pH 7.1 was initiated with 200 µM R2 peptide on ice.
Time points were taken out and quenched 1:1 in 20% TFA. Precipitated protein was
removed through centrifugation, and the resulting supernatant containing the modified
peptide was hydrolyzed with concentrated HCl. Samples were derivatized with the
AQFluor reagent and analyzed by HPLC. The HPLC chromatogram indicates that only
arginine (Arg) and monomethylated arginine (MMA) at 24.5 min and 31.7 min,
respectively, were present after a 5 minute reaction on ice (bold line). MMA and ADMA
standards injected separately are shown in gray.

Fig. 5-5, B), the reaction was chased with an excess amount (1 mM) of JMH1W-CH3
peptide (KGGFGGR(CH3)GGFGGKW). Time points were taken out at 6.5, 9, 12, 15,
and 20 minutes (Fig. 5-5, C) and compared to time points from a control reaction that had
been pulsed with R2 and chased with water at 6 minutes (data not shown). Fig. 5-5, C
shows that the chase peptide (475.88 m/z) was dimethylated (479.9 m/z) with time. On
the other hand, the peak intensity of the dimethylated R2 peptide product (571.29 m/ z)
did not increase as much with time when the reaction was chased with the JMH1W-CH3
peptide (Fig. 5-5, D) when compared to the control reaction containing the R2 pulse only.
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Importantly, a sample of the chase peptide alone verified that the dimethylated chase
peptide peak was not present in the JMH1W-CH3 peptide standard (data not shown).
Furthermore, the peak intensities obtained from the raw mass spectrometry data
were plotted against time (as described in the methods section) in Fig. 5-5, E for the R2
only control reaction (left panel) and the chase reaction (right panel). Dimethylation of
R2 was clearly influenced by the chase peptide. The dimethylated R2 peak increased
0.08 from 6.5-20 minutes in the control reaction but only increased 0.03 from 6.5-20
minutes in the chase reaction (Fig. 5-5, E). Because the chase peptide was methylated
almost immediately in this experiment, the monomethylated R2 peptide had to have been
released from the PRMT1 active site. These results indicate that dimethylation of a
single arginine residue is dissociative on a substrate containing multiple arginine
residues.
Finally, we examined if methylation from one arginine to the next arginine
residue on the same substrate was processive. In a separate modified pulse chase mass
spectrometry experiment (Fig. 5-6, A), we tested if the mechanism going from
dimethylated-R2

(at

the

N-terminal

arginine)

to

trimethylated-R2

(GGRdimethylGGFGGKGGFGGRGGFG → GGRdimethylGGFGGKGGFGGRmethylGGFG)
was processive. A reaction containing 4 µM PRMT1 and 1200 µM AdoMet was pulsed
with the 200 µM R2 peptide substrate at 37 ºC. At 60 minutes, a time point where only
the mono- and dimethylated product peaks were detected by mass spectrometry (see
bottom trace of Fig. 5-6, B), the reaction was chased with an excess amount of JMH1WCH3 peptide (1 mM). Later time points were quenched and analyzed by MS. The data
showed that the chase peptide was dimethylated with time (479.9 m/z in Fig. 5-6, C).
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Fig. 5-5. PRMT1 performs dissociative methylation of a single arginine residue on a
multiple arginine-containing substrate. (A) Modified pulse chase mass spectrometry
experimental design. PRMT1 was allowed to methylate the R2 peptide (pulse) for a
period of time wherein the first methylation event could occur. A time point is taken out
to verify the presence of the monomethylated species. The reaction is then chased with
an excess of JMH1W-CH3 peptide. Subsequent time points are taken out and analyzed
by mass spectrometry to identify if the chase peptide gets methylated immediately, a
result indicative of a dissociative mechanism. (B) MS samples of the R2 peptide control
reaction at 6, 9, 12, and 15 minutes where the native (R2), monomethylated (mono), and
dimethylated (di) R2 peaks are labeled at 561.9 m/z, 566.6 m/z, and 571.3 m/z,
respectively. (C-D) At 6 minutes, a reaction that had been pulsed with 200 µM R2 was
chased with 1 mM JMH1W-CH3 peptide. Subsequent time points (6.5, 9, 12, 15, and 20
minutes) were quenched and analyzed by MS to identify if the chase peptide (475.88
m/z) or the R2 peptide was dimethylated. (C) Mass spectrums reveal that the chase
peptide was dimethylated (di-chase=479.9 m/z) with time while the R2 peptide was not
dimethylated (R2-di=571.29 m/z) with time (in D). The bottom mass spectrum from the
59.5 minute time point (in both C and D) was taken out before the chase peptide was
added. (E) Time dependent formation of mono- and dimethylated R2 from the R2 only
control reaction (left panel) and chase reaction (right panel). Peak intensities associated
with each product were normalized as discussed in the materials and methods section and
were plotted as a function of time. Filled circles (●), open circles (○), and triangles (▲)
represent monomethylated-R2, dimethylated-R2, and the dimethylated-chase peptide,
respectively.
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The peak intensities of trimethylated-R2 grew slower (Fig. 5-6, D) than the peak
intensities from the R2 only pulse reaction (raw data not shown). The ratios of the peak
intensities obtained from the raw MS data were plotted against time (as described in the
methods section) in Fig. 5-6, E for the R2 only control reaction (left panel) and chase
reaction (right panel). Both the di- and trimethylated R2 peak intensities did not increase
as much with time when the chase peptide was added. PRMT1 preferentially methylated
the chase peptide over both the mono- and dimethylated R2 peptides.

In fact, the

dimethylated R2 peak increased 0.27 from 60-200 minutes in the control reaction but
increased only 0.02 during the chase reaction (Fig. 5-6, E). The trimethylated R2 peak
increased 0.14 from 60-200 minutes in the control reaction but only increased 0.02 from
60.5-200 minutes in the chase reaction (Fig. 5-6, E). Our results indicate once again that
the catalytic event going from mono- to dimethylated R2 is dissociative
(GGRmethylGGFGGKGGFGGRGGFG

→

GGRdimethylGGFGGKGGFGGRGGFG).
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However, these results do not definitively prove that going from di- to trimethylated
(GGRdimethylGGFGGKGGFGGRGGFG

R2

→

GGRdimethylGGFGGKGGFGGRmethylGGFG) is dissociative. In order to prove whether
this event was truly dissociative, the reaction was chased at 200 minutes instead of 60
minutes wherein a larger buildup of the dimethylated-R2 product had been generated.
Unfortunately, the activity of the enzyme used to perform this chase experiment had
decreased upon storage at 4 ºC for days. The buildup of dimethylated-R2 product was
comparable to the previous 60 minute chase experiment. Despite any experimental
complications, the preliminary data suggest a dissociative mechanism wherein PRMT1
releases the N-terminally dimethylated-R2 product before it rebinds and monomethylates
the Cterminal arginine.
DISCUSSION
PRMT1 preferentially methylates monomethylated
substrates dissociatively
Previously, we demonstrated that the dimethylation of a single argininecontaining fibrillarin-based peptide substrate occurs through a dissociative mechanism
based on an observable lag in the formation of the dimethylated product using mass
spectrometry (see Chapter 4).

Mass spectrometry analysis suggests that the eIF4A1

peptide was also dissociatively methylated by PRMT1 (Fig. 5-1, A). Our results are
consistent with Frankel and coworkers who also observed dissociative methylation of a
minimal peptide (WGGYSRGGYGGW) by PRMT6 [35], but are different from the
findings of Thompson and co-workers who defined a partially processive dimethylation
of a histone 4 peptide (AcSGRGKGGKGLGKGGAKRHRKV) by PRMT1 [33, 34].
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Fig. 5-6. PRMT1 may dissociatively dimethylate multiple arginine residues. (A)
Modified pulse chase mass spectrometry experimental design. PRMT1 methylates the
R2 peptide (pulse) for a period of time wherein only two methylation events have
occurred. The reaction is chased with JMH1W-CH3 peptide in excess. Subsequent time
points are quenched and analyzed by MS. If the chase peptide gets methylated
immediately (before R2 trimethylation), PRMT1 is dissociative. (B) MS samples of the
R2 peptide control reaction at 59.5, 60, 70, 80, 100, 120, 150, and 200 minutes where the
native (R2), monomethylated (mono), dimethylated (di), and trimethylated (tri) R2 peaks
are labeled at 561.9 m/z, 566.6 m/z, 571.3 m/z, and 576.3 m/z respectively. Only the top
spectrum is labeled for clarity. (C-D) At 60 minutes, the reaction with 200 µM R2 was
chased with 1 mM JMH1W-CH3 peptide. Time points (60.5, 70, 80, 100, 120, 150, and
200 minutes) were quenched in TFA (10% final). Mass spectrums revealed that the
chase peptide was dimethylated (di-chase=479.9 m/z) with time in (C) while the R2
peptide underwent little trimethylation (R2-tri=576.3 m/z) (D). The 59.5 minute sample
(bottom spectrum in C and D) was taken out before the chase peptide was added. (E)
Time dependent formation of mono-, di-, and trimethylated R2 from the R2 only control
reaction (left panel) and chase reaction (right panel). Peak intensities associated with
each product were normalized as discussed in the materials and methods section and were
plotted as a function of time. The mono- (●), di- (○), and trimethylated (▲) R2 peptides
along with the dimethylated chase peptide (□) are shown.
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Because the fibrillarin-based substrates (see Chapter 4 and [35]) and the eIF4A1based substrate (Fig. 5-1, A) were 12-13 amino acids long and the histone 4 peptide was
21 amino acids long, substrate length could influence the PRMT1 mechanism. However,
despite an increase in peptide length, our results suggest that the longer fibrillarin-based
peptide substrate was dissociatively dimethylated as indicated by a lag in the formation of
the dimethylated product (Fig. 5-1, B). In a dissociative mechanism, the formation of the
dimethylated peptide product depends upon how easily PRMT1 can recapture the
monomethylated

product.

Frankel

and co-workers

have

reported

that

the

monomethylated peptide substrate is a better substrate for PRMT6 than the naked peptide
[35]. We observed similar results with two fibrillarin-based peptides (JMH1W and
JMH1W-CH3) (Table 5-2).

PRMT1 preferentially methylated the monomethylated

substrate versus the naked peptide 3 to 1.
In order to understand if the sequence differences between a fibrillarin-based
peptide and a histone 4-based peptide may be the basis for the different mechanistic
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observations, we examined the kinetic parameters of an additional peptide substrate
pair (eIF4A1 and eIF4A1-CH3) derived from eIF4A1, another PRMT1 protein substrate.
This time, we observed that the monomethylated peptide substrate was a better substrate
for PRMT1 than the naked peptide (Table 5-2), but the preference for the
monomethylated eIF4A1 substrate versus the naked peptide was not as significant (1.33
to 1).

The mechanistic basis for the observed preference for the monomethylated

substrate is not due to binding as evidenced by the similar dissociation constants between
eIF4A1 and eIF4A1-CH3 (Table 5-3).

A slight preference for the monomethylated

substrate must be due to other factors in the kinetic mechanism.
Perhaps the methylated peptides examined adopt a conformation in the active site
that facilitates a better SN2 attack of the methyl group on AdoMet than the nonmethylated
peptide. Alternatively, the central position of the substrate arginine in the peptides tested
may structurally constrain the arginine only allowing for a more restricted mechanism
where the peptide has to dissociate from the enzyme before dimethylation can occur. An
arginine located towards the N or C-terminal end of the peptide (as in the case of the H4
peptide [33, 34]) may have more flexibility allowing a second methyl group to transfer to
the substrate arginine resulting in more of a semi-processive mechanism. A crystal
structure of PRMT1 with a monomethylated peptide would allow us to visualize how a
monomethylated substrate interacts with PRMT1 and may help us understand the
mechanism.
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PRMT1 methylation of substrates containing
multiple arginine residues
PRMT1 methylation of substrates containing multiple modification sites was
shown to be systematic (not random) using mass spectrometry (Fig. 5-3).
Monomethylation of the R2 peptide occurred first at the N-terminal arginine residue.
This monomethylated arginine was then dimethylated, a result that is consistent with the
fact that PRMT1 prefers to methylate arginine residues that have already been
monomethylated versus non-methylated arginine residues (Table 5-2). PRMT1 then
went on to trimethylate and then fully methylate R2 at the C-terminal peptidyl arginine.
PRMT1 systematically methylated arginine residues in a multiple arginine-containing
substrate. Preliminary MS/MS evidence suggests that the N-terminal arginine of R3
(GGRGGFGGRGGFGGRGGFG) is also methylated first suggesting that methylation
does not occur randomly (data not shown). Although these results were obtained using
peptide substrates, PRMT may also methylate multiple arginine residues in protein
substrates in a systematic manner. PRMT1 methylation of multiple arginine residues on
a protein substrate may result in different biological responses depending on the order in
which a series of arginines is methylated.
Next, using two carefully designed modified-pulse chase experiments, we found
that the methylation of a substrate containing multiple arginine residues was dissociative.
First, we found that going from monomethylated to dimethylated R2 at the N-terminal
arginine

(GGRnakedGGFGGKGGFGGRGGFG

→

GGRdimethylGGFGGKGGFGGRGGFG) was dissociative when the reaction containing
R2 was flooded with chase peptide. Because the chase peptide was methylated shortly
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after its addition (Fig. 5-5, E), the R2 peptide had to have been released from
PRMT1. Also supporting a dissociative mechanism was the fact that the concentration of
MMA was greater than the concentration of enzyme in the reaction when no ADMA was
present (Fig. 5-4).

If the mechanism were processive, the concentration of MMA

(monomethylated-R2) could never exceed the concentration of enzyme. A dissociative
mechanism is consistent with what we (see Fig. 5-1 and Chapter 4) and others [35] had
already determined for peptides containing a single arginine residue.

Although the

presence of another arginine residue in the peptide sequence could have altered how
PRMT1 performed catalysis, the dissociative mechanism remained the same.
Finally, preliminary results suggested that the methylation of one arginine to the
methylation of another arginine residue on the same peptide substrate was dissociative
(GGRmonomethylGGFGGKGGFGGRGGFG

→

GGRdimethylGGFGGKGGFGGRmethylGGFG). The reaction was chased at a time (60
minutes) in which most of the R2 peptide was not mostly dimethylated. When this
reaction was flooded with chase peptide, the chase peptide was methylated before the R2
peptide could be di- or trimethylated (Fig. 5-6, E).
trimethylation were substantially impeded.

Both R2 dimethylation and

These results 1) verify that R2

monomethylation to dimethylation follows a dissociative mechanism and 2) suggest that
PRMT1 releases the dimethylated peptide product before it can rebind and
monomethylate the C-terminal peptidyl arginine residue. In order to definitively prove if
the mechanism from di- to trimethylated-R2 is dissociative, however, the reaction was
chased at a later time point (200 minutes) wherein R2 should have been mostly
dimethylated. Although some trimethylation of R2 will have already occurred by this
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time, the correct mechanistic event (methylation of one arginine to another on the
same peptide) will be probed.

Unfortunately, the PRMT1 used to perform this

experiment was nearly inactive due to multiple freeze/thaw cycles and the data was not
usable. If PRMT1 is found to methylate multiple arginine residues in a dissociative
manner, the following scheme will be proposed (Scheme 5-4).
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Scheme 5-4. Suggested reaction mechanism scheme of PRMT1 with the R2 peptide.
PRMT1 (E=enzyme) interacts with AdoMet and the R2 peptide. The first methylation
event takes place, and both products (AdoHcy and R2mono-CH3) dissociate from
PRMT1. Monomethylated-R2 and AdoMet re-bind to PRMT1. Dimethylation occurs,
and both products are released. Dimethylated-R2 and another molecule of AdoMet rebind to PRMT1 and trimethylated-R2 is generated. AdoHcy and R2tri-CH3 are released.
Finally, R2 is fully methylated when the trimethylated peptide and another molecule of
AdoMet bind to PRMT1. Fully methylated-R2 and AdoHcy are released from the
PRMT1 active site. Note, because the order of substrate binding and product release is
not known, the rebinding event of the peptide products are not shown for simplicity.
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We have shown that PRMT1 methylates arginine-containing peptide
substrates in a systematic manner preferring to methylate substrates that have already
been monomethylated. These results may be extended to help explain how PRMT1
methylates protein substrates; however, the structural surface of a protein substrate may
be more restrictive (less flexible) than a peptide substrate. Based on the fact that PRMT1
did not methylate multiple arginines within the same substrate randomly, PRMT1 may
exhibit directional methylation of protein substrates or even utilize a type of scanning
mechanism. All in all, methylation of multiple arginine residues on a protein substrate by
PRMT1 has the potential to result in different biological responses depending on the
order in which a series of arginines is methylated.
Conclusion
Many PRMT1 protein substrates such as fibrillarin, the hnRNPs, and SAM68 are
asymmetrically dimethylated at multiple arginine residues.

In order to explain the

biological predominance of ADMA, we investigated the catalytic mechanism of PRMT1.
Although some methyltransferases have been shown to catalyze processive methylation
[37-40], an enzymatic feature that would help explain the predominance of ADMA,
PRMT1 does not catalyze processive methylation of fibrillarin-based peptides. Instead,
we have shown that PRMT1 methylates single arginine-containing peptides in a
dissociative manner. Methylation of a single arginine in a multiple arginine-containing
peptide was shown to be dissociative. PRMT1 preferentially monomethylated substrates
versus the unmodified peptide substrates, a phenomenon that may result from substrate
length, sequence, and/or the location of the substrate arginine within the substrate. Based
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on these results, the predominance of dimethylated protein substrates in vivo is likely
due to the PRMT1 mechanism and the preference for monomethylated proteins.
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CHAPTER 6
DETERMINANTS OF PRMT1 PRODUCT FORMATION: ROLES OF ACTIVE SITE
RESIDUES1

ABSTRACT
Protein arginine methyltransferases (PRMTs) play important roles in biology.
Type I methyltransferases, PRMT1, 3, 4, 6, and 8, catalyze the formation of monomethyl
arginine (MMA) and asymmetric dimethylarginine (ADMA) on protein arginine residues
via methyl group transfers from S-adenosyl methionine (AdoMet/SAM). PRMT5, a
Type II methyltransferase performs symmetric dimethylation generating symmetric
dimethylarginine (SDMA).

Encoded in each isoform is the necessary active site

geometry and chemical functionalities to generate SDMA or ADMA and regulate how
much MMA versus ADMA is made. Using the crystal structure of ratPRMT1 as our
guide, we analyzed the effect of several active site mutations on the rate of methylation
and the ability of PRMT1 to selectively perform asymmetric dimethylation. Met155 has
been proposed to play a direct role in dictating ADMA formation. M155A-PRMT1 was
assayed with R3, a 19 amino acid peptide derived from the in vivo PRMT1 substrate
fibrillarin and exhibited approximately one tenth the activity of wild type PRMT1.
Peptide products were hydrolyzed and analyzed by fluorescent derivatization via RPHPLC. Only MMA and ADMA were produced. Thus, removing steric bulk afforded by
Met155 in the PRMT1 active site is not by itself sufficient to transform PRMT1 into a
1

Coauthored by W.L. Wooderchak, J.M. Hevel, Determinants of PRMT1 product
formation: Roles of active site residues, Biochemistry (2009), manuscript in preparation.
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Type II PRMT. Other PRMT1 mutants (M48A, M146A, S154A, W145A, Y148S,
and M48L-PRMT1) displayed altered methyltransferase activity generating only MMA
and ADMA. Importantly, we show that Met48 plays a critical role in PRMT1-catalysis.

INTRODUCTION
Protein arginine methyltransferases (PRMTs) catalyze the transfer of a methyl
group from S-adenosyl methionine (SAM/AdoMet) to one of the terminal guanidino
groups of arginine generating monomethyl arginine (MMA) and S-adenosyl
homocysteine (SAH/AdoHcy).

Type I methyltransferases, PRMT1, 3, 4, 6, and 8,

asymmetrically dimethylate arginine on the same guanidino nitrogen and form
asymmetric dimethylarginine (ADMA) [1-6]. Type II methyltransferases, PRMT5 and
PRMT7, perform symmetric dimethylation wherein the guanidino nitrogens are modified
to produce symmetric dimethylarginine (SDMA) (Scheme 6-1) [7, 8].

Selective

formation of ADMA by PRMT1 has many biological implications [9]; specifically, Arg 3
of histone H4 can be aymmetrically dimethylated by PRMT1 or symmetrically
dimethylated by PRMT5 resulting in antagonistic biological consequences (reviewed in
[10]). Because of this, we wanted to study why PRMT1 selectively forms ADMA versus
SDMA.
Once a protein has been modified, it is eventually degraded in the proteasome and
free MMA, SDMA, and ADMA are released. Interestingly, higher levels of free ADMA
have been linked to cardiovascular disease (reviewed in [11]) and stroke [12]. ADMA is
also second only to age as a predictor of mortality and cardiovascular events in chronic
renal failure patients [13]. ADMA and MMA are endogenous inhibitors of nitric oxide

151
synthase (NOS) [14] which catalyzes the formation of nitric oxide, a vasodilator that
prevents atherosclerosis. Fortunately, free MMA and ADMA levels are controlled by
dimethylarginine dimethylaminohydrolases (DDAHs), but the misregulation of DDAH or
the hyperactivity of PRMTs may contribute to cardiovascular disease [15]. In fact,
PRMT1 has been shown to be overexpressed in myocardial tissue taken from coronary
heart disease patients [16]. Because PRMT1 performs an estimated 85% of all protein
arginine methylation in vivo [17], this isoform generates more ADMA than all other
PRMT isoforms combined. Therefore, it is important to understand how PRMTs control
Type I (asymmetric) versus Type II (symmetric) dimethylation.
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+
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+
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Scheme 6-1.
Reactions catalyzed by PRMTs.
PRMTs catalyze the Sadenosylmethionine (AdoMet) dependent methylation of a protein substrate arginine
residue to form monomethyl arginine (MMA). Type I methyltransferases, PRMT1, 3, 4,
6, 8, and 10 dimethylate arginine asymmetrically to form asymmetric dimethyl arginine
(ADMA). Type II methyltransferases, PRMT5, 7, and 9 catalyze the formation of
symmetric dimethyl arginine (SDMA).
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The crystal structure of PRMT1 [18] has been used to offer an explanation as
to why Type I PRMTs exclusively perform asymmetric dimethylation versus symmetric
dimethylation.

Interestingly, all Type I PRMTs contain an active site methionine

(Met155 for rat PRMT1) which is not conserved among Type II PRMTs. Methionine
155, located at the end of an alpha helix positioned near the reactive arginine of the
substrate peptide (Fig. 6-1), has been proposed to exclude monomethylated arginine from
binding in a conformation that would allow its symmetric dimethylation [18]. The
residue corresponding to Met155 in the Type II PRMT5 is a serine (amino acid 446 in rat
PRMT5 and amino acid 474 in yeast PRMT5). PRMT7, another Type II PRMT, has an
alanine residue in place of the bulky methionine at this location. It was hypothesized that
the smaller bulk of the serine and alanine side chains at this location may enable the free
rotation of the substrate arginine about the terminal C-N bond resulting in the formation
SDMA formation.

Fig. 6-1. Active site methionines position the substrate arginine. The active site of rat
PRMT1 (PDB code 1OR8) is shown with AdoHcy (cyan) and the R3 peptide in orange.
The substrate arginine of R3 is depicted in ball and stick mode with the two guanidino
nitrogens pointing towards the sulfur atom (blue) of AdoHcy. Met 155 (left) and Met 48
(right) are shown in yellow as sticks with their electron densities depicted in dots.
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In addition to Met155, we hypothesized that another active site methionine
residue (Met48 in rat PRMT1) positioned near the reactive substrate arginine (Fig. 6-1)
plays a role in selective ADMA formation. This methionine residue is conserved among
all Type I enzymes but is replaced by a proline in the Type II PRMT5. The presence of a
proline instead of a methionine at this position could open up the active site pocket
enough to allow for the free rotation about the substrate arginine terminal C-N bond. In
addition to controlling exclusive ADMA formation, Met 155 and Met 48 may serve
another role. Mechanistically speaking, the pair of methionines (Met155 and Met48
depicted in Fig. 6-1) could act as a molecular tweezer aligning the guanidino nitrogen for
the most efficient SN2 methyl transfer among Type I PRMTs.
The crystal structures of ratPRMT3 [19] and ratPRMT1 bound to AdoHcy and
substrate peptide [18] have offered much insight into the PRMT reaction. A mechanism
has been proposed where the carboxylate of an active site glutamate (Glu153 in rat
PRMT1) localizes the positive charge on one of the guanidino nitrogens, allowing the
lone pair of electrons of the other guanidino nitrogen to become a better nucleophile. The
residue required to deprotonate the guanidino nitrogen of the substrate arginine or the
mono-methylated product has not been identified. Thompson and coworkers recently
elucidated the kinetic mechanism of PRMT1 [20]. They report a different mechanism
wherein PRMT1 utilizes a rapid equilibrium random sequential mechanism to methylate
the histone H4 peptide. In this type of reaction mechanism, the order of substrate binding
to the enzyme and product release from the enzyme does not matter. Although the
mechanism for Type I PRMTs has become clearer, the mechanistic roles of certain
PRMT1 active site residues have not been identified.
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The goal of this work was to identify residues in the PRMT1 active site that
are important for substrate binding and catalysis and may affect ADMA formation. We
hypothesized that two active site methionine residues (Met155 and Met48) positioned
near the reactive substrate arginine (Fig. 6-1) enable PRMT1 to selectively form ADMA
instead of SDMA. M155A and M48A mutant proteins were characterized according to
their ability to catalyze methylation of a multiple arginine-containing peptide based on
the in vivo substrate fibrillarin. Removing the steric bulk afforded by each of these
residues did not allow for the formation of SDMA. The mutation of Met48 to an alanine
in the PRMT1 active site rendered the enzyme virtually inactive. When this residue was
mutated to a leucine, activity was partially restored indicating that the length of Met48 is
critical to PRMT1 catalysis. Our results indicate that removing the steric bulk afforded
by either Met155 or Met48 in the active site of PRMT1 is not by itself sufficient to
transform PRMT1 into a Type II PRMT. Additional PRMT1 mutants (M146A, S154A,
W145A, and Y148S-PRMT1) displayed altered methyltransferase activity generating
only MMA and ADMA. Interestingly, M48L-PRMT1 was capable of automethylation
while wild type PRMT1 was not.

MATERIALS AND METHODS
AdoMet was purchased from Sigma as a chloride salt (≥80%, from yeast). The
R3

peptide,

acylGGRGGFGGRGGFGGRGGFG;

acylKGGFGGRGGFGGKW;
acylKGGFGGRmethylGGFGGKW

≥95%.

and

the

the

JMH1W

JMH1W-CH3

peptide,
peptide,

were synthesized by the Keck Institute and purified to
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Expression and purification of mutant
PRMT1 proteins
PRMT1 mutant proteins were generated using the QuikChange® Site-Directed
Mutagenesis kit (Stratagene) with sets of complementary oligonucleotide primers
spanning the desired site of mutation.

For each PCR reaction, the pET28b vector

(Novagen) containing the gene that codes for N-terminal histidine tagged wild type
PRMT1 plasmid (pET28b-PRMT1) (see Chapter 3) was used as template.

Desired

mutations (M155A, M48A, M48L, S154A, M146A, Y148S, W145A, and M48P) were
confirmed through DNA sequencing. Mutant proteins were expressed and purified using
the same methods used to express and purify wild type His-PRMT1 (described in Chapter
3). Each mutant protein was expressed at the same level as wild type PRMT1 in cell
culture except for the M48A mutant which exhibited slightly lower expression levels
when compared to wild type. Purified proteins were ≥95% pure by SDS-PAGE. Mutant
protein sequences were verified using mass spectrometry. The binding of AdoMet is
consistent with a properly folded structure for all mutants.

Kinetic assays of PRMT1 mutants
A continuous spectrophotometric assay for AdoMet-dependent methyltransferases
(described in Chapter 3) was used to assay PRMT1 mutants with arginine-containing
peptides.

Two coupling enzymes, AdoHcy nucleosidase (MTAN) and adenine

deaminase, were used to hydrolyze and deaminate the AdoHcy generated from
methyltransfer, respectively. This assay avoids any product inhibition that could occur
from AdoHcy. Each 110 µL reaction contained 4 µM His-PRMT1 (WT or mutant), 0.02
µM adenine deaminase (purified as described in Chapter 3), 250 µM AdoMet, 10 nM
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MTAN (purified as in [21]), 100 µM MnSO4, and 50 mM sodium phosphate buffer
pH 7.1. Reactions equilibrated at 37 ºC for ten minutes before they were initiated with
various amounts of peptide. The decrease in absorbance at 265 nm was monitored
continuously using a Cary300 Bio UV-visible spectrophotometer.

Initial rate data

representing no more than 10% of product formation were fit to the Michaelis Menten
equation [22] to obtain Km,app and kcat, app values. Each reaction was performed at least in
duplicate. The limit of detection for this assay was 0.1 μM CH3/min (which corresponds
to a kcat of 0.025 min-1).

HPLC analysis of methylated amino acids
Assays containing 4 μM WT- or mutant-PRMT1 proteins, 1200 μM AdoMet, 10
nM MTAN, and 50 mM sodium phosphate buffer (pH 7.1) equilibrated at 37 ºC for 8
minutes. Reactions were initiated with 200 μM R3 and were terminated after 3 hours
with 10% TCA final. TCA-precipitated protein was removed through centrifugation, and
the supernatant (containing the peptide) was added to a glass vial. An equivalent volume
of 12.1 M HCl was added to each vial. Vials were crimp-sealed and heated to 110 ºC for
approximately 24 hours to carry out acid hydroloysis. Hydrolyzed amino acids from the
mutant catalyzed peptide product were analyzed by fluorescent derivatization
(AccQ●Fluor reagent kit, Waters) using a well-established RP-HPLC protocol [23]. This
method uses a gradient of acetonitrile and a C18-Luna column (Phenomenex) to separate
MMA, ADMA, and SDMA based on their hydrophobicity. To verify the presence and
peak times of the methylated arginine products, subsequent runs of samples incubated
with 0.6 μM [H3]-AdoMet (specific activity of 83 μCi/μmol) for 3 hours and analyzed via
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HPLC [24].

Fractions (0.5 mL) were collected and radioactivity was counted in 4

mL scintillation cocktail (Fisher Scientific). MMA, ADMA, or SDMA standard amino
acids were also used to verify the identity of the methylated products generated. Peak
times were 37.5, 43.65, and 48 min for MMA, ADMA, and SDMA respectively. Shifting
of the product peaks was observed from one run to another, so standards were run before
and after each sample to accurately identify the presence of each arginine species.

Intrinsic fluorescence
An RF-5301PC spectrofluorophotometer (Shimadzu) was used for fluorescence
measurements.

For R3 peptide and AdoMet affinity determinations, an excitation

wavelength of 290 nm was used and emission spectra from 300-420 nm were collected.
The change in fluorescence intensity at the maximum emission (333 nm) was monitored.
The excitation and emission slit was 5 nm and the scan speed was 100 nm/min using
1325 µL containing 0.7 µM PRMT1 in 150 mM sodium phosphate buffer pH 7.1.
Increasing concentrations from 1 to 50 µM peptide ligand (or 1 to 50 µM AdoMet in a
separate experiment) were added at 2-3 min intervals. Data from at least two titrations
were averaged and analyzed using the Stern-Volmer [24] or modified Stern Volmer [25]
plots. Data were evaluated by least squares linear regression analysis using Kaleidagraph
in order to obtain the dissociation constant (Kd). For the modified Stern Volmer plots,
the following equation was used: Fc= F (10 εcd/2) where Fc is the corrected fluorescence, ε
is the extinction coefficient of AdoMet, c is the concentration of AdoMet, and d is the
pathlength. Finitial/(Finitial-Fc) was then plotted against 1/[AdoMet] and the data was fit to a
line where the yintercept=1/fa, the slope=1/fa*KQ, and the KQ=1/KD.
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RESULTS
Active site methionines do not govern
strict ADMA formation
It was proposed [18] that Met155 helps determine the formation of ADMA
because of the increased steric bulk of the residue. If the length of Met155 is solely
responsible for the strict formation of ADMA in the PRMT1 active site, then the
mutation of this residue to a smaller amino acid might allow for the formation of SDMA.
To investigate this hypothesis, we mutated Met155 to an alanine residue. M155APRMT1 was expressed, purified, and demonstrated saturation kinetics with a peptide
derived from the in vivo substrate fibrillarin (R3=acylGGRGGFGGRGGFGGRGGFG)
(see Fig. 6-2). Compared to WT-PRMT1, this mutation did not affect kcat, but Km
increased by a factor of ten (Table 6-1). As a result of this, the catalytic efficiency
(kcat/Km) of M155A-PRMT1 was only 10.3% the activity of WT-PRMT1 (Table 6-1)
indicating that Met155 is important to catalysis.

Table 6-1 Kinetic constants for mutant and WT-PRMT1 with R3 peptide
Vmax (µM CH3/min) kcat/Km (M-1s-1)
PRMT1
Km (µM)
<10
10.7 ± 0.803
4460 ± 333
WT
118
±
29.6
12.9
±
1.12
457 ± 121
M155A
303 ± 214
0.959 ± 0.470
13.2 ± 13.1
M48A
17.6 ± 2.65
7.06 ± 0.209
1670 ± 255
M48L
439 ± 205
6.69 ± 1.49
63.4 ± 30.2
M48P
Activity was assessed using various concentrations of R3 peptide (25-1000 µM), 250 µM
AdoMet, 4 µM His-PRMT1 (WT or mutant), 10 nM MTAN, 10 µM MnSO4, and 50 mM
NaPO4 buffer pH 7.1 at 37 °C. Reactions were performed at least in duplicate, and initial
reaction rates were used to assess activity.
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Fig. 6-2. M155A-PRMT1 methylates R3. Various concentrations of R3 peptide [251000 µM] were used to initiate reactions containing 4 µM M155A-PRMT1, 250 µM
AdoMet, 10 nM MTA nucleosidase, 10 µM MnSO4, and 50 mM NaPO4 buffer pH 7.1 at
37 °C. Initial rates were used to plot the Michaelis-Menten curve.

Next, we analyzed the products generated from an extended reaction between
M155A-PRMT1 and R3 to determine if mutating M155 to a smaller alanine residue
converted PRMT1 into a Type II PRMT. Using a reverse phase-HPLC method that
provides baseline separation between MMA, ADMA, and SDMA [23], we show that
similar to wild type (Fig. 6-3, A), M155A-PRMT1 catalyzed the formation of only MMA
and ADMA (Fig. 6-3, B). Interestingly, an additional peak whose identity is unknown
was found to incorporate radioactively labeled AdoMet and eluted at approximately 39
minutes (between MMA and ADMA) in the M155A-PRMT1 sample.

All in all,

removing the steric bulk afforded by Met155 in the PRMT1 active site was not enough to
transform the Type I PRMT into a Type II PRMT that is capable of catalyzing the
formation of SDMA.
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Fig. 6-3. M155A-PRMT1 catalyzes the formation of MMA and ADMA. Acid
hydrolyzed amino acids from reactions that had been initiated with 200 µM R3 and
catalyzed by wild type in (A), or M155A-PRMT1 in (B), were derivatized using the
AccQFluor reagent. HPLC [23] was used to separate the methylated products based on
their hydrophobic properties (solid lines). 3H-AdoMet was used as a tracer to verify the
presence of the methylated species in each reaction (dashed lines). MMA, ADMA, and
SDMA standard amino acids were used to identify the methylated species in each sample.
MMA and ADMA are labeled appropriately according to the retention times of the
standards. SDMA, which had a later retention time, was not generated.

161
Because Met155 was not responsible for the strict formation of ADMA versus
SDMA, we next examined the role of another active site methionine residue (Met48) due
to its proximity to the substrate arginine of the R3 peptide in the PRMT1 crystal structure
(Fig. 6-1) [18]. To determine if the bulk of this methionine is responsible for aiding in
the strict formation of ADMA in the PRMT1 active site, we mutated Met48 to a smaller
amino acid (alanine). Unlike the M155A-PRMT1 mutant, M48A-PRMT1 demonstrated
extremely low activity with the R3 peptide (Table 6-1 and Fig. 6-4, A). When an
extended reaction with M48A-PRMT1 and R3 was analyzed by HPLC, methylated
arginine species may have been formed but levels were only slightly above background
when using radioactivity (Fig. 6-4, A). M48A-PRMT1 was not capable of methylating
two additional single arginine-containing fibrillarin-based peptides that wild type PRMT1
is capable of methylating (acylKGGFGGRGGFGGKW and its monomethylated
counterpart acylKGGFGGRmethylGGFGGKW) (data not shown). Thus, mutating Met48 to
an alanine obliterated PRMT1-activity altogether and eliminated the catalysis of both
arginine and monomethylarginine-containing substrates.
Based on these findings, we proposed that the length of Met48 is critical to
catalysis. Perhaps mutating Met48 was too drastic of a change in length. Therefore, we
mutated Met48 to a leucine, a residue that was in between alanine and methionine in
length. Interestingly, M48L-PRMT1 displayed saturation kinetics with R3 (data not
shown).

The catalytic efficiency of M48L-PRMT1 (1670 ± 255 M-1s-1) was

approximately 40% of wild type (Table 6-1) indicating that the length of this active site
residue is critical for catalysis. Further HPLC analysis of the products generated from an
extended reaction with M48L-PRMT1 and R3 indicated that higher levels of MMA and
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ADMA had been generated (Fig. 6-4, B) compared to the reaction with M48APRMT1. The shape of the ADMA peak was not as defined as in other samples due to
sample overloading.
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Fig. 6-4. M48A/L-PRMT1 mutants catalyze the formation of MMA and ADMA.
Acid hydrolyzed amino acids from reactions that had been initiated with 200 µM R3 and
catalyzed by M48A in (A) or M48L-PRMT1 in (B) were derivatized using the
AccQFluor reagent. HPLC [23] was used to separate the methylated products based on
their hydrophobic properties (solid lines). 3H-AdoMet was used as a tracer to verify the
presence of the methylated species in each reaction (dashed lines). Standard amino acids
were used to identify methylarginine products in the sample. MMA and ADMA are
labeled appropriately according to the retention times of the standards. SDMA, which
had a retention time of approximately 51 minutes, was not generated in (A).
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Like M48A-PRMT1, M48L-PRMT1 was not capable of methylating two
additional

single

arginine-containing

(acylKGGFGGRGGFGGKW
acylKGGFGGRmethylGGFGGKW)

and

its

fibrillarin-based
monomethylated

peptides
counterpart

(data not shown). It is unclear why the Met 48 mutant

proteins were unable to methylate these peptides. Based on these results, however,
M48L-PRMT1 may not be able to methylate arginine residues located in the center of
peptides.

Peptide substrate and cofactor binding
To further investigate the role of Met48, we measured the dissociation constants
of WT, M48A, and M48L-PRMT1 for each substrate (R3 peptide and AdoMet). The
PRMT1 crystal structure depicts two tryptophans at positions 145 and 294 which lie in
the catalytic region near the substrate arginine residue opposite the AdoMet binding
region [18].

The intrinsic fluorescent-properites of PRMT1 were exploited in

fluorescence-quenching assays to determine the dissociation constants for the R3 peptide
with WT and mutant PRMT1.

Stern-Volmer plots [24] were used to analyze the

quenching data. A representative Stern-Volmer plot for WT-PRMT1 with R3 is shown in
Fig. 6-5, A. These plots revealed that WT and M48A/L-PRMT1 had nearly the same
affinity for the R3 peptide as judged by the similar Kd values (Table 6-2). Lehrer’s
modified Stern-Volmer plot [25] was used to interpret the fluorescence-quenching data
from the titrations of WT and M48A/L-PRMT1 with AdoMet. A representative modified
Stern-Volmer plot for WT-PRMT1 with AdoMet is shown in Fig. 6-5, B. The results in
Table 6-2 indicate that the diminished activity of M48A-PRMT1 or M48L-PRMT1 is not
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due to differences in AdoMet binding. The affinity of WT-PRMT1 and both mutants
for AdoMet was nearly the same. Importantly, results obtained from isothermal titration
calorimetry (ITC) were consistent with the dissociation constant values obtained using
intrinsic fluorescence. When WT-PRMT1 was titrated with AdoMet, a value of 4.2 ± 1.5
µM was obtained using intrinsic fluorescence (Table 6-2) versus 2.5 µM from ITC (data
not shown).
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Fig. 6-5. Stern Volmer and modified Stern Volmer plots. In (A), a Stern Volmer plot
is shown for the titration of WT-PRMT1 with R3. The slope of the line is equivalent to
the dissociation constant. In (B), a modified Stern Volmer plot is shown for the titration
of WT-PRMT1 with AdoMet. The data was fit to a line where the yintercept=1/fa, the
slope=1/fa*KQ, and the KQ=1/KD.
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Table 6-2 Dissociation constants for mutant and WT-PRMT1 for AdoMet and R3
Fluorescent
Kd, AdoMet
Fluorescent
PRMT1 Kd, peptide (nM)
quenching (%)
(µM)
quenching (%)
36 ± 11
36 ± 19
4.2 ± 1.5
17 ± 0.13
WT
47 ± 8.2
47 ± 2.0
7.1 ± 1.8
15 ± 0.17
M48A
49 ± 18
39 ± 7.8
7.1 ± 0.94
29 ± 4.2
M48L
Dissociation constants were obtained using intrinsic fluorescence quenching assays
(performed at least in duplicate) as described in the methods section.

Active site residues affect PRMT1
substrate processing
Because the active site methionine mutations did not govern the strict formation
of ADMA versus SDMA, the roles of several additional active site residues that were
conserved among Type I PRMTs but not among Type II PRMTs were evaluated. The
following mutations to the PRMT1 sequence were verified by DNA sequencing: Y148S,
S154A, W145A, and M146A-PRMT1. Proteins were overexpressed and purified to
homogeneity before being assayed with the R3 peptide.

All mutants demonstrated

saturation kinetics with R3 (data not shown). However, each mutant PRMT1 protein
resulted in a substantial decrease in catalytic activity (kcat/Km, app) when compared to wild
type PRMT1 except for S154A-PRMT1 (Table 6-3).
Next, we analyzed the peptide product generated from extended reactions with the
four mutant PRMT1 proteins and R3. Mutant proteins did not generate a detectable
amount of SDMA but were able to catalyze monomethylation and asymmetric
dimethylation of the R3 peptide (data not shown). These results are summarized in Table
6-3. Thus, the strict formation of ADMA versus SDMA in the PRMT1 active site is not
governed by Tyr148, Ser154, Trp145, or Met146.
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Table 6-3 PRMT1-mutant activity and product formation
Catalytic efficiency
MMA
ADMA
SDMA
-1 -1
(M s )
4458 ± 333 [22]
yes
yes
no
WT
457 ± 121
yes
yes
no
M155A
13.19 ± 13.05
yes
yes
no
M48A
1668 ± 255
yes
yes
no
M48L
151
±
39.5
yes
yes
no
Y148S
4406 ± 1366
yes
yes
no
S154A
139 ± 20.8
yes
yes
no
W145A
463 ± 162
yes
yes
no
M146A
63.4 ± 30.2
yes
yes
no
M48P
PRMT1

Activity was assessed using various concentrations of R3 peptide (25-1000 µM), 250 µM
AdoMet, 4 µM His-PRMT1 (WT or mutant), 10 nM MTAN, 10 µM MnSO4, and 50 mM
NaPO4 buffer pH 7.1 at 37 °C. Reactions were performed at least in duplicate, and initial
reaction rates were used to assess protein activity. HPLC analysis [23] and a radioactive
tracer (3H-AdoMet) were used to confirm the presence or absence of MMA, ADMA, and
SDMA formation for each PRMT1 protein reaction with the R3 peptide.

DISCUSSION
PRMT1 mutants catalyze the formation of MMA
and ADMA at varying efficiencies
The purpose of this study was to identify a residue that was responsible for
controlling the strict formation of ADMA (versus SDMA) in the active site of the Type I
PRMT, PRMT1. First, Met 155 was probed because this residue had previously been
hypothesized [18] to determine ADMA formation based on its steric bulk. Due to the
proximity of this residue to the substrate arginine (Fig. 6-1) and the fact that it was
conserved among Type I PRMTs but not Type II PRMTs, this residue was mutated to a
smaller amino acid residue to see if SDMA could be generated. M155A-PRMT1 did not
form SDMA (Fig. 6-2) and displayed a decrease in catalytic activity when compared to
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WT-PRMT1 (Table 6-1). Thus, reducing the size of this methionine to an alanine at
this active site location did not allow for the free rotation about the terminal C-N bond of
the arginine residues in R3 and the formation of SDMA. Met 48, the methionine on the
other side of the substrate arginine (Fig. 6-1), was shown by HPLC analysis not to alter
Type I versus Type II product formation either (Fig. 6-4). In fact, all mutations made to
the PRMT1 active site (M155A, M48A, M48L, M146A, W145A, S154A, and Y148S)
did not result in a detectable amount of SDMA but did result in the formation of both
MMA and ADMA (Table 6-3).

When Met 48 was mutated to a proline, the

corresponding residue found in the Type II PRMT5 active site, activity dropped
dramatically (kcat/Km= 63.4 ± 30.2 M-1s-1) (Tables 6-1 and 6-3). No detectable amount of
SDMA was detected by HPLC after an extended reaction (data not shown). Ultimately,
these results indicate that transforming a Type I PRMT into a Type II PRMT is more
complex than previously thought and may extend beyond the composition of the active
site. Alternatively, the mutation of other residues or a combination of active site residues
(such as an M48L/M155A-PRMT1 double mutant) could govern ADMA versus SDMA
formation.
PRMT1 mutants utilized R3 as a peptide substrate but did so at varying
efficiencies. All PRMT1 mutations resulted in a substantial decrease in catalytic activity
(kcat/Km, app) when compared to wild type PRMT1 except for S154A-PRMT1 (Table 6-3).
Interstingly, M48A-PRMT1 had very little to no activity with the R3 peptide, the most
kinetically competent fibrillarin-based peptide substrate suggesting that this methionine is
critical to catalysis (Table 6-1). Further kinetic analysis of Met 48 with the M48L-
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PRMT1 mutant and R3 (Table 6-1) proved that the length of this amino acid residue
is important to catalysis.
Surprisingly, the M48L-PRMT1 mutant methylated the R3 peptide with nearly
half the activity of WT-PRMT1 but would not methylate two single arginine-containing
peptides,

acylKGGFGGRGGFGGKW

acylKGGFGGRmethylGGFGGKW

and

its

monomethylated

counterpart

(data not shown). This inactivity may be due to the

central position of the arginine in the substrate. Perhaps M48L-PRMT1 methylated the
R3 peptide on the two terminal arginines in bold (acylGGRGGFGGRGGFGGRGGFG)
but was unable to access the central arginine residue. MS/MS analysis of the R3 peptide
product from this reaction will reveal if this hypothesis is true.
Although it is unclear how Met 48 affects PRMT1 catalysis, this residue may help
position AdoMet or the substrate arginine so that a more direct SN2 attack of the methyl
group of AdoMet can be made (Fig. 6-6). The active site appears to ‘open up’ more
when Met 48 is replaced with a leucine (Fig. 6.6). Because the M48L-PRMT1 mutant
was unable to methylate two central single arginine-containing peptides but was able to
methylate R3, Met 48 may play a significant role in substrate specificity. Interestingly,
M48L-PRMT1 was also capable of automethylation (described further below). Further
examination of this residue may provide crucial mechanistic details because of its close
proximity to the substrate arginine.

Automethylation of PRMT1
M48L-PRMT1 was capable of automethylating itself when incubated with
tritiated AdoMet (data not shown). This phenomenon was not observed for the wild type
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Fig. 6-6. Methionine 48 positions PRMT1 substrates for catalysis. AdoMet (purple)
was modeled into the PRMT1 active site (PDB ID, 1OR8). The AdoMet methyl group
(carbon shown in red) is positioned for a direct SN2 attack from the R3 peptide substrate
arginine (yellow). The wild type active site (M48 in gray) is depicted in the top panel
while the M48L mutant is depicted below (gray).

enzyme under the identical reaction conditions (data not shown). PRMT6 and PRMT8
have been shown to automethylate themselves [5, 26]. PRMT6 was found to be monoand dimethylated at certain arginine residues [5]. PRMT8 automethylates two arginine
residues (monomethylarginine 58 and dimethylarginine 73) on its N-terminal tail, an
ability that is thought to regulate and possibly inhibit the methylation of other substrates
[26]. Although PRMT1 and PRMT8 are highly identical in sequence, the methylated
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arginine residues in PRMT8 do not align with arginines in PRMT1. In the same
study, Clarke and coworkers detected that WT-PRMT1 had also underwent
automethylation to a lesser degree [26]. Under our reaction conditions, however, we
could not detect WT-PRMT1 automethylation. It will be interesting to see where M48LPRMT1 has been methylated.

Conclusion
Our results indicate that transforming a Type I PRMT into a Type II PRMT is
more complex than previously thought and may extend beyond the composition of the
active site. Importantly, our study identified PRMT1 active site residues that are critical
to catalysis. The mutation of Met 48 to an alanine in the PRMT1 active site rendered the
enzyme virtually inactive. In particular, the length of Met 48 is critical to PRMT1
catalysis.

Further examination of this residue may provide crucial mechanistic details.
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CHAPTER 7
ONGOING PROJECTS

INTRODUCTION
This chapter includes experimental results from several projects that have yet to
be completed. In the first section, we found that the amino acid sequence of certain
peptide substrates directly affects the extent that a particular substrate is mono- and
dimethylated.

We also found that two ‘RGA’-containing fibrillarin-based peptides

demonstrated substrate inhibition at high substrate concentrations when incubated with
PRMT1. This indicates that substrate sequence can regulate PRMT1 activity at a higher
level by altering the amount of dimethylation that can occur physiologically. Together,
these data show that the sequence around the substrate arginyl group affects how the
substrate arginine is being modified and indicate that although many protein sequences
may be PRMT1 substrates, the identity of the sequence and its abundance in the cell may
dictate how the substrate arginine residue is mono- or dimethylated in vivo.
Next, I examined the importance of interactions between the substrate and the
conserved THW loop among PRMTs by mutating two residues (H293 and W294 to an
alanine on PRMT1) and assessing the activity of each with several substrates. I found
that both residues were essential for PRMT1 catalysis. In another section, I investigated
how the AdoMet/AdoHcy ratio present in healthy and diseased individuals affected
PRMT1 activity. The AdoMet/AdoHcy ratio is higher in healthier individuals (~4-6) [1]
and lower in patients with Type II diabetes [2], Alzheimer’s disease [3], and cystic
fibrosis [4] (~1.4-3.5). Interestingly, the lower the AdoMet/AdoHcy ratio, the more
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severe the disease [2]. As expected, I found that as the concentration of AdoHcy
increased (meaning the AdoMet/AdoHcy ratio decreased), PRMT1 activity decreased.
Because PRMT1 performs over 85% of all protein arginine methylation in the cell, a
decrease in PRMT1 activity due to an alteration in the AdoMet/AdoHcy ratio could cause
a decrease in total protein arginine methylation. This inhibition could have numerous
biological ramifications that have yet to be fully explored.

Finally in a related

experiment, I determined the Ki for a fibrillarin-based peptide containing ADMA.

RESULTS AND DISCUSSION
Effect of amino acid sequence context
on activity and end-products
In Chapter 4, we identified that PRMT1 was capable of methylating a variety of
peptide sequences that extended beyond the ‘RGG’ paradigm using a small fibrillarinbased peptide library. We also observed that methylation was contextual with the ‘RSG’
sequence. The ‘RSG’ sequence presented within the fibrillarin context was not a PRMT1
substrate while the same sequence presented within the eIF4A1 context was a PRMT1
substrate. This suggested that amino acids in one position affect whether or not amino
acids in a second position are favored. To explore the effects of substrate sequence on
PRMT1 activity further, we examined the end products generated with time from
reactions that had been initiated with the WT-eIF4A1, eIF4A1-S, or eIF4A1-Y peptide.
Because the eIF4A1 peptides contain three arginine residues, we employed tandem mass
spectrometry first to prove that R7 (bolded in
AcYIHRIGRSGR,

AcYIHRIGRGGR, AcYIHRIGRYGR,

and

respectively) was the only modified arginine after incubating with

PRMT1 and AdoMet (Fig. 4-6).

177
The MS analysis of the eIF4A1 peptides revealed that the proportion of the
mono- and dimethylated arginine products observed was different in the eIF4A1 peptides
(Fig. 7-1). The ‘RGG’ containing WT-eIF4A1 peptide was almost fully dimethylated
(97.3%) while the eIF4A1-peptide containing the ‘RSG’ motif was mostly not modified
after 105 minutes. Only 7.1% of the eIF4A1-S had been monomethylated after 105
minutes (Fig. 7-1). The eIF4A1-peptide containing the ‘RYG’ motif only underwent
monomethylation (3.7%) after 105 minutes. After an extended reaction with PRMT1, the
‘RGG’ containing WT-eIF4A1 peptide was mostly dimethylated while the ‘RSG’ and
‘RYG’ containing eIF4A1 peptides were mainly monomethylated. PRMT1 and AdoMet
were shown to be viable during the extended reaction time period (Fig. 7-2) indicating
that the reaction conditions were such that the reaction should have gone to completion
(i.e., peptides should have been fully dimethylated instead of partially monomethylated).
Perhaps the reactions with eIF4A1-Y and eIF4A1-S peptides did not go to completion
due to substrate inhibition (described more fully in the next section). These data suggest
that sequence differences around the substrate arginyl group in peptide substrates may
affect whether mono- or dimethylation is the major end-product and demonstrate that the
amino acid sequence of a PRMT1 substrate may dictate how an arginine is modified.
Thus, many sequences may be PRMT1 substrates, but the identity of the sequence may
dictate how the substrate arginine residue is mono- or dimethylated in vivo.
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Fig. 7-1. Effect of sequence on methylated product distribution. Reactions were
prepared as described in Fig. 4-2 and were initiated with WT-eIF4A1 in (A), eIF4A1-S in
(B), and eIF4A1-Y in (C). Mass spectrometry was used to identify the parent (gray
lines), monomethylated (solid lines), and dimethylated (dashed lines) peptide products.
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Fig. 7-2. PRMT1 and AdoMet are viable during extended reactions. Continuous
spectrophotometric assays with 4 μM PRMT1, 250 μM AdoMet, and coupling enzymes
in 50 mM sodium phosphate buffer (pH 7.1) that had equilibrated to 37 °C were initiated
with 300 μM eIF4A1-Y peptide. At 105 minutes (A) and 405 minutes (B), reactions
were spiked with 200 μM R3 peptide. When comparing this methylation rate to the rate
from a reaction initiated with 200 μM R3 at t=0 (with no eIF4A1 peptide), PRMT1 was
92% active at 105 minutes and 89% active at 405 minutes.

Substrate inhibition

In another experiment, both the RGA-peptide (KGGFGGRGAFGGKW) and
RGA-CH3 peptide (KGGFGGRmethylGAFGGKW) were tested to identify if the sequence
context near the substrate arginine dictated how the substrate was methylated. The RGApeptide (Fig. 7-3) and the RGA-CH3 peptide (data not shown) displayed substrate
inhibition at high substrate concentrations, a phenomenon which may prove to be
important biologically. Protein substrates that are methylated in the context of something
other than a glycine/arginine rich motif may undergo such inhibition in the cell. For
instance, an ‘RGG’-containing protein may get fully dimethylated whereas the same
concentration of an ‘RGA’-containing protein may only get monomethylated due to
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substrate inhibition. If dimethylation is required to elicit the biological response, then
the biological response will not happen.
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Fig. 7-3. Peptides caused substrate inhibition at high substrate concentrations.
Reactions containing 4 μM PRMT1, 0.2 μM adenine deaminase, 10 nM AdoHcy
nucleosidase, 1050 μM MnSO4, and 250 μM SAM in 100 mM sodium phosphate buffer
pH 7.1 were initiated with various concentrations of RGA-peptide
(KGGFGGRGAFGGKW).
Higher peptide concentrations demonstrated substrate
inhibition, an observation that may be found to be important biologically.

THW loop mutations alter PRMT1 activity
In Chapter 4, new substrate motifs were identified that went beyond the ‘RGG’
paradigm.

Two of these motifs (‘RYG’ and ‘RFG’) surprisingly had large, ring-

containing amino acids directly C-terminal to the substrate arginine residue. How could
such large amino acid residues adjacent to the substrate arginine facilitate methylation
when several smaller amino acids such as alanine were not tolerated in the X1 position?
Perhaps PRMT1 could tolerate phenylalanine and tyrosine in this position because they
were ring containing and could make pi-pi stacking interactions with PRMT1. When
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looking at the PRMT1 crystal structure [5] and sequence alignments among the
PRMT family, a conserved THW loop positioned near the substrate X1 position could
potentially make pi-pi stacking interactions the substrate. In order to test this hypothesis
and further understand the role of the active site THW loop residues H293 and W294,
these residues were mutated to an alanine.
H293A and W294A-PRMT1 proteins were purified and assessed for activity with
the R3 peptide (GGRGGFGGRGGFGGRGGFG). H293A-PRMT1 utilized R3 (kcat=
0.27 ± 0.11 min-1) while W294A-PRMT1 did not (data not shown). W294A-PRMT1 was
not active with either an ‘RYG’ or an ‘RFG’-containing fibrillarin-based peptide (data
not shown). Further HPLC analysis of this protein revealed that AdoMet was still able to
bind suggesting that the AdoMet binding pocket had not been disrupted by the mutation
and that the protein was able to fold properly (data not shown).
The activity of H293A-PRMT1 was analyzed next with ‘RYG’ and ‘RFG’containing peptides. Preliminary data suggests that H293A-PRMT1 was not capable of
methylating the peptide housing the ‘RFG’ sequence very well as demonstrated by a low
Vmax (Fig. 7-4, A). These data suggest that the pi-pi interactions between enzyme and
substrate at this location have been disturbed; however, further investigation is needed.
Interestingly, H293A-PRMT1 was able to methylate the tyrosine-containing peptide
(kcat/Km= 10.2 ± 8.01 M-1s-1) (Fig. 7-4, B). H293A-PRMT1 was also able to methylate
the ‘RYG’-containing eIF4A1-Y peptide (YIHRIGRYGR) at a catalytic efficiency of 27
± 13 M-1s-1 (data not shown). Although the kcat/Km values were extremely low, the rate
of methylation increased as the concentration of peptide increased suggesting that pi-pi
stacking interactions are not by themselves responsible for PRMT1 activity with ‘RYG’-
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containing peptides. Perhaps the ability of tyrosine to hydrogen bond to the enzyme
via its hydroxyl group facilitates methylation.
Our main objective to determine if pi-pi interactions are important in substrate
selection and catalysis remains somewhat elusive because I was unable to perform
additional follow-up studies. Despite this, I was able to show that each peptide tested
with either the H293A or W294A-PRMT1 mutant proteins was not methylated very
efficiently. These preliminary results suggest that histidine and tryptophan from the
conserved THW loop are necessary for PRMT catalysis.
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Fig. 7-4. Mutations in the THW loop alter PRMT1 activity. Reactions containing 4
μM H293A-PRMT1, 0.2 μM adenine deaminase, 10 nM AdoHcy nucleosidase, 1050 μM
MnSO4, and 250 μM SAM in 100 mM sodium phosphate buffer pH 7.1 were initiated
with various concentrations of ‘RFG’-peptide (KGGFGGRFGFGGKW) in (A) or
‘RYG’-peptide (KGGFGGRYGFGGKW) in (B).
Although the reactions were
performed in duplicate, the data remained scattered in (A).
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AdoMet/AdoHcy ratio affects PRMT1
activity in vitro
A measurement of the AdoMet/AdoHcy ratio reflects the wellness of an
individual [1-4]. We were interested in determining if the biologically significant ratios
that we chose to classify as healthy (4.0), diseased (2.0), and extremely sick/near death
(1.0) had any effect on PRMT1 activity. We found that as the amount of AdoHcy present
in the methylation reaction increased, PRMT1 activity decreased accordingly when
initiating the reaction with an unmodified fibrillarin-based peptide substrate (Fig. 7-5, A)
or a monomethylated fibrillarin-based peptide substrate (Fig. 7-5, B). In both (A) and
(B), addition of any AdoHcy to the reaction reduced methyltransferase activity as
expected. Despite the large standard deviations observed in the reactions containing
peptide only, PRMT1 was clearly able to methylate peptides in these reactions more
easily than in the reactions containing AdoHcy. Although it is more apparent with the
monomethylated substrate (Fig. 7-5, B), increasing the amount of AdoHcy diminished
PRMT1 activity in a dose dependent manner.

Interestingly, both peptides were

methylated by PRMT1 in AdoMet/AdoHcy conditions approaching death. Based on
these preliminary results, the activity of PRMT1 is reduced by biologically relevant
AdoHcy concentrations such as those found in healthy individuals. This implies that
future in vitro PRMT activity studies may obtain a more biologically relevant
measurement of kinetic parameters if a healthy AdoMet/AdoHcy ratio was included in
the study.
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Fig. 7-5. PRMT1 activity is reduced during disease states. PRMT1 activity was
probed under various AdoMet/AdoHcy ratios using the JMH1W peptide
(KGGFGGRGGFGGKW)
in
(A)
and
the
JMH1W-CH3
peptide
(KGGFGGRmethylGGFGGKW) in (B). Reactions containing 4 μM PRMT1, 0.3 μM
[H3]-AdoMet (specific activity of 83 μCi/μmol), 50 μM AdoMet (S-isomer only) in 100
mM sodium phosphate buffer pH 7.1 were initiated with peptide or a mixture of peptide
and AdoHcy. Methylation was monitored discontinuously with time using a P81
membrane assay (as described in Chapter 3). Reactions initiated with peptide only (●)
exhibited the highest activity. Reactions initiated with a mixture of peptide and AdoHcy
decreased PRMT1 activity according to the amount of AdoHcy present. The data
corresponding to the following AdoMet/AdoHcy ratios: 4 to 1, 2 to 1, and 1 to 1
represent individuals that are healthy, (○); diseased, (▲); and near death, (open triangles),
respectively. Control reactions (x) containing only PRMT1 and AdoMet displayed little
activity as expected. Reactions were performed in duplicate, and the standard deviations
are shown.

Obtaining the Ki for a fibrillarin-based
peptide containing ADMA
In order to determine which type of mechanism PRMT1 performs (random
sequential or ordered sequential); I looked at product inhibition profiles.

First, I

examined the JMH1W-ADMA peptide inhibitor (KGGFGGRdimethylGGFGGKW)
kinetically because AdoHcy could not be examined using the continuous assay (see
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Chapter 3). Each reaction containing 4 µM His-PRMT1 and 250 µM AdoMet in 50
mM sodium phosphate buffer pH 7.1 equilibrated at 37 ºC for 10 minutes before being
initiated with various amounts of JMH1W-CH3 peptide or a mixture of JMH1W-CH3 and
JMH1W-ADMA inhibitor peptide. For calculation of kinetic constants, the concentration
of peptide was varied at several fixed concentrations of JMH1W-ADMA inhibitor
peptide (0 µM - 150 µM). The average initial velocity representing no more than 10% of
product formation was obtained from two measurements for each pair of substrate
concentrations and was used to construct Michaelis-Menten plots (Fig. 7-6, A). The data
were graphed as Lineweaver-Burk plots (Fig. 7-6, B) and linear regression was employed
to construct slope and intercept replots (data not shown). These replots were used to
calculate the value of the inhibition constant, Kii. A larger Kii of 462 µM was determined
for the JMH1W-ADMAinhibitor peptide. Because this value is larger than both the Km
for JMH1W and JMH1W-CH3, it is not a potent PRMT1 inhibitor.

Although the

Lineweaver-Burk plot rules out uncompetitive inhibition, we could not conclude whether
the peptide inhibitor was a competitive or noncompetitive inhibitor without performing
additional product inhibition profiles.

Recently, the mechanism of PRMT1 was

published in September 2008, so any further studies were aborted.

Using peptides

derived from the in vivo substrate histone H4, Thompson and coworkers concluded that
PRMT1 performs a random sequential mechanism [6].
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Fig. 7-6. (A) Velocity versus μM JMH1W-CH3 plot. The following velocities were
plotted against μM JMH1W-CH3 substrate concentration to obtain Michaelis Menton
parameters: 0 μM ADMA inhibitor (●), 25 μM ADMA inhibitor (♦), 50 μM ADMA
inhibitor (crosses), 100 μM ADMA inhibitor (▲), and 150 μM ADMA inhibitor (■). (B)
Lineweaver-Burke plot. The values for 1/velocity (μM CH3/min) at different ADMA
inhibitor concentrations were plotted against 1/substrate (μM JMH1W-CH3) to obtain the
slope and y-intercept values of each line at 0 μM ADMA inhibitor (●), 25 μM ADMA
inhibitor (♦), 50 μM ADMA inhibitor (crosses), 100 μM ADMA inhibitor (▲), and 150
μM ADMA inhibitor (■).

Conclusion
The purpose of this chapter was to introduce several projects that were started and
have yet to be fully developed. Importantly, I have shown preliminary data that suggests
that sequence differences around peptide substrate arginyl groups may affect whether
mono- or dimethylation is the major end-product.

Although many sequences may be

PRMT1 substrates, the identity of the sequence may dictate how the substrate arginine
residue is mono- or dimethylated in vivo. I also found that certain substrates cause
substrate inhibition at high concentrations, a factor that may have played a role in the
inability of PRMT1 to fully methylate the eIF4A1-Y and eIF4A1-S peptides (Fig. 7-1).
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Next, I showed that the histidine and tryptophan from the conserved THW loop are
necessary for PRMT catalysis and that this made it difficult to probe specific pi-pi
interactions that exist at this location between enzyme and substrate. Finally, I showed
that PRMT1 activity decreased when AdoHcy or a peptide housing ADMA were added.
Interestingly, AdoHcy was a more potent inhibitor than the ADMA-containing peptide
because the addition of a biologically relevant concentration of it regulated PRMT1
activity. Altogether, these studies provide good starting points for the development of
future interesting projects.
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CHAPTER 8
SUMMARY

Protein arginine methyltransferases (PRMTs) play an important role in a diverse
set of biological processes. PRMTs methylate a variety of protein substrates including
histones, RNA-binding proteins, and various enzymes. While PRMT biology has been in
the forefront, much of the biochemistry for this class of enzymes has remained a mystery.
The purpose of my study was to develop a biochemical understanding for how PRMT1
substrates are recognized and modified. I chose to characterize PRMT1 because it
methylates over 85% of all protein arginine residues in vivo and has been implicated in
cardiovascular disease and cancer. Using a continuous spectrophotometric assay for
AdoMet-dependent methyltransferases that I helped develop, we first investigated the
substrate specificity of PRMT1. Next, in order to understand why most methylated
proteins are found in the fully dimethylated state in vivo, we analyzed the mechanism of
asymmetric dimethylarginine (ADMA) formation of single and multiple argininecontaining peptide substrates. Finally, we probed a variety of amino acid residues in the
PRMT1 active site to understand their role in catalysis, specifically their ability to control
ADMA formation.
Defining how PRMT1 works and what the preferred substrates are is pivotal for
understanding the role that PRMT1 plays in biology. A major milestone of my research
was the development of the continuous spectrophotometric assay for AdoMet-dependent
methyltransferases. Instead of assaying PRMT1 with radioactively labeled [H3]-AdoMet,
I helped develop a continuous assay that enabled me to quickly and inexpensively assess
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PRMT1 activity with a variety of peptide substrates.

In the continuous assay,

AdoHcy the transmethylation product of AdoMet-dependent methyltransferases, is
hydrolyzed to S-ribosylhomocysteine and adenine by recombinant AdoHcy nucleosidase
(SAHN/MTAN).

Adenine generated from AdoHcy is further hydrolyzed to

hypoxanthine and ammonia by recombinant adenine deaminase. This deamination is
associated with a decrease in absorbance at 265 nm that can be monitored continuously
with time.
The continuous spectrophotometric assay is robust, inexpensive, and amenable to
high throughput when evaluating methyltransferases that have been targeted for drug
discovery. One main advantage of this assay is the destruction of AdoHcy by AdoHcy
nucleosidase,

which

alleviates

AdoHcy

product

feedback

inhibition

of

S-

adenosylmethionine-dependent methyltransferases. In the absence of enzyme inhibition,
more accurate measurements of kinetic parameters can be made. This method may also
be used to assay enzymes that produce AdoHcy, 5’-methylthioadenosine, or compounds
that can be cleaved by AdoHcy nucleosidase.
Using the continuous assay, we made the important discovery that PRMT1
selectively recognizes and methylates a set of amino acid sequences in substrates that
extend beyond the ‘RGG’ paradigm.

Prior to this study, PRMT1 was thought to

methylate substrates only within glycine arginine rich motifs such as ‘RGG’ and ‘RXR’
with one exception, histone H4. Using a focused peptide library based on a sequence
derived from the in vivo substrate fibrillarin, we observed that PRMT1 methylated eleven
substrates that had amino acid residues other than glycine in the ‘RX1’ and ‘RX1X2’
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positions (Fig. 8-1). Notably, our results illustrate that the two residues on the Nterminal side of the modification site are important and need not both be glycine.

Fig. 8-1. New model for PRMT1 substrate specificity. Substrate profiling of PRMT1
revealed that PRMT1 methylates a broad range of substrate motifs when compared to the
old paradigm.

This study also demonstrated the importance of amino acid sequence in PRMT1
protein substrates. Methylation of two eukaryotic initiation factor 4A protein isoforms,
eIF4A1 and the similar eIF4A3, could be affected using single site mutations adjacent to
the modification site. After comparing eIF4A peptides and proteins, we concluded that
recognition of protein substrates was not governed by amino acid sequence alone. Other
factors such as global protein-protein surface interactions may dictate protein substrate
recognition.

Future crystallographic studies that examine specific PRMT1-protein

substrate interactions will help identify important surface interactions.
Before examining the substrate specificity of PRMT1, limited studies and
selective tools promoted the idea that PRMT1 substrates conform to an ‘RGG’ sequence
with few rare exceptions such as histone H4. Our study clearly showed that PRMT1 is
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capable of methylating sequences that go beyond the ‘RGG’ paradigm and suggests
that residues N-terminal to the modification site are also important in substrate
recognition. This suggests that the methyl arginine proteome may be larger and more
diverse than previously thought. Hopefully, investigators that previously discounted
arginine methylation as a regulatory factor in their system because the arginine of interest
was not in a glycine arginine rich motif will now give this modification more thought.
PRMT1 has recently emerged as a potential new target for the development of a
novel therapeutic for heart disease because it generates the majority of cellular
asymmetrically dimethylated arginine (ADMA). Interestingly, most PRMT1 substrates
are found dimethylated instead of monomethylated on multiple arginine residues within
the same protein.

In order to understand the biological prevalence of ADMA, we

investigated why PRMT1 preferentially asymmetrically dimethylates protein arginine
residues.

Using kinetics and mass spectrometry analysis, we showed that PRMT1

preferentially methylated monomethylated peptide substrates versus their unmodified
counterparts. PRMT1 did not processively methylate single arginine-containing peptide
substrates.

Interestingly, methylation of a multiple arginine-containing peptide was

systematic (not random) and dissociative (not processive). Based on these results, the
predominance of dimethylated protein substrates in vivo may be due to the preference
that PRMT1 has for monomethylated substrates over unmodified substrates. It will be
interesting to see if PRMT1 methylates multiple arginine-containing protein substrates in
the same manner.
Finally, we investigated the role of several amino acid residues in the PRMT1
active site in order to understand their role in catalysis and if they specifically controlled
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ADMA formation.

We hypothesized that two active site methionine residues

(Met155 and Met48) positioned near the reactive substrate arginine (Fig. 6-1) enable
PRMT1 to selectively form ADMA instead of SDMA. M155A and M48A mutant
proteins were characterized according to their ability to catalyze methylation of a
multiple arginine-containing peptide based on the in vivo substrate fibrillarin. Removing
the steric bulk afforded by each of these residues did not allow for the formation of
SDMA. The mutation of Met48 to an alanine in the PRMT1 active site rendered the
enzyme virtually inactive. When this residue was mutated to a leucine, activity was
partially restored indicating that the length of Met48 is critical to PRMT1 catalysis. Most
importantly, our results showed that removing the steric bulk afforded by either Met155
or Met48 in the active site of PRMT1 was not by itself sufficient to transform PRMT1
into a Type II PRMT. Therefore, something else about the active site of Type I PRMTs
governs the specific formation of ADMA.

Perhaps the way in which the

monomethylated substrate is forced to orient itself in the active site due to strict
geometric/structural constraints of the active site as a whole facilitates ADMA formation
and prohibits SDMA formation.
Further analysis of the M48L-PRMT1 mutant revealed that it was capable of
automethylation while wild type PRMT1 was not. This is not a unique, unheard of
phenomenon because PRMT6 and PRMT8 are capable of automethylation. It will be
interesting to identify which arginines of M48L-PRMT1 are methylated and how
automethylation regulates PRMTs.

Clearly, something about having a methionine

residue at this active site location juxtaposed to the substrate arginine in wild type
PRMT1 1) prohibits PRMT1 automethylation and 2) is essential to catalysis.
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Overall, the research presented in this dissertation mainly focuses on the
development of a paradigm for understanding how PRMT1 substrates are recognized and
modified. First, we identified eleven new substrate motifs that are modified and go
beyond the typically modified glycine arginine rich motifs (Fig. 8-1). Second, single and
multiple arginine-containing peptide substrates are modified dissociatively, and PRMT1
prefers to methylate monomethylated substrates over their nonmethylated counterparts.
We also showed that altering select active site residues one at a time did not convert
PRMT1 into a Type II PRMT. Although Met 48 was shown to be critical to catalysis, its
exact mechanistic role has yet to be determined.
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2004

J. Hardman, W. Wooderchak, P. Pande, A.E. Aust, and J.M. Hevel.
Protein Arginine Methyltransferases: Role in Cell Stress and
Substrate Specificity. FASEB Summer Conference on Biological
Methylations. Vermont Academy, Saxtons River, VT

2003

W. Wooderchak and L. Wen. Purification of the Protein eIF-5A.
WIU honors thesis and defense. Macomb, IL

2003

J.A. Ruppert, W. Wooderchak, S.H. Tsai, J.K. Huang, and L. Wen.
Site-Directed Mutagenesis of Bovine Deoxyhypusine Synthase.
Argonne National Laboratory Symposium for Undergraduates in
Science, Engineering,& Mathematics. Argonne, IL

2003

W. Wooderchak, J.T. Lamer, N. Yu, S.H. Tsai, J.K. Huang, and L.
Wen. Purification of Recombinant eIF-5A Precursor Protein and
Preparation of Its Deoxyhypusine Intermediate. Argonne National
Laboratory Symposium for Undergraduates in Science,
Engineering, & Mathematics. Argonne, IL

2001

L. Sperry, L. Ruppert, W. Wooderchak, J. Ferguson, and
J. Hartman. Synthesis of Flavenoid Compounds using a Platinum
Catalyst. ACS Mark Twain Local Section poster presentation.
Macomb, IL

Awards and Honors
Utah State University
2007
Center for Integrated BioSystems Graduate Student Support
Program Grant
2007
Maeser-Bauer Graduate Teaching Assistant Award

204
2007
2006
2006
2004

D.A. Greenwood Memorial Award in Biochemistry
Graduate Student Senate Travel Award
Women and Gender Research Institute Travel Award
Department of Chemistry and Biochemistry Fellowship

Western Illinois University
2003
Cecile A Christison Sterrett College Scholar in the College of Arts
and Sciences Award
2003
National Dean’s List
2003
Suma Cum Laude
2003
Abraham Lincoln Laureate Award for Western Illinois University
2003
Hardin Chemistry Award
2003
Chemistry Departmental Scholar
2003
Natural Sciences and Mathematics Award
2003
Graduation Marshall
2002
Sheila and Paul Nollen Phi Kappa Phi Science Scholarship
2002
Currently Enrolled Student Award
2001-2002
ACS Organic Chemistry Student Award
2000-2001
Roy M. Salee Biology Award
2000-2001
Incoming Freshman Chemistry Award

Student and Professional Organizations
*American Chemical Society
*ASBMB
*Golden Key Club-volunteer coordinator

*Phi Kappa Phi
*Marching & Jazz Band
*Chemistry club-treasurer

Technical Skills
Biochemistry: assay development, protein purification, enzyme kinetics, HPLC,
crystallography, PyMol, fluorimetry, spectrophotometry
Cell biology: mammalian cell culture, western blot, immunoprecipitation, microscopy
Microbiology: microbial genetics, mutagenesis, qRT-PCR, microbial cell culture
Chemistry:
chemical synthesis, compound isolation, compound identification and
analysis (NMR, IR, GC-MS, TLC, mass spectrometry)
Radioactivity: trained to properly use radioactive substances

